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Abstract____________________________________________
The transpeptidase, Sortase A is an enzyme that has been used in this fimction previously 
ligate eGFP to polymer beads, short polymers and other proteins with great success. To 
further demonstrate the site specific and universal nature of Sortase A, the ligation reaction 
was expanded to a range of materials that included graft-to, graft-from and graft-through 
polymers and a number o f short and self-assembling peptides.
Enhanced green fluorescent protein (eGFP) and DNA-binding protein (Tus) were expressed 
with a LPTEGG tag for Sortase A mediated ligation followed by a Hexa-His tag, whilst 
Sortase A was expressed with a Hexa-His tag to aid with purification. The proteins, Sortase A 
and enhanced green fluorescent protein were expressed and purified successfully from 
Escherichia coli in yields of 141 mg in each case.
The synthesis o f a peptide initiator utilised two routes in the form of solution peptide 
synthesis and solid phase peptide synthesis. Both methods presented difficulties due to poor 
solubility of the peptide initiators and synthetic intermediates. The latter was more successful 
and involved the synthesis of a number of initiators containing diglycine and a bromo- 
isobutyrlamide group. The most successful of these was the peptide initiator 
GG[COCBr(CH3)2]-E-OH that was synthesised in a high yield (73%), was highly soluble in a 
number of solvents and was used effectively in ATRP and SET-LRP.
Polymerisation involved a number of controlled radical polymerisation strategies including: 
ATRP, SET-LRP and RAFT. ATRP generated a number of peptide-polymers (98,723 g/mol, 
PDI 1.41, 20,387 g/mol, PDl 1.19 and 30,066 g/mol, PDl 1.45) that were suitable for 
attachment to the eGFP. SET-LRP also generated a number of peptide-polymers that were 
suitable for attachment to the eGFP in the graft-to (20,066 g/mol, PDl 1.26) and graft-through 
strategies (26,861 g/mol, PDl 1.19) and for use in peptide self-assembly (34,465 g/mol, PDl 
1.52). RAFT was also used to test the possibility of post-polymerisation modification o f the 
peptide-polymer (30,066 g/mol, PDl 1.45) for use in conjugation to eGFP.
Graft-to and through conjugation of the peptide-polymers from ATRP and SET-LRP to eGFP 
was successfully mediated by Sortase A. The grafting of pOEGMA from eGFP-peptide 
initiator using ATRP and SET-LRP also successfully generated protein-polymer conjugates. 
This demonstrates that Sortase A and the peptide initiator can be used as a universal method 
for graft-to, graft-from and graft-through conjugation. The grafting methodologies showed
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that conjugates synthesised using the graft-from had a higher yield during ligation compared 
to the graft-to conjugates.
Site-specific conjugation of DNA-binding protein (Tus) to the self-assembling di-gly peptide 
had no effect on the morphology of the hydrogel and the DNA-binding protein Tus was still 
accessible within the gel network to complimentary binding sequences.
With Sortase A it is possible to synthesise protein-polymer conjugates using a number of 
grafting methodologies. It is possible due to the universality of the method to transfer the 
technology to other proteins and polymers for efficient synthesis o f novel protein-polymer 
conjugates.
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1 Introduction
1.1 Protein-polymer conjugates
Proteins have a variety of roles and applications in therapeutics, catalysis, and biosensing J 
Both naturally occurring and recombinant proteins have been utilised in the areas of 
biotechnology, protein therapeutics, '^  ^nanotechnology and more recently fuel cells as a result 
of their evolved properties in molecular recognition, transport and catalysis.^ Modification 
(termed ligation or conjugation) of proteins (Figure 1) with synthetic polymers has been 
shown to improve significantly stability, biocompatibility and solubility for use in these 
fields.^ Covalent attachment of polymers has also shown to modulate activity; this can be 
useful in areas such as sensors where a measurement range is required and is especially 
important for nanomedicines where toxicity can be a large factor.
Increase in solubility due 
to the PEG hydrophilicity
4/
Decreased accessibility for 
proteolytic enzymes and
Figure 1. Advantages of protein conjugation to synthetic polymers
An important application of protein-polymer conjugates are protein-therapeutics, where 
conjugates have been used since 1970’s.^  The first examples involved the modification of the 
lysine side-chains with polyethylene glycol (PEG),* in a process termed PEGylation. A 
significant number of PEG-conjugates using therapeutic proteins have been synthesised since 
then and approved by the FDA for use as nanomedicines in the treatment of cancer, hepatitis 
C, anaemia and diabetes.  ^(Table 1)
Table 1. FDA-approved therapeutic protein-polymer conjugates and their properties10
Drug PEG PEG size 
attachment
Protein name Site(s) o f  
attachment
Native
half-life
Conjugated
half-life
Adagen (1) 0  0  5kD a Adenosine
deaminase
Lysine, serine, 
tyrosine, histidine
- -
Oncaspar P) 0  % 5 kDa L-
Asparaginase
Lysine, serine, 
tyrosine, histidine
20 h 357 h
Krystexxa m ,  ^ N „ 1 0 k D a (1 0 - Mammalian 
urate oxidase
Lysines 4 h 154-331 h
PEG-
INTRON
w 0  q 12 kDa Interferon
alfa-2a
Histidine 34 
(Major)
7-9 h 48-72 h
Somavert p) „ ° 5 kDA hGH
antagonist
B2036
Lysines, N- 
terminal 
phenylalanine
Neulasta (6) 20 kDa G-CSF N-Terminal
methionine
3.5-3.S
h
42 h
The conjugates (1-6) presented above, are all synthesised by the incorporation of hydrophilic 
polymers on to the protein. Pre-formed polymers are modified with protein-reactive end- 
groups, such as activated esters, that facilitate coupling between the polymer and a variety of 
functional sites in the protein. This method is non-specific as a number of functional sites can 
be modified with the polymer as can be seen in Table 1, this can lead to polydisperse protein- 
polymer conjugates due to there being a variation in the number of polymer chains attached 
to each protein. Therefore, the development of such conjugates has traditionally required 
extensive case-by-case optimisation.^^
1.2 Design of protein-polymer conjugates_____________________
1.2.1 Protein attachment
1.2 .1.1 Modification via naturally occurring amino acid residues 
L2.LL1 Amino group modification
The modification of proteins using amino groups (NH2 , commonly from lysine) represents 
the most common method of conjugation at present. Its popularity is due to amino groups 
being very common in proteins, with all containing at least one modifiable amino group 
found at the iV-terminus of the amino acid sequence. The nucleophilicity of amines is also a 
significant advantage as they can react with a wide number of easily synthesisable 
electrophiles.^^
Commonly used methods of amino group conjugation include alkylation (8) with alkyl 
halides and chlorotriazines/^ acylation (1 1 ) with A-hydroxysuccinimidyl esters, acyl halides, 
anhydrides, carboxylic ac id san d  less commonly reductive amination (15) with aldehydes. 
The reaction scheme for these modifications can be seen in Figure 2.
Acylation
N -O  RzHN
(7) (8)
Alkylation
Cl Cl NH2R2 NHR2
N-^N N-^N
Reductive Amination
O
R
^  NH2R2 OH .H2O NR2 NaCNBHg NHR2
(12) (1 3 ^ '  (14) (15)
Ri, Polymer Chain, R2, Protein
Figure 2. Common methods of protein-polymer conjugation using amino groups
This chemistry, although efficient, is also problematic. To maintain protein function, a single 
site of modification is usually required and as proteins have several functional sites (e.g. more 
than one lysine), the protein can be modified at any number of them making this the least 
specific method of modification. The chemistry of amide bond formation can be competitive 
with other groups that are present in the protein such as carboxyl groups (C-terminus and side 
chain) this can result in protein crosslinking. As these exposed residues may be commonly 
involved in protein function, this method of modification can also cause a reduction of 
protein functionality.^^
2 NHz
HpN /
H2N |\|H
>  7  NH2 NH
NH, >
H0 _ /O
HO. ,0
CT2N NH
H O . , 0
H,N f
CT2N NH
C hzN  NH
Figure 3. A) Non-specific modification of the lysine side chain of a protein at a variety of 
functional sites with an amino reactive polymer, B) Crosslinking of proteins due to the 
formation of an amide bond between the amino and the carboxyl group of the protein
It is, however, possible through careful control of the pKa of the reaction to target specific 
amino groups. Gegg and co-workers demonstrated that it possible to modify the A-terminus 
(pKa 7.6-8.0) of recombinant human granulocyte colony-stimulating factor with a single 
methoxy functionalised poly(ethylene glycol) chain through a reductive alkylation, whilst 
leaving lysine side chains un-modified (pKa 10.0-10.2).*"  ^ Site-specific attachment using this 
methodology has been reported in the literature including: modifying the e-amino group of 
lysine present in lysozyme using an iridium catalyst (pKa 7.4),*  ^and targeting the A-terminus 
of type I soluble tumor necrosis factor receptor (pKa 5.0),*  ^recombinant human granulocyte 
colony-stimulating factor (pKa 5.0)^* and recombinant human epidermal growth factor (pKa 
5.5)’^  with poly(ethylene glycol). There is, however, possible competition from other 
nucelophilic groups present in the protein such as the sulfhydryl group (pKa 8.8-9.1) of 
cysteine. According to pKa values, ligation should not be efficient below a pH of 8.5. In 
practice it is possible to modify these groups with high yield at pH values not much higher 
than neutrality (overlapping with the pKa value used for A-terminus targeting in the site- 
specific modification of recombinant human granulocyte colony-stimulating factor by Gegg 
et al), due to the microenvironmental effects experienced by the residues in the three- 
dimensional structure of the protein.This illustrates that the method is mildly site-specific
and to make the ligation strictly site-specific would require some level of case by case 
optimisation for each new conjugate synthesised.
1.2.1.1.2 Thiol group modification
Disulphide bridge formation with thiol groups from cysteine residues represents another 
frequently used method of protein-polymer conjugation. Thiols are commonly found in native 
(naturally occurring) protein, although there are cases where they have been introduced using 
genetic engineering.^
HS
Figure 4. Modification of thiol group of cysteine in a protein through the formation of a 
disulphide bridge.
The modification is advantageous as cysteine has a lower frequency of occurrence in proteins 
than lysine, making any method of thiol conjugation more site-specific. A number of 
functionalization methods have been employed, these include Michael Addition (17) and (19) 
with vinyl sulfones and maleimides ^^ and thiol-disulphide exchange (2 2 ) with activated 
disulphides.^ (Figure 5)
Michael Addition
HS—R;
R
(16)
OIt HS—R'
O 
(18)
Thiol-Disulphide Exchange
HS—R2
(17) H
«„,,s
(20) (21)
Ri, Polymer Chain, R2 , Protein
(22)
Figure 5. Common methods of protein-polymer conjugation using thiol groups
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Using this methodology a number of model polymer-protein conjugates have been 
synthesised these include: the modification of enzyme lipase B with polystyrene,^^ and 
bovine serum albumin (BSA) with 2-hydroxyethyl methacrylate using controlled 
polymerisation?^
Protein conjugation through thiol groups can be problematic. This is due to the hydrophobic 
nature of cysteine resulting in thiol groups, commonly found in disulphide bridges being 
situated deep inside the protein and only being partially accessible to conjugation.^ Thiol 
group accessibility can be improved by reduction of the disulphide bridge but until recently 
this was thought to have resulted in protein denaturing. It has however, been shown by 
Brocchini and co-workers as early as 1990 that it is possible to reduce the disulphide bridge 
of mouse anti-human tumour monoclonal Immunoglobulin G with 3-mercaptoethanol and re­
bridge with a,a-jB/5'[[(/7-chlorophenyl)sulfonyl]methyl]acetophenone without effecting the 
tertiary structure of the protein.^ "^
Y O
OgSOgS
(24)
(26)(23)
NH
NH
HN
HN S - S
(25a)HN
NH
(25)NH
(25b)
NH
NH
HN
HN
NH NH
(28) (27)
NH NH
Figure 6. Schematic of disulphide bridge reduction and bridging with a,a-Bis{{{p- 
chlorophenyl)su!fonyl] methyl] acetophenone
More recently, this methodology has been used by the same group in synthesis of number of 
protein-polymer conjugates including: modifying human interferon a-2b,^ '^^  ^ human CD4 
receptor-blocking antibody fragment (Fab),^ '^^  ^ L-asparaginase,^ ’^^  ^ somatostatin,^  ^ reduced
glutathione^  ^ with PEG mono-sulfone following reduction with either tris{2- 
carboxyethyI)phosphine (TCEP) or dithiothreitol (DTT). All conjugates showed no change to 
the tertiary structure of the protein.
SO2R2 (31) 
o
or DTT
Figure 7. Reaction scheme of reduction of the disulphide bridge of a protein and re-bridging 
with PEG mono-sulfone
Another route by Schumacher and co-workers used a similar methodology where the 
disulphide bond bridge of the peptide hormone somatostatin (33) was reduced with tris(2- 
carboxyethyi)phosphine (TCEP) and the disulphide bond re-bridged with dibromomaleimide
(34) functionalised PEG. This method resulted in the biological activity again being retained
(35).'°
H -A la —Gly—Cys—Lys—Asn—Phe—Phe
S Trp (*)TCEP
(33)
Lys
H O -C y s —Ser—Thr—Phe—Thr
N -P E G
H -A la -^ ly -C y s —Lys—Asn—Phe—Phe
P E G -N (35)
Trp
LysO ?
H O -C y s —Ser—Thr—Phe—Thr
Figure 8. Synthesis of the PEGylated somatostatin (35) using A-PEG-dibromomaleimide (34)
Further experiments by Haddleton and co-workers have also shown it is possible to modify 
salmon calcitonin with dibromomaleimide functionalised methoxy PEG '^ and use a 
functionalised dibromomaleimide as a suitable initiator for RAFT polymerisation?^ however 
it has not proven possible to use it in ATRP.^’
This method of conjugation presents another problem, once the disulphide bridge has been 
reduced and re-bridged with the thiol functionalised initiator there is no certainty that the 
protein will refold correctly to maintain activity and although it has been demonstrated that 
salmon calcitonin is not affected by the process of refold, '^ it may affect larger proteins
exhibiting disulphide bridges that are more deeply embedded. If this method of synthesis was 
followed extensive optimisation of the maleimide and polymer chemistry would be required 
to ensure that the tertiary structure was not modified, this chemistry could be classed as site- 
specific due to the lower occurrence of thiol in the peptide backbone in comparison to lysine, 
however, it is possible that if there is more than one disulphide bridge in the backbone it 
could modify at more than one site or as a consequence of disulphide bridges forming a 
deeply buried hydrophobic core, may result in no modification at all.
1.2.1.2 Modification via synthetically incorporated residues
L2,L2.1 Oxime formation
Formation of an oxime bond between a hydroxylamine (37) and a ketone/aldehyde (36) is 
another possible method of conjugation. The formation of an oxime bond (40) proceeds 
through a nucleophilic addition reaction as shown below (Figure 7).
g  : NH20R2 oh H2O
r , ' Y nhor2 ~  r A h -  hA h
(36) (38) (39) (40)
Ri, Polym er Chain, R2 , Protein
Figure 9. Formation of an oxime bond between an aldehyde and hydroxylamine
However, both of these functionalities are not present in any naturally occurring amino acid 
and need to be incorporated before conjugation can take place. This usually involves 
modifying an existing amino acid residue prior to the conjugation. A number o f studies have 
successfully proven it is possible to introduce these groups.^ ’^^ '^
The introduction of these functional groups varies within the literature. Both Haddleton and 
co-workers, and Schlick and co-workers chose to modify the tyrosine residues using ketone 
functionalised diazonium salts (45).^ ’^^  ^Maynard modified the protein at A-terminal alanine 
residue via a transamination reaction with pyridoxal-5-phosphate leaving an A-terminal a- 
ketoamide residue for an oxime bond formation (49).^  ^ The Kochendoerfer research group 
introduces fiinctionality much more elegantly through native chemical ligation of ketone 
functionalised PEG with Chemokine (C-C motiQ ligand 5 (CCL-5) to produce a peptide- 
polymer conjugate (56).^ ^^  ^as can be seen in Figure 10.
.OMe
(42) COCH
COCH
OH NOH OH N
pH 3.0, rt. 2h
(45)
(43)(41)
(49)
Boe. Boc. Boc.
(47) (48)
1. Bake
2. Rinse
C) ^ 1.20% piperidine
,N-Fmoc 
\  2. DIC/NHS
(50)
(51) / L
O N  O N
(52) (53)
methoxylamine -  HOI 
(54)  ^ O ^ N ^
(56)
O N
Figure 10. Formation of oxime bonds with the functional groups in the peptide of A) 
tyrosine^ ’^^  ^B) alanine^  ^and C) functionalised side-chain of lysine^ ’^^'*
1.2,1.2,2 Click chemistry
Click chemistry is the umbrella term for reactions that occurs with near quantitative yields, 
generate easily removal by-products, proceed quickly under relatively mild reaction 
conditions and are site specific.^  ^A number of reactions contain these features including the 
thiol-ene reaction,^  ^ however by far the most popular is the 1,3-dipolar cycloaddition 
involving bond formation between an azide and alkyne in either its copper catalysed (Copper- 
Catalysed Azide-Alkyne Cycloaddition, CuAAC) or uncatalysed (Huiggen Cycloaddition) 
form.^  ^An example of CuAAC (59) is shown below in Figure 11.
n Ri
(57) ®  (58) (59)
Figure 11. Reaction Scheme of Copper-Catalysed Azide-Alkyne Cycloaddition
Click chemistry presents a very efficient method for the conjugation of proteins and polymers 
containing an azide and alkyne moiety. However, although the reaction is site-specific once 
the corresponding functionalities have been introduced, since these groups do not occur 
naturally in proteins they have to be introduced, typically using methods that have been 
described previously in section 1.2.1.1 . Therefore, the introduction of azide or alkyne groups 
into proteins, is not a site-specific methodology per se. CuAAC methodology has been used 
in the site specific conjugation of both bovine serum albumin (BSA/^ by Nolte and co­
workers (62) (Figure 12) and human superoxide dismutase (SOD) by Shultz and coworkers.'^* 
This is a result o f BSA having a naturally occurring exposed thiol group on the surface and 
SOD being mutated at the trytophan33 residue meaning that although the ligation is site 
specific for these two cases it is non-generic for use with other proteins. To make this generic 
it would require the reduction of disulphide bridges and would present the same problems as 
the modification of cysteine directly. This, combined with the issues associated with copper 
removal from the protein samples, and its related toxicity, makes the method problematic.
(61)
SH
PB 20  mM. pH 7 .2
O (62)
Figure 12. Preparation of alkyne functionalised BSA
1.2.1.3 Enzymatic conjugation o f  proteins
A number of cases of chemical ligation have yielded conjugates that are modified at a single 
site; the scope of proteins that have been modified in this manner is small, most commonly 
this has been limited to and lysozyme.'^ ’^'*^ '^  ^Therefore, for conjugates that contain
other proteins, an optimisation of the attachment chemistry is required on a case by case basis 
for the protein of interest. It is therefore necessary to find a method that is mild, site specific 
and generic for use with any protein. This can be accomplished through the use o f enzymes. 
For well-characterised systems it is possible to know where the conjugation will take place 
and the conjugation reaction can be optimised more efficiently than chemical conjugation.
1 0
A number of enzymes have been utilised for this conjugation, these include 
sialyltransferase,^  ^ subtiligase,"^  ^ tyrosinase*^  ^ and most recently Methanococcus jannaschii 
tyrosyl-tRNA synthetase/tRNAcuA-^  ^ However, the two enzymes that have been used most 
commonly are transglutaminases^*’^  ^and Sortase A^^^.
1.2.1.3.1 Transglutaminases
In 2002 Sato et a l demonstrated that guinea pig transglutaminase is capable o f binding the 
surface glutamine of a protein to the amino derivative of poly(ethylene glycol) via acyl 
transfer, if  the amino group acts as a nucleophile.^* The enzyme is site specific as it 
recognises the AQQIVM sequence of amino acids surrounding the glutamine on the protein 
as the signal for binding.^  ^More recently the use of microbial tranglutaminase (mTGase) has 
allowed for less stringent substrate requirements; in this case the glutamine must be located 
near a highly flexible backbone^  ^ and contain a variety of polar, charged and non-polar 
residues around the active Gin. These requirements seem highly specific and difficult to find. 
For example, if  the position o f the active Gin is assigned 0, with negative positions towards 
the N-terminus, and positive positions towards the C-terminus, then plausible combinations 
are (Threonine at —3, OR Glutamine at +2, OR Serine at +5) AND Lysine at +2 , Glycine at 
-1  AND Proline at +5, with the absence of Leucine at -1  and Serine at +3 positions for the 
ligation to be successful. *^*
H 2 N '* 'Q '’^ 'C ^ N " '" V ' ' '^ 'C 0 0 H  + PE G -N H j ,  ^ ----- —  H 2 N '* 'Q ' '^ 'C '^ N " ' 'V '“ 'GOOH
J H Ca2* I H
<  (63) (64) r  (65)
O^NH; O'^NH-PEG
Figure 13. Schematic representation of enzymatic PEGylation conducted by guinea pig 
transglutaminase
The specificity of transglutaminases has been demonstrated in the modification of 
apomyoglobin (apoMb) and human growth hormone (hGH) by an amino derivative of 
poly(ethylene glycol) (PEG-NHi).^^ It was found that the apoMb was only modified at a 
single site and hGH at two sites as a result of the glutamines occurring in regions where the 
sequence of amino acids were suitable as a substrate, whereas other residue glutamines did 
not. Additional optimisation through the addition of different concentrations of EtOH, 
MeOH, TFE, ACN and DMSO as solvents by the same group has yielded human growth 
hormone modified at a single glutamine site.^ ^
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However, highly specific transglutaminases have disadvantages. At present there is no 
mention that the methodology has the capability to modify at the terminus of the amino acid 
sequence and it appears to be limited to the mid-sequence of the polypeptide chain. 
Modification mid-sequence could cause incorrect folding of the protein once the polymer is 
incorporated on to the glutamine resulting in a loss of activity. A solution to this would be to 
modify the protein at the N or C-terminus as these are not usually involved in protein folding 
and structure. However, it is already possible to achieve this through the use o f Sortase A.
1.2,1.3.2 Sortase A
Staphylococcus aureus (S. aureus) is a gram-positive bacterium that can be found in 40% of 
the human population.^* It is responsible for a large number of pathologies including 
pneumonia, meningitis and toxic shock syndrome.^  ^In gram-positive bacteria, the cell wall is 
generally composed of polymeric peptidoglycan, with secondary units such as proteins 
immobilised to the surface.
In S. aureus, the most common surface protein is an immunoglobulin-binding protein, which 
is covalently attached to a pentaglycine chain on the cell wall precursor.^  ^ Once this is 
incorporated into the cell wall, the bacterium is able to interact with and infect cells. This 
linkage was later found to be catalysed by a set of enzymes known as sortases.^ "*
1.2.1.3.2.1 Structure of Sortase A
The most common of this family is Sortase A (SrtA) also known as “housekeeping sortase”.^  ^
It is a transpeptidase that contains 206 amino acids with N-terminal membrane-spanning 
region and a C-terminal catalytic domain.^  ^ The active site o f the enzyme contains the 
catalytic residues His 120, Cys 184 and Argl27. The structure was first determined by Clubb 
and co-workers using nuclear magnetic resonance (NMR) spectroscopy. The NMR structure 
(PDB IB HJA) is shown below in Figure 14.^ ^
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Catalytic Domain 
(Active Site)
87 M Loop
Figure 14. Structure of S. aureus Sortase A, reproduced from^ ^
1.2.1.3.2.2 Recognition and mechanism of action
Sortase A catalyses a transpeptidation reaction of any protein that contains a C-terminus Leu- 
Pro-X-Thr-Gly (LPXTG) peptide recognition sequence, where X is any amino acid with a N- 
terminus polyglycine containing molecule.^  ^ Catalysis involves three residues within the 
active site: His 120, Cys 184, and Argl97. The Argl97 plays a key role in catalysis by 
enabling the correct positioning of the substrate through hydrogen bonding to the peptide 
backbone.It  is well established that the thiol group of the amino acid Cys 184, then 
nucleophilically attacks the carbonyl carbon of the threonine residue to form a tetrahedral 
intermediate. (Step ii. Figure 15)^ ^
Next it is hypothesised that His 120 acts as an acid to catalyse the breakage of the threonine- 
glycine amide bond, leading to the formation of more stable thioacyl enzyme-substrate 
linkage. (Step The now deprotonated His 120 then acts as a base to activate the terminal 
amino group of the polyglycine resulting in nucleophilic attack of the thioacyl intermediate. 
(Step iv)^ * The protein-linked product is subsequently released following the breaking of the 
enzyme-substrate bond. (Step v)
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Figure 15. Sortase A transpeptidation mechanism reproduced from^^
L2.L3,3 Sortase A mediated ligation o f protein-material conjugates
It is well established that the main substrate of Sortase A in bacteria is pentaglycine,^^ 
However in 2003, an experiment by Huang et al?^ demonstrated that it is possible to use 
other oligoglycines as substrates with the exception of mono-glycine. The best affinity (Am) 
for the active site was found in substrates that contained an A-terminus that had at least two 
glycine residues adjacent to each other, as shown in Table 2. The binding affinity was found 
not to differ significantly between the oligoglycine peptides, and interestingly aminoglycine, 
that share some structural similarities. The mono-glycine residue had no affinity for the active 
site, possibly as a result of having structural similarities to the acylated leaving group.^  ^The 
rate of catalysis (Vm) in the study was also found not to differ significantly between the 
different lengths o f oligoglycine suggesting that the acylation step in transpeptidation is rate 
limiting.
Table 2. Possible Nucleophiles for the Sortase Transpeptidation Reaction70
Nucleophile An.aoo Fm (//M/min)
H-GlyGlyGlyGly-OH 1 6 ± 2 0.11 ±0.01
H-GlyGlyGly-OH 24 ± 4 0.09 ±0 .01
H-GlyGlyHis-OH 2 0 ± 2 0.11 ±0 .01
H-GlyGlyLeu-OH 35± 5 0.10 ±0 .01
H-GlyGly-OH 3 0 ± 4 0.10 ±0.01
H-GlyAla-OH 127 ±  22 0.10 ±0 .01
H-GlyVal-OH 208 ±  28 0.09 ±0 .01
H-Gly-OH No Affinity
H-Gly-NH; 23 ± 2 0.12 ± 0.01
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Mao and co-workers were the first to demonstrate that Sortase-mediated ligation was a viable 
method for protein engineering/^ In the experiment oligo-glycine containing peptides (where 
the number of repeating glycine residues were 1,2,3, or 5) were synthesised and incubated 
with a fluorescent peptide RE(Edans)LPKTGK(Dabcyl)R. Fluorescence measurements made 
on these conjugates confirmed the results of the Mao experiment and showed that the length 
of the polyglycine chain had no effect on the final yield (approximately 30%). However, it 
did have an effect on rate, showing a slight increase as a result of the increasing length of the 
oligo-glycine chains. The use of Sortase A in protein-peptide and protein-protein ligation was 
then evaluated, a protein-peptide of GFP-LPETG-His6 conjugated to an A-terminus oligo-G- 
RRNRRTSKLMLR peptide was synthesised with high yield (90%) after 24 hours. Sortase A 
also successfully mediated protein to protein conjugation that contained an A-terminus 
diglycine but at a much slower rate. This demonstrated that it was possible to use larger 
molecules containing an A-terminal di-glycine as a substrate in conjugation to proteins that 
have a LPETG tag.
The experiments by Parthasarthy were the first to recognise that Sortase A could be used in 
the synthesis of protein-polymer conjugates.^  ^ The study successfully demonstrated that it 
was possible for tri-glycine to participate as a nucleophile even when the C-terminus is 
covalently bound to amino-functionalised polystyrene beads (Figure 16) and that an 
alkylamine derivative of PEG can also function as a nucleophile in the conjugation reaction. 
The latter was described as a less efficient nucleophile than the tri-glycine derivative, 
although the degree to which the conjugation efficiency had been impaired was not 
quantified.
iGiyl* (X = 1.2 3 a'ld 5 gtyc "e lesdues)
6*H I8
Drlase rr^ diated o
9 ... A
NH. e -  8%Hi»
Figure 16. Sortase A mediated coupling of eGFP-LPXTG-Hise with Gly„-polymer beads^^
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Fluorescence-activated cell sorting (FACS) data of the GFP-polystyrene bead ligation by 
Sortase A showed an increase with time in the Partbasaratby study.^  ^This was also noted by 
Neylon and co-workers who produced similar results in the ligation of blue (BFP), enhanced 
green (eGFP) and red fluorescent protein (DsRed) to Glycidyl methacrylate (GMA) beads 
using Sortase A.^  ^ The rate of the ligation of triglycine modified polystyrene to eGFP by 
Sortase A, normalised by protein concentration in Partbasaratby s tudy,are  quantitatively 
comparably to the work of Neylon et This is shown below in Figure 17 and shows that 
when the number of TV-terminal glycines increases the rate of conjugation also increases. It 
also shows that there is not a large increase in fluorescence once the number o f glycines at 
the TV-terminus has exceeded two, demonstrating that di-glycine would be the minimum 
suitable length for a quantitative attachment. The type of bead used also does not affect the 
rate of conjugation suggesting that this method is universal; this trend is fiirtber confirmed by 
the rate studies of Huang et al. shown in Table 2.
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Figure 17. Kinetics of 85 pM eGFP coupling to 3pm GMA beads modified with (c) one, (d) two, 
or (f) four glycine residues^ and normalised 85 pM eGFP coupling to (e) 3 pm Glys-terminated 
polystyrene beads®^  by 40 pM Sortase A
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However, Sortase A has not only been utilised in the conjugation of polymers, a number of 
different functional substrates have been used, including biotin, tetramethylrhodamine, Alexa 
Fluor and mycin for labelling, as a probe, and antibiotics respectively/"^ This demonstrates 
the diversity of materials that can be modified using Sortase A.
All o f these studies highlight that Sortase A, like transglutaminases, is more site-specific than 
chemical conjugation approaches. This is a result of a defined sequence o f amino acids that is 
required for substrate recognition by the enzyme.^^’^ ’^^ ’^^  ^ However, unlike microbial 
transglutaminase, Sortase A is easier to overexpress and purify in E. colL, where it is 
produced in large quantities in a soluble form.^  ^ In addition, the substrate specificity 
requirements have been rigorously elucidated, another advantage over transglutaminases, 
where the exact requirements for a substrate are still not fully understood.^  ^ It is possible to 
modify exclusively at the terminus of the protein with only a handful of naturally occurring 
amino acids being added to the native protein. This is straightforward and it is not bound to 
affect overall folding at least for the examples shown.^ ’^^  ^ If these modification do have an 
effect they are bound to be less dramatic for protein folding (hence activity) than if you 
modify deeply imbedded disulphide bridges, for example. In the case o f Sortase A, 
modification of proteins is, however, limited only to the C-terminus of the amino acid 
sequence, although there is also promise in reversing the peptide requirements to an TV- 
terminus oligo-Gly containing protein and an LPETG-modified polymer. This can be both 
advantageous and disadvantageous as, unlike microbial transglutaminase, the attachment 
does not modify the protein at any intra chain amino acid residue, which could lead to 
potential folding issues. However, this implies Sortase A modification is either limited to the 
C-terminus of the protein or requires the incorporation of the LPETG sequence o f amino 
acids at other sites in the protein.
17
1.2.2 Well-defined protein-polymer conjugates
Molecular weight and polydispersity control, as well as site-specific attachment are 
fiindamentally important in the synthesis of well-defined protein-polymer conjugates. The 
introduction of polymer chains can be achieved through any one of three grafting approaches: 
“graft-from”, “graft-to” and “graft-through”. These are summarised in Figure 18 below:
y — ^  Attachment Site
Graft to
R—dZl + M
Q —EZZZl + M 
Graft from
GRP Rn/V^/CD
End-group
transformation
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+ M
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R-CZ3 +
CZl Initiator
R reactive end-group
O protein/peptide reactive 
functional group
G protein/peptide
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GRP Gontroiled Radical 
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R - d + GRP
Figure 18. “Graft-from”, “graft-to” and “graft-through” methods of conjugation modified 
from74
The graft-to approach is the most common^  ^ and utilises polymerisation o f monomer units 
using a bifiinctional initiator that can either be transformed after polymerisation or used 
directly for attachment to the protein. The graft-fi*om approach involves fiinctionalising the 
protein with initiating moiety and then grafting (or growing) the polymer chain away from 
the protein.
Both methods have their own advantages and disadvantages: the use of graft-to conjugation 
allows for a high degree of control over the polymerisation as ideal conditions optimised for 
the monomer in conditions where protein is not present can be used. It is also less likely that 
the protein will be denatured as in many cases the grafting process can take place under
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biologically relevant conditions using aqueous solvents, unlike grafting-from where less 
suitable solvents may be required to offer good control over polymerisation. Grafting-ftom 
does however, offer a number o f advantages: following successful conjugation o f the protein 
to the polymer after polymerisation it is easier to isolate the conjugate as the monomer can be 
removed simply through dialysis due to a significant difference in molecular weight between 
the monomer and protein-polymer conjugate. This is not the case for the graft-to approach 
where the molecular weight of un-grafted polymer, un-grafted protein and protein-polymer 
conjugate are likely to be similar, making separation more problematic. It is also possible to 
synthesise hydrophobic polymer conjugates more readily as the active hydrophobic polymer 
chain grows away from the protein meaning that the issues of hydrophilic, hydrophobic 
repulsion found in the graft-to polymerisation are not encountered.
Grafting-through is not as common and involves the production of multimeric protein-
polymer conjugates, where two or more proteins are attached to a single polymer chain.
Grafting-through is usually achieved through functionalised polymers containing protein
reactive groups (similar to graft-to approach but on multiple sites of the polymer) or protein
reactive monomers (similar to graft-from approach) that are incorporated into the polymer
backbone. Producing these conjugates can be advantageous as it is possible to generate
materials with higher affinity for a specific biological receptor or that is able to target
multiple biological processes due to a number of proteins being present in a single conjugate
making it multi-valent. This has promise in vaccine-development and immunology, for
example, where presentation of multiple binding sites on a single entity elicits a stronger bio- 
74response.
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1.2.2.1 Living Polymerisation
Polymerisation methods where there is close management of the molecular weight and 
polydispersity index (PDI) are described as "living" or “controlled”.^  ^ A living 
polymerisation has a reactive centre that remains active/dormant following complete 
conversion of the monomer and can be used to further propagate the chain if 
additional/different monomer is added to the system. The living character is due to negligible 
chain transfer and termination and results in a linear increase in molecular weight o f the 
polymer with monomer conversion and the narrow distribution of mass of the polymer 
chains.^^
Although it is possible to synthesise conjugates using a number methods of living 
polymerisation (for example; anionic, cationic or ring opening), controlled/living radical 
polymerisation (CRP) is the most prevalent, this is a result of the high tolerance to a larger 
variety of monomers and to aqueous conditions.^^’^ ^
1.2.2.2 Controlled radical polymerisation (CRP)
Controlled radical polymerisation involves establishing a rapid dynamic equilibrium between 
a very small amount o f chain-growing free-radicals and a large excess of dormant species 
(Pn—X); this acts to minimise the chance o f irreversible reactions.^®
'^ act
(p-x) ^
^deact
P- + X"w
Figure 19. Conceptual scheme for controlled radical polymerisation
The balanced rates of deactivation (kdeact) and activation (kact) in the equilibrium of controlled 
radical polymerisation (CRP) result in a steady state being achieved in the process whereby 
the formation and termination of the propagating radicals (P*) remain constant throughout the 
polymerisation.^  ^ This differs from conventional radical polymerisation (RP) where the rate 
of conversion is high initially and then slows as the polymer chains grow. As a consequence 
of that the conversion of monomer is linear with time for CRP but not RP. This is illustrated 
the schematic in Figure 20.^ ^
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Figure 20. Monomer Conversion as a function of time for controlled (CRP) and conventional 
radical polymerisation (RP)
In controlled radical polymerisation, formation of a rapid equilibrium through fast initiation 
results in all of the chains growing at the same rate. This is due to a steady state of 
propagating radicals throughout the reaction that means the molecular weight (Mn) increases 
linearly with time. In conventional radical polymerisation initiation is slow and free radical 
initiator is often left unconsumed, this leads chains to being continuously generated resulting 
in a statistical distribution of molecular weights due to conditions changing to favour longer 
or shorter chains. This can be seen in Figure 21 and highlights the importance of a controlled 
reaction for a suitable polymer conjugate.
 CRP
 RP
M onom er C onversion  (%)
Figure 21. Molecular weight as a function of monomer conversion for controlled (CRP) and 
conventional radical polymerisation (RP)
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Controlled radical polymerisation can be divided into three main categories: stable free 
radical polymerisation (SFRP) (e.g. nitroxides), atom transfer radical polymerisation (ATRP), 
and degenerative transfer (e.g. Reversible Addition Fragmentation Transfer(RAFT)). The 
first method is seldom used for the synthesis of protein-polymer conjugates,therefore it will 
not be discussed here. However, the latter two have found widespread use within the field 
and will be discussed below.
1.2.2.3 Atom Transfer Radical Polymerisation (ATRP)
Atom transfer radical polymerisation (ATRP) is a technique that was first developed by the 
Krzysztof Matyjaszewski research group at Carnegie Mellon University in 1995.^  ^For ATRP 
to operate a number of reagents and conditions are required: a halogen based initiator (I-X), a 
transition metal (commonly copper) capable of undergoing a single electron redox reaction, a 
ligand that can form a complex with the transition metal, a radically polymerisable monomer 
and an oxygen fi*ee environment (Figure 22).
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Figure 22. Atom Transfer Radical Polymerisation (ATRP) reproduced from^
ATRP involves a reversible homolytic halogen transfer between a dormant species (initiator 
or propagating chain end) (R-X or R-Pn-X) and a transition metal complex in the lower 
oxidation state (M"/Ln) resulting in the formation of propagating radical (Pn*) and the metal 
complex in the higher oxidation state with a coordinated halide ligand (X-M"^‘/Ln). As the 
reaction progresses radical termination is diminished as a result of the persistent radical effect 
(PRE) resulting in an increase in chain length, monomer conversion and viscosity.
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It has been shown in the literature that it is possible to perform polymerisation at lower 
temperatures (commonly 25 °C), under aqueous conditions and still obtain near 
monodisperse polymer chains/ '^^  ^ These characteristics make it ideal for the synthesis of 
well-defined protein-polymer conjugates under protein-tolerant conditions. It does suffer 
from one main problem, though, the removal of the catalyst complex can prove very difficult 
in highly viscous media and the presence of copper in an oxidised state results in a green 
product, making in non-ideal for a commercially viable product due to possible toxicity 
issues.^  ^ This problem has however been largely overcome for protein-polymer conjugates 
through the use of new low concentration copper complex methodologies such as Activator 
Generated by Electron Transfer (AGET-ATRP) and Initiators for Continuous Activator 
Regeneration (ICAR-ATRP).*’ *’
1.2.2.4 Single Electron Transfer-Living Radical Polymerisation (SET-LRP)
In 2006, ATRP was modified by Virgil Percec’s research group at the University of 
Pennsylvania as single electron transfer-living radical polymerisation (SET-LRP).^° The 
generally agreed mechanism involves elemental copper, Cu^  transferring an electron from its 
outer sphere to the alkyl halide to form Cu^  and radical anions. The Cu^  species then 
disproportionates back to Cu° and Cu^  ^and radical anions cleave to form propagating radicals 
and anions that associate with the Cu \^ The propagating radicals are then trapped by Cu" to 
form the dormant chains and the Cu* complex instead of activating the dormant species as 
seen in ATRP where Cu^  disproportionates to Cu^  and Cu".^ ^
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Figure 23. Single Electron Transfer-Living Radical Polymerisation (SET-LRP) reproduced
from84
23
The exact nature o f the mechanism is still contentious/^ although it is generally agreed that 
polar solvents are fundamental to polymerisation as they promote Cu^  disproportionation to 
Cu° and Cu°/^-^
Despite the lack of understanding of the exact mechanism, SET-LRP does offer some distinct 
advantages over ATRP. The Cu^  catalyst has a greater activity than Cu^  used in ATRP, it is 
easier to remove the catalytic species by simple filtration and has a higher atom economy as 
one Cu® atom can take two bromide atoms to form a CuBri species.^  ^ The polymerisation is 
also fast at room temperature, tolerant to a wider range of initiators and monomers and can 
provide polymers with very low PDI. SET-LRP is not free o f limitations as it introduces more 
transition metal into the reaction mixture, however the transition metal in the zero valent state 
can be present as a macroscopic powder or wire that is simple to remove.^^
1.2.2.5 Reversible Addition-Fragmentation Chain Transfer (RAFT)
The first reports of living radical polymerization using thiocarbonylthio RAFT agents 
followed a few years after ATRP, when the process was highlighted by the Commonwealth 
Scientific and Industrial Research Organisation (CSIRO) in 1998 by Thang and co-workers/"  ^
It origins, however, go back much further, to as early as 1988, when xanthate esters and 
reversible chain transfer were first proposed as a convenient source of alkyl radicals by Zard 
and co-workers.^  ^RAFT can be divided into two distinct processes. One, degenerative chain 
transfer, where a dormant species (Pn—X) is attacked by a propagating radical (Pm') to form a 
dormant species (Pm—X) and the radical Pn* and the other re-initiation by the radical Pn* to 
form a growing chain. The dormant species in the process is generated through a reversible 
chain transfer process normally involving a dithio species following initiation of the 
polymerisation. The mechanism for this can be seen in Figure 24.
As the method utilises commonly used radical initiators, it can adapted easily for all fi*ee 
radically polymerisable monomers, is highly suitable for aqueous polymerisation and the ease 
of modification of the terminal thiocarbonylthio group using a number of chemical reactions 
(Figure 25) makes the method extremely versatile in the synthesis o f biological conjugates.^^
24
It is not, however, free of limitations as RAFT techniques require careful selection of chain 
transfer agent depending on the type of monomer. RAFT agents suffer from a lack of 
commercial availability (although this is improving in recent times) and poor stability of the 
transfer agents, the removal of thiocarbonylthio group may be necessary due to highly 
coloured, toxic, or odorous product.^^
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Figure 25. Processes for RAFT end-group transformation (R'* = radical, [H] = hydrogen donor.
96M = monomer) reproduced from
ATRP/^ RAFT^  ^ and SFRP^  ^ are all suited for use in the synthesis o f conjugates in the 
“grafling-to” approach, with the literature discussing numerous methods for the synthesis of 
well-defined methacrylates (except SFRP), acrylates and methacylamides.^^ This is due 
polymerisation being conducted under the optimum conditions for polymer synthesis (for 
example the ideal solvent and temperature) with non consideration needing to be made for the 
effect on the protein as conjugation takes place as a subsequent step. This approach allows for 
the synthesis of a large number of different polymers that have both controlled molecular 
weight and low polydispersity prior to conjugation with the protein making it ideal for well- 
defined materials.
It is not actually the polymer synthesis that the most challenging component when it comes to 
conjugate synthesis, particularly in “grafling-to” approaches, it is how the polymer is 
conjugated to the protein that presents greatest problems. The use of SFRP, particularly 
nitroxide mediated polymerisation (NMP) has limited use in the synthesis of conjugates due 
to the difficulty in introducing end functionality to the polymer chain,^  ^ usually requiring 
novel macroinitiators exhibiting protein-reactive group such as 7V-hydroxysuccinimide to
26
facilitate conjugation.^  ^ It is similar for ATRP where for “graft-to” conjugation specialised 
macroinitiators need to be synthesised. These have included initiators that contain NHS, 
maleimide, aldehyde or pyridyl disulphide as a reactive group,although it is possible to 
achieve conjugation through post-polymerisation modification using ‘click’ chemistry.The  
most diverse chemistry for “graft-to” conjugation is available for polymers synthesised via 
RAFT polymerisation, given the variety of available methods for post-polymerisation end 
group modification (Figure 25). Numerous examples have utilised novel macroinitiators for 
the synthesis of protein-polymer conjugates,^^’^ ®^*®^ although the vast majority use post­
polymerisation modification as a means of facilitating protein-polymer conjugation. These 
methods as summarised in Figure 25.
RAFT represents the best method for “graft-to” due to the wide availability o f commercial 
initiators for polymerisation, well-defined polymers can be synthesised using conditions that 
have already been optimised in the literature, with the only additional step being post­
polymerisation modification to facilitate conjugation unlike ATRP and NMP where novel 
initiators are required. Usually this can be achieved simply, under mild conditions due to 
reactivity o f the thiocarbonylthio group and the large number of chemistries that can used to 
modify this group means that most polymers can be modified in a universal manner. The 
technique does not require the synthesis novel initiators and the extensive individual 
optimisation of the polymerisation reaction that comes with there use. There is also no need 
for catalyst removal as is the case with ATRP (although the concentration has been largely 
reduced using the activators generated by electron transfer (AGET) and initiators for 
continuous activator regeneration methodologies (ICAR).) and some NMP reactions.
All of the polymerisations do, however, suffer fi*om the same underlying problems that affect 
all “graft-to” conjugates is the requirement of excess functional polymer for the conjugation 
reaction. The steric effects present between the protein and polymer in close proximity of  
conjugation reaction and low concentrations of functional groups requires that an excess of 
polymer be present .This  results in free polymer being present following the conjugation to 
the protein which makes the purification highly problematic due to the subtle differences in 
molecular weight. It is therefore highly unlikely that a 100% pure conjugate will result.
This can be overcome through the use of the “graft-from” approach o f protein-polymer 
conjugate synthesis due to reduced steric hinderance, the active chain growing away from the 
protein and simplied purification due to the large molecular weight difference between
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protein-polymer conjugate and the unreacted monomer. Of the various methods of controlled 
radical polymerisation, RAFT and ATRP have proven the most effective for the “grafting- 
from” a p p r o a c h . N M P  has not yet found a use in this approach possibly due to the high 
temperatures that are required for polymerisation.^^
The ease with which RAFT can be conducted in water in the presense of a diverse range of 
functional groups has made it highly suited for the synthesis o f protein-polymer conjugates 
using the “grow-from” approach. To facilitate this, the protein is modified with the RAFT 
agent so that it conjugated to the protein via the R-group with the thiocarbonylthio group 
distal to the protein and readily accessible for chain transfer with propagating chains in 
solution.^  ^This results in the active chain growing direactly away from the protein and has 
the added advantage of a direct potential transformation of the chain end to facilititate 
binding to other proteins, surface or for chain extension.
However, despite these clear advantages, difficulties arise from the synthesis o f the novel 
protein-initiators/agents for RAFT, they are usually more complex to synthesise than the 
commercially available intiating moieties (bromo-isobutyryl group) that are commonly 
introduced for use in ATRP. Granted, both may be introduced in a less than site-specific 
manner, but it is the ease at which the acid bromide commonly used in the synthesis o f ATRP 
intiators is introduced that presents the simplest route for protein initiator synthesis.
This is a clear advantage over RAFT and this meant that it was ATRP that was the first CRP 
method used in the synthesis of protein-polymer c o n j u g a t e s . A T R P  has been used 
extensively since then to generate “graft-from” conjugates based on a number proteins and 
biological m o l e c u l e s . I t  is not only the ease at which the initiator can be introduced that 
is an advantage but also the applicability o f ATRP to polymerise a wide range o f polymers 
that are commonly synthesised in aqueous environments ((meth)acrylates and 
(meth)acrylamides).^®  ^This property can afford conjugates that are responsive and that could 
find use in a number therapeutic applications.^^
Despite this success, the main concern with ATRP is the use o f a transition metal catalyst 
(commonly copper). This complication is a three-fold problem, the first is an issue o f  
contamination, residual catalyst can become trapped in the polymeric product and if the 
following degradation in the body if the conjugate is used in a therapeutic application can be 
subsequently released. This may not be dangerous initially but it is likely that this could
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present a problem over time as a result of accumulation and would if  present be unlikely to 
gain approval by regulatory authorities.
The second is compatibility and tolerance of the catalyst complex in the protic media and 
buffers. Possible outcomes include halide dissociation from the copper(II) deactivating 
species by competive coordination with the solvent or buffer, destabilisation of the Cu/ligand 
complex rapid disproportion/oxidation o f the Cu(I) activating species and possibly hydrolysis 
of the alkyl halide initiators and chain end without proper precautions.^®  ^All of which could 
result in loss of control over the polymerisation that would result in non-uniformed 
conjugates. There have, however, been a number of successftil cases that have utilised ATRP 
in protic media, this has included the modification BSA using both n o r m a l a n d  the highly 
deactivated and more tolerant ARGET ATRP^ ®^  suggesting that is is possible to generate 
conjugates despite these problems.
The third issue is the effect of the protein on the transition metal catalyst and the effect of the 
catalyst on the protein structure. Due to the large number of frmctional groups in the protein 
(including numerous amino groups that may mimic the ligand used in the transition metal 
catalyst) there may be the possibility that these may compete and bind with the transition 
metal of the catalyst, this will inevitably lead to loss o f control of the polymerisation leading 
to poorly defined molecular weight and high polydispersity. There is also the problem that 
this binding or possible displacement of other transition metals that are present in the protein 
may cause chains to the proteins tertiary and quartenery structures and possible denaturing. 
Again is has been shown that it is possible to perform ATRP without effecting the protein 
structure, however, it is likely that this is achieved on a case by case basis following 
extensive optimisation.
All of these methods of synthesis represent a compromise, although RAFT and ATRP are the 
most highly suited. ATRP is better for the introduction of the initiating group, whereas 
RAFT appears to be superior for polymerisation due to a much higher tolerance in aqueous 
conditions. It is important to remember that whatever the method o f synthesis careful 
consideration needs to be made to the material being synthesied and the conditions under 
which that occurs for the conjugate synthesis to be successful.
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1.2.3 Self-assembling peptides
It is not only protein-polymer conjugates that have applications in biomedicines and 
pharmaceuticals, self-assembling molecules such as peptides can also be useful. Self­
assembling peptide are specifically useful for biomedical applications as they interact three 
dimensionally through physical interactions or entanglement  ^ to form self-supporting 
hydrogels. Research into the hydrogels has focussed on materials that are stimuli responsive 
and react to environmental stimuli present in the body, including differences in pH, 
temperature and the presence of enzymes or small substrates such as glucose.**’’*’^  The 
advantage o f using peptides is that they produce building blocks with different properties, this 
is a result of there being 20 natural amino acids with different physical properties such as 
polarity, acidity, basicity and aromaticity. This is in addition to the infinite possibilities of 
non-natural residues. ^  ^  ^
Self-assembling peptides that form gels are described by Ulijn and co-workers as usually 
amphiphilic in nature, forming different (protein) secondary structures that result in a gel 
network.’*"* These structures can be informed from nature and include a-helices, p-sheets, and 
p-hairpins (Figure 26), but in addition may involve short hydrophobic (aromatic) peptides”  ^
and peptide combined with synthetic fragments as utilised by Hubbell et This s e lf -
assembly is usually driven by favourable thermodynamics, often mediated through weak non- 
covalent interactions such as hydrogen bonding, electrostatic interactions involving dipoles 
and formal charges, hydrophobic interactions, van der Waals interactions and metal 
coordination.” ^
a-helix
P-sheet
p-hairpin
Figure 26. Schematic representation of the three-dimensional structure of p-lactoglobulin 
showing representative a-helix, p-sheet, and P-hairpin"’
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1.2.3.1 Self-assembling peptides based on a-Helices
a-Helices are the most common type of the secondary structure found in proteins/^** they are 
visualised as a single spiral of amino acids that are fully hydrogen bonded with the amide NH 
group binding with the carbonyl group of the amide bond four residues further down the 
peptide chain. In addition to these structures it is possible by careful matching of amino 
acids of typically two or three helices they may assemble by burying hydrophobic pockets to 
form superhelices known as coiled-coils.*^* The assembly of multiple helices is commonly a 
result of the repeating motif of seven residues (abcdefg) (a heptad) in the peptide 
sequence.”"* In the peptide, residues a and d are usually hydrophobic {i.e. leu, He or 
Val)”"*’**^* and interact as described above, with e and g present as charged residues that form 
salt bridges to further stabilise the structure (Figure 27).*^ ^
Figure 27. Schematic representation of a coiled-coil structure using a helical wheel. The letters 
indicate the position of the residues*^^
a-Helical self-assembling peptides were first studied by Kojima and co-workers in 1997.*^  ^
The study showed that a triple helical coiled-coils (as-peptide) that contained three repeats of 
the seven-residue sequence LETLAKA formed many fibrils o f 5 -  10 nm width at pH 6.0 and 
upon increasing the salt concentration a conformational change took place forming longer 
thinner fibers assembled from these many fibrils.
Woolfson et al. developed this work, pioneering the “sticky end” design.*^ "* The “sticky end” 
involves a-helices with charged patterns (glutamic acid and lysine) that are partly 
complementary, this gives rise to a peptide overhang, and oppositely charged residues in the 
neighbouring a-helices can then interact to form a fiber.
It was also discovered by the same group that is was possible to form hydrogels by modifying 
the solvent exposed amino acid residues (b, c, and f) with alanine and glutamic acid.*^  ^These
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modifications, meant that under heating the a-helix would undergo a conformational change 
to a p-hairpin and then form a gel.
Similar systems have also been observed: Kopecek and co-workers showed that a hybrid 
hydrogel system, constructed from a synthetic polymer and a coiled-coil protein folding motif 
collapsed when the temperature was increased fi-om 25 °C to 70 °C due to the conformational 
transition of the coiled-coil.*^  ^Kajava et al. studied the influence of pH on an a-helical fibril- 
forming peptide of 34 residues. At slightly acidic pH values, it assembled into fibrils that 
were composed of five-stranded coiled coils. At pH 7.0, however, spherical aggregates were 
formed.
The applications o f these properties are not only limited to responsive material sbut  also 
actin/myosin filament mimics,*^* tissue regeneration*^ ** and neurodegenerative*^* and cancer 
apoptosis research. *^  ^ It also shows that it is possible to tailor a response to a particular 
change in temperature, pH or salt concentration. However, to facilitate this tailored response 
extensive, time consuming optimation of the peptide sequence is required and due to the long 
sequence of amino acid involved, this is difficult to achieve. Despite this the a-helix shows 
promise due to the presence o f exposed residues on the outside of the helix that can be 
modified with drugs, proteins or polymers with minimal affects to the self-assembling nature 
of the peptide.
1.2.3.2 Self-assembling peptides based on f-H airpins
Another important secondary structure involved in self-assembly is the )9-hairpins, this occurs 
when an amino acid sequence contains turn inducing residues such as proline followed by 
glycine and threonine.*^  ^ Proline (/+7,Figure 28) causes a slight kink in the a-carbon 
backbone and in combination with the subsequent flexible threonine or glycine residues (j+2) 
causes a complete reversal of the direction of the a-carbon backbone. The loop is stabilised 
by hydrogen bonding by the two residues before and after the turn, holding the peptide 
backbone in a tight hairpin.**"*
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Figure 28. Schematic of a p-hairpin structure
This phenomena has been studied extensively by Pochan, Schneider and co-workers, their 
peptide sequence (MAXI), consists of a 20 amino acid long peptide consisting of alternating 
polar lysine and nonpolar valine either side of the turn inducing V ^PT  tetrapeptide. This 
resulted in an amphilic hairpin structure that was able to self-assemble and form a hydrogel. 
The peptide was found to be soluble at pH 7.4 due to electrostatic repulsion between positive 
charged lysine residues and gel by either increasing the pH to 9.0 to neutralise the lysine 
residues^ "^^ ’^ ^^ or at pH 7.0 by increasing the ionic strength o f the solution to 150 mM to 
screen the charges. The groups have also developed a number of other materials of a 
similar motif that undergo the same solution to gel (sol-to-gel) transition in response to 
changes in temperature, ionic strength, light and shear stress these are summarised in Table 3.
Table 3. Responsive hydrogels based on p-hairpin formation
Stimulus System Peptide Sequence Application Reference
pH 9.0 MAXI VKVKVKVKV^PTKVKVKVKV-NHa Biomedical and tissue 
engineering
}^ 4!
Ionic Strength MAXI VKVKVKVKV^PTKVKVKVKV-NHa Tissue engineering 136
(ISOmMNaCl) MAX2 VKVKVKVKV^PTKVKTKVKV-NHa /regeneration 137
MAX4 KVKVKVICVK*^PSKVKVKVKV-NH2 138
MAX5 VKVKVKVKV^PSKVKVKVKV-NHa
(Fast Gelation) MAX8
K15Q
K15T
VKVKVKVKV°PPTKVEVKVKV-NH2
VKVKVKVKV°PPTKVQVKVKV-NH2
VKVKVKVKV*^PPTKVTVKVKV-NH2
139
Heat (-2 5  °C) MAXI VKVKVKVKV°PPTKVKVKVKV-NH2 Stimuli responsive 140
Heat (-4 0  °C) MAX2 VKVKVKVKV^PTKVKTKVKV-NH2 materials
Heat ( -4 0  °C) MAX8 VKVKVKVKV^PTKVEVKVKV-NH2 141
Heat (-6 0  °C) MAX3 VKVKVKTXV^PTKVKTKVKV-NH2
Light MAX? VKVKVKVKV^PTKVKXKVKV-NH2 Tissue engineering. 142
VKVKVKVKV^PTKVKVKVKV-NH2
drug delivery
Shear Stress MAXI Drug delivery 143
MAX8 VKVKVKVKV^PTKVEVKVKV-NHs
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The use of p-hairpins has some very interesting applications in drug delivery the use of the 
MAX8 and MAXI peptides to encapsulate curcumin^ "^ "^  and MGbScells^ "^  ^ showed that the 
hydrogels can shear-thin and flow under a sufficient shear stress but immediately recover 
back into a solid upon removal o f the stress, this is usefiil as it allows the gel to flow during 
injection and then when in the body protect the drug and cells through the formation of a gel 
network in a similar manner to polymer conjugation. This is advantageous as the 
encapsulation was found to have little effect on the bioactivity*'^’^ '^  ^ but acts to shield the 
drug or cells from enzymatic degradation and increases the residence time in the body of the 
patient. yff-Hairpins suffer fi*om one distinctive disadvantage in comparison to a-helices in that 
if chemical bonding is required between the peptide chain and a protein this is limited to the 
C or iV-terminus due to the other residues being involved in the )ff-hairpin. This is a problem 
due to the synthesis of such conjugates suffering fi-om the same non-selective ligation found 
in protein polymer due to a number of amino and carboxyl groups found in the peptide chain.
1.2.3.3 Self-assembling peptides based on short hydrophobic (aromatic) 
peptides
The self-assembly of short hydrophobic peptides was first discovered in early experiments by 
Gazit et al. during studies of the aromatic dipeptide, diphenylalanine that was known to be 
present in a Alzheimer’s p-amyloid peptide sequence. these  peptides self-assembled as a 
result of a combination of hydrogen bonding and tt- il interactions of the phenyl rings. it 
was hypothesised at the time that this may have been a consequence o f interaction between 
the N- and C-termini, however, application of a tert-hutyX group resulting in self-assembly of 
an extremely stable spherical structure. The formation of a stable hydrogel is also observed 
under protection of the A-terminus with fluorenylmethoxycarbonyl (Fmoc), naphthalene and 
carbobenzyloxy. *
Ulijn et and Xu et extended the work by studying a small library o f dipeptides
made up of combinations of the amino acids: serine, threonine, glycine, alanine, leucine and 
phenylalanine protected with an Fmoc group. The gelation was found to be dependent on the 
amino acid sequence with no gelation found for Fmoc-GF^ "^  ^and Fmoc-GT.* '^  ^Ulijn and co­
workers continued this work in the study of the dipeptide Fmoc-FF, this peptide was found to 
self-assemble as a cylindrical structure as a result of the structure being composed o f anti­
parallel p-sheets where the Fmoc groups acted as zippers in bringing the neighbouring sheets
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together.^^^  Further experiments by the group showed that at high pH, a weak gel formed due 
to an entangled network of flexible fibrils being present, while at intermediate pH non-gelling 
flat rigid ribbons form.^ ^^
The group also reported a similar structure for Fmoc-LLL, albeit with a larger diameter. 
The exact design rules are still being investigated, however experiments have been carried 
out to establish this.*^ "^ ^^  ^Applications of short aromatic peptides have included peptides that 
are responsive to enzyme catalysed in a gel-to-sol transitions for use in liquid crystal 
displays^^  ^and sol-to gel transition for sel f -assembly.The clear advantage of this type of 
self-assembling peptide is the simplicity at which it can be synthesised in large amounts 
through solid phase peptide synthesis. However, the addition of a protein directly or other 
residues that could facilitate conjugation, could cause the short peptide sequence to assemble 
weakly or not at all. This means that applications would be limited.
1.2.3.4 Self-assembling peptides based on p S h e e t
Another important secondary structure used for responsive hydrogels are P-sheets. The 
sidechains of alternative residues are positioned on opposite sides of p-sheet to allow for 
facial discrimination and construction of higher order structure. Commonly the residues may 
consist o f alternating cationic , hydrophobic and anionic amino acid residues, for example: 
arginine-alanine-aspartic acid (RAD), phenylalanine-glutamic acid-lysine (FEK) or glutamic 
acid-alanine-lysine (EAK).'^^
EAK16 was the first ionic complementary peptide that was studied by Zhang and co- 
workers,^ ^® the peptide was found to assemble into p-sheets and membrane like structures 
when salt was added. Further experiments by Hong et al. on the EAK16 sequence also 
showed that it displayed sensitivity to pH,^ *^ ionic strength^ ^^  and displayed different 
morphologies under different conditions.
The related FEK 16 has also been shown to exhibit this behaviour under the influence of ions 
and infrared light. A related octapeptide synthesised from phenylalanine (F), lysine (K) and 
glutamic acid (F) in the sequence FEFEFKFK was also found to adopt a p-sheet confirmation 
in solution, which can be seen in Figure 29.
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-  4 tun
J1 3Figure 29. Schematic representation of four FEFEFKFK peptides in an anti-parallel p-sheet
The self-assembly in this case is driven by strong hydrogen bonding interactions along the 
fibre axes. These interactions are highly directional and link each peptide in the p-sheet to the
two next to it, to form a significantly stable structure. 113
Saiani et al. demonstrated that modification of the FEFEFKFK via free-radical 
polymerisation with /V-isopropylacrylamide (NIPAAm) resulted in a conjugate that had two 
phase transitions: one at -30  °C due to PNIPAAm lower critical solution temperature (LCST) 
and another at -75 °C due to the peptide mel t ing, thi s  can be visualised in Figure 30.
 Temp > -  75°C_________________
Time, RT Temp.
< -  30 C <
Figure 30. PNIPAAm-FEFEFKFK conjugate behaviour during a heat-cool cycle^ ^^
Further experiments by the same group showed that by using the same methodology and 
varying the ratio of peptide initiator and monomer it is possible to shift the LCST of the
conjugate. Ill
Self-assembling materials based on p-sheets are useful as a result of this sensitivity to pH, 
ionic strength and temperature making them suitable for drug delivery, wound healing and 
tissue engineering. The presence of exposed groups in the peptide chain that are not involved 
in self-assembly also make it simple for covalent attachment of polymer and protein albeit in 
a non-site-specific manner. Attachment at C or A-terminus should also present little problem 
due the multiple charges in the peptide chain being the dominant effect. At present there have 
been no reports of hydrogel-polymer conjugates produced using the FEFEFKFK peptide 
sequence via controlled radical polymerisation so this would need to be established.
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1.2.4 Proposal for functional materials through bioconjugation with 
Sortase A
1.2.4.1 Design o f  site-speciflcally modified proteins
To synthesise a site-specifically modified protein it was decided to concentrate the research 
on enzymatic rather than chemical modification of the protein. Sortase A was chosen as the 
enzyme of choice, as it was easy to express and isolate in large yields and would modify the 
protein site selectively at the C-terminus due to a rigorously defined recognition sequence 
with minimal effect on the protein structure as had been demonstrated previously.^^ 
Conjugation can also be achieved in a quantitative manner under mild conditions to yield 
site-specifically modified proteins.
Enhanced green fluorescent protein (eGFP) was chosen to be evaluated as a model protein as 
it had been used in the synthesis of a number of protein-polymer conjugates previously. 
50,55,56,167 proteiu is good for demonstrating the principle of enzymatic ligation due to 
simple characterisation o f the natural fluorescence of the protein making it easy to establish if  
the protein is being denatured following conjugation. Another advantage o f using eGFP is 
that it can be expressed in high yields fi-om E. Coll
L 2,4 ,l.l Rational design o f initiator fo r conjugation
To facilitate polymer growth in the grafi-fi-om and graft-to approaches, three components are 
required for a successful initiator (Figure 31). The first (6 6 ) is the incorporation di-glycine for 
recognition by the Sortase A. The second (67) is a short linker to join the di-glycine to the 
initiator (6 8 ).
^  O O
o Br
(6 6 ) (67) (6 8 )
Figure 31. Requirements for peptide initiator: diglycine (6 6 ), short linker (67), initiator (6 8 )
The use o f diglycine in the initiator presents problems in the first instance as once activated 
both the amino group and the carboxyl group are reactive with each other and oligomerisation 
could result. It is therefore necessary to have some form of protection for either the amino or 
carboxy group and as the requirement for Sortase A is a free A-terminus it makes it necessary
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to build the initiator from the carboxyl end group. Most commonly the acid labile tert- 
butyloxycarbonyl (Boc) (69) or the base labile 9-fluorenylmethyloxycarbony (Fmoc) (70) are 
utilised in this role (Figure 32).^ ^^
g  R
(69) (70)
Figure 32. Common protecting groups for the protection of the iV-terminus of amino groups.
To facilitate the introduction of an initiator a bifunctional linker is required. Two functional 
groups are generally used for this, these are the hydroxyl group to form an ester bond,^ ’^^ ®^’^ ^^ 
and the amino group to form an amide The amide bond is the most
common method of linking due to the greater stability and bond order in comparison to the 
ester bond.
The introduction of the initiator can be achieved using either an acid halide or an activated 
carboxylic acid to facilitate amide bond formation. The final initiator is then suitable for use 
as an ATRP initiator for polymerisation and for encompassing into the protein using sortase 
A. By developing a system using this framework, it is also possible to introduce other 
functional groups that would be suitable for further modification of the polymer chain, a 
suitable example would be a methacryloyl group (71) (Figure 33) leading to a monomer 
containing system for a graft-through approach.
O
R
(71)
Figure 33. Methacryloyl group for graft-through approach
1.2.4.2 Choice o f  monomer
The choice of monomer for conjugation largely depends on the final application of the 
product. For instance, in biosensors or fuel cells, stability is by far the most significant 
consideration.*^ "^  Whereas in nanotherapeutics, biocompatibility, responsiveness and 
hydrophilicity are far more important.
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Monomers that have proven popular for the conjugation to proteins include: 2-hydroxyethyl 
methacrylate (HEMA) (72), A-(2-hydroxypropyl) methacrylamide (HPMA) (73), 
poly(ethylene glycol) methacrylate (PEGMA) (74), oligo(ethylene glycol) methyl ether 
methacrylate (OEGMA) (75), dimethylaminoethyl methacrylate (DMAEMA) (76), and N- 
isopropylacrylamide (NIPAAm) (77).
OH
(73)
O
-C H .
OH
.N,
O'
(74)
O
(76) (77)
Figure 34. Common monomers for protein modification
These monomers have tended to be the focus in the synthesis of a protein-polymer conjugates 
firstly due to the ‘ease’ at which they are polymerised by ATRP, SET-LRP and RAFT,^ ’^ 
and secondly due to their ubiquitous nature in biomedical applications.*^^
Of all of these monomers, the use of oligo(ethylene glycol) methyl ether methacrylate is 
increasing in popularity mostly due to it being analogous to the heavily utilised and “FDA 
approved” linear analogue poly(ethylene glycol).***’*^  It is also hydrophilic and offers similar 
thermoresponsive characteristics, greater biocompatibility and a lower degree of protein 
fouling compared to pNIPAAm.*^  ^The choice of OEGMA is also pertinent for the project as 
it allows the specificity and efficiency of Sortase A to be evaluated in a more complex 
environment compared to those prior studies.^ "*'^ ^
N-Terminus Pendant group
GG
Amino beads Random Coil 
of Linear PEG
Comb-like OEGMA
Figure 35. Schematic showing prior examples of Sortase A mediated ligation to polymers in the 
form of giycidyl methacrylate and polystyrene amino funetionalised beads, linear amino 
functionalised PEG and the proposed ligation to Brush-like OEGMA
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Conjugation by Sortase A of GFP onto amino functionalised beads presents a hard surface 
that is relatively free of interference meaning that access for the Sortase A ligation should be 
simpler/ '^^  ^ Linear amino-functionalised poly(ethylene glycol) (PEG) is slightly more 
difficult to conjugate to, due to the flexible nature of the PEG chain causing steric 
hindrance/^ Grafting-to/through to the comb-like oligo(ethylene glycol) methyl ether 
methacrylate presents a far greater challenge, the area around the conjugation site is 
significantly more sterically hindered and bulkier than the 5 kDa PEG used in the experiment 
by Boder and co-workers/^ Although difficult it has proven possible using other enzymes to 
conjugate eGFP to pOEGMA/**’*^  ^ The use of pOEGMA will really test the boundaries of 
conjugation for Sortase A and to this author’s best knowledge it has not been attempted using 
significantly sterically hindered pendant groups in the graft-through methodology making this 
the perfect opportunity for it to be evaluated.
The conjugation reaction between self-assembling peptide GGFEFEFKFKK and Tus will 
demonstrate how site-specific ligation using Sortase A is, this is due to the peptide having 4 
free amino groups and 3 free carboxylic acid groups that could be involved in conjugation. If 
Sortase A did not recognise the two A-terminal diglycine, a conjugate would result that not 
only contained a peptide that was modified randomly at a number of different sites by the 
protein but also a peptide that would not assemble properly due to poor intermolecular 
interactions between the different peptide chains that are vital for self-assembly. If the 
peptide does, however, self-assemble this would demonstrate that the peptide had been 
modified at a single point of attachment and feat that would be difficult by chemically 
modifying via an amino, thiol, or carboxyl group due to the large number present in the 
peptide.
Unlike eGFP, Tus is functional, so modifying the peptide with the protein will not only allow 
the site-specificity o f the peptide ligation to be established but also the effect of modifying a 
functional protein with a peptide to be interrogated. This can be achieved by monitoring the 
Tus binding activity for ter DNA in the ligated and unligated state, if there is no significant 
difference between the activités of the two states this would demonstrates the effect of 
Sortase A ligation is minimal on the protein activity. Performing conjugation on hydrogels 
will also act to test the universality of Sortase A conjugation on a variety o f materials.
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2 Results and Discussion
2.1 Peptide synthesis
Within this study, the synthesis of novel peptides has been divided into two forms: solution 
peptide synthesis (SPS) and solid phase peptide synthesis, (SPPS). Solution peptide synthesis 
allows for large amounts of peptides to be produced at one time, however this method can be 
cumbersome and time consuming as it requires numerous isolation, purification and 
characterisation steps following each stage of the synthesis, including protection and 
deprotectection steps. Despite this, solution peptide synthesis still holds importance in the 
synthesis of peptides on an industrial scale. On a laboratory scale the synthesis of peptides 
has largely migrated to synthesis on insoluble solid support following the first use of the 
technique by Bruce Merrifield in 1963.*^  ^This is largely due to isolation consisting of simple 
washing of the support, with purification and characterisation remaining largely unnecessary 
until the very end as the growing peptide chain remains firmly attached to the support. 
Merrifield resin is a copolymer of styrene and chloromethylstyrene crosslinked with 1-2% 
divinylbenzene and is commonly used in the synthesis of Boc-protected peptides. The 
problem with Merrifield resin is that it requires hydrofluoric acid (HF) to liberate the final 
product. This has been addressed through the use of Wang (p-benzyloxybenzyl alcohol resin) 
and Fmoc-protected peptide synthesis whereby the product is cleaved using the milder 
trifiuoroacetic acid (TFA).
2.1.1 Solution peptide synthesis of peptide initiators
2.1.1.1 Solution peptide synthesis o f  peptide initiator (80) using Fmoc- 
diglycine
Initially, synthesis of peptides using solution peptide synthesis was chosen for this study as 
the reaction would be higher yielding and produce the product most efficiently for the short 
type of peptide required in this work. The most commonly available starting materials were 
diglycine (6 6 ), an A-Boc-ethylenediamine (78) and bromo-isobutyrl bromide (79) (Figure
" ' ' V
o
(6 6 ) (78) (79)
Figure 36. Commonly available starting materials for the solution phase synthesis of peptide 
initiator
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The chosen synthesis route to the final product involved protection of the diglycine with an 
Fmoc-protecting group that was orthogonal to the Boc group protecting the iV-Boc- 
ethylenediamine. The Boc group would then be removed using 4M HCl in dioxane before a 
nucleophilic acylation with the acid bromide to synthesise the final product (83).
70%
(80)(66)
33%(iii)
79%
NH;
(IV)
(82) (81)
59%
H 9  H 9
o o *
(83)
Figure 37. Synthetic route of peptide initiator (83)
Reaction Conditions: (i) Fmoc-OSu, NaHCOs, 21h, (ii) iV-Boc-ethylenediamine, 1-Hydroxybenzo 
triazole, DIC, 0°C for 30 min, rt for 12h, (iii) 4M HCl in dioxane, 40 min, (iv) 2-bromoisobntyl 
bromide, TEA, 16h
The Fmoc protecting group was introduced using iV-a-(9H-fluoren-2-ylmethoxycarbonyl 
oxy)-succinimide utilising a modified procedure according to what was reported by Madder 
et with Fmoc-diglycine (80) successfiilly obtained as a clean white solid in a 70% 
yield.
The product identity was confirmed through characterisation by MS and NMR, consistent 
with previously reported data.^ ^^  The ESI-MS gave the expected molecular ion at 377 m/z. 
The ^H-NMR showed the incorporation of the aromatic fluorenyl hydrogens present as two 
doublets and two triplets with integrals of 2H at 7.88 (H-b) and 7.72 ppm (H-e) and 7.41 (H-
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c) and 7.33 ppm (H-d) respectively. This was further confirmed through the new carbamate 
signal in the ^^C-NMR at 156.4 ppm (C-i).
Our chosen linker between diglycine and the initiating moiety was introduced as JV-Boc- 
ethylenediamine (78) on to Fmoc-diglycine (80) through amide bond formation via 
DIC/HOBt mediated activation using a modified procedure as reported by Zelder and co­
workers.
NMR and MS of the crude product, showed that the reaction proceeded to completion, 
however product purification by liquid chromatography only afforded the product as an 
impure brown solid (81) in a 30% purity due to the presence of A^#-diisopropylurea. The 
ESI-MS gave the expected molecular ion at 519 m/z. The ^H-NMR showed the incorporation 
of the ethylenediamine demonstrated by four peaks corresponding to methylene groups at 
3.96 (H-k), 3.90 (H-n), 3.36 (H-q) and 3.37 ppm (H-r) in environments adjacent to an amide 
bond and carbamates, two shifted from the original resonances in the Fmoc-diglycine and two 
due the incorporation of the ethylenediamine. Lack of pure material following extensive 
purification using liquid chromatography meant that there was not a sufficient quantity of  
material to produce a carbon spectrum, so it was decided to combine the fi*actions with the 
least impurities and separate the product at the next step.
The Boc-protecting group was successfully removed by HCl (4M in dioxane) in a 79% yield 
of pure product (82). The ESI-MS gave the expected molecular ion at 397 m/z. The ^H-NMR 
showed the successful removal of the Boc-group due to loss o f the tert-h\i\y\ signal at 1.41 
(H-v in A5) ppm and a shift upfield of a CH2 signal fi-om 3.36 ppm to 3.68 ppm (H-n).
The initiating 2-bromoisobutyryl group was finally introduced via the corresponding acid 
bromide (79) in a poor yield, with the product isolated as a tan coloured solid in a yield o f  
59% (83). The ESI-MS gave the expected molecular ion at 567 and 569 m/z. The ^H-NMR 
showed the incorporation of the bromo-isobutyryl group due to the presence o f an additional 
signal at 1.92 ppm (H-r) corresponding to 6  protons. The shift in the signal fiom 3.03 ppm to 
3.39 ppm (H-o) also corresponds to the formation of an amide bond from an amino group.
The low yield and poor solubility of the final Fmoc-diglycine peptide initiator (83), as well as 
some of the intermediates, made it difficult to purify them and obtain them in a high enough 
yield quantities for subsequent reactions. Therefore, it was decided to attempt another 
synthetic route involving the more soluble Boc-diglycine as a starting material
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2 A A 2  Solution peptide synthesis o f  peptide initiator (87) using N-Boc- 
diglycine
iV-Boc protected peptides are known to be more soluble than Fmoc-analogues/^ However, 
the use of Boc-diglycine (84) presented its own problems compared to the synthesis of Fmoc- 
protected peptide initiator (83). We had access to 7V-Boc-ethylene diamine (78) as a building 
block because of the high cost of iV-Fmoc-ethylenediamine or otherwise protected linkers. 
Therefore, in this case, rather than rely on the use of orthogonal protecting groups for the 
sequential synthesis of diglycine-initiator, it was decided to synthesise it in a convergent 
manner as shown in Figure 38.
(IV, V, Vi)
> r ° Y
' O
NH,
(ii)
87%
(78)
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Figure 38. Synthetic route of peptide initiator (87)
Reaction Conditions: (i) BocgO, TEA, 16h, (ii) 2-bromoisobutyl bromide, DIPEA, 0°C for Ih, rt 
for 18h, (iii) 4M HCl in dioxane, Ih, (iv) PyBOP, TEA, 22h, (v) HOBt, DCC, TEA 24h, (vi) 
HOBt, DIPEA, EDC.HC1,24h
The W-Boc protecting group was introduced using di-rerf-butyl dicarbonate in a procedure 
that was reported by Kratz, et with Boc-diglycine (84) successfully obtained as a clean 
white solid in a 46% yield
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The product identity was confirmed through characterisation by MS, FTIR and NMR, 
consistent with previously reported data/^  ^ The ESI-MS gave the expected molecular ion at 
232 m/z. The ^H-NMR showed a resonance at 1.38 ppm (H-a) due to the successfiil 
incorporation of the fer/-butyl protecting group and was Anther confirmed through the new 
carbamate signal in the ^^C-NMR at 155.7 ppm (C-c) and the C=0 signal o f the carbamate at 
1690 cm'^  in the FTIR.
The initiating 2-bromoisobutyryl group was then introduced via the corresponding acid 
bromide to the second half o f the initiator assembly and was produced as an off-white solid in 
a high yield o f 87% (85).
The product identity was confirmed through characterisation by MS, FTIR and NMR, 
consistent with previously reported data.^ "^^  The ESI-MS gave the expected molecular ions 
with equal intensity at 331 and 333 m/z indicative of the presence of bromine. The ^H-NMR 
showed a methyl singlet at 1.95 ppm (H-j) due to successful incorporation o f the 
bromoisobutyryl group and the overlap of the quartets at 3.38 ppm (H-e+^ as a result o f the 
two CH2 protons now occurring in similar environments. This was Anther conArmed through 
the new amide signal in the ^^C-NMR at 172.7 ppm (C-h) and the C=0 signal o f the amide at 
1643 cm'^  in the FTIR.
The Boc-protecting group was removed by electrophilic protonation o f the carbonyl in the 
carbamate using 4M HCl. The reaction was successful and the product was isolated as an off 
white solid with quantitative yields of 99% (8 6 ).
The product identity was conArmed through characterisation by MS, FTIR and NMR, 
consistent with data that was previously reported. The ^H-NMR showed the successful 
removal of the Boc group due to the loss of the proton resonance at 1.45 ppm (H-a in A 15) 
and two CH2 signals at 3.51 (H-d) and 3.09 ppm (H-e) due to the CH2 groups again occurring 
in different environments. This was further conArmed through the loss of the carbamate 
signal in the ^^C-NMR at 156.8 ppm (C-c in A 16) and at 1691 cm'^  in the FTIR
Numerous attempts were made to synthesise peptide initiator (87) in sufficient yield for use 
in polymerisation, the Arst attempt (87a) was made using a (benzotriazol-l-yl)- 
oxytripyrrolidino phosphonium hexaAuorophosphate (PyBOP) mediated coupling of peptide 
intermediates (84) and (8 6 ). The ^H-NMR resonance at 3.40 ppm (H-g+h) showed the 
successAil coupling of peptide intermediates (84) and (8 6 ) due to the ethylenediamine CH2
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signals overlapping as a result of the protons occurring in similar environments after 
coupling. This was confirmed by a resonance at 9.51 ppm (H-f+i) due to an overlapping 
broad singlet caused by the two NH groups on the ethylenediamine.
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Figure 39. H NMR spectrum of peptide initiator (87a) crude product
The persistence of the DMF in the sample presented a problem in isolation as it increased the 
polarity of the sample when it was diluted in DCM. The TLC of the product indicated that the 
product should separate, however column chromatography did not prove to be as efficient 
and the product was co-eluted with PyBOP and triethylammonium chloride. This is evident 
from the proton NMR where resonances can be found at 7.97-7.18 ppm, 3.14 ppm and 1.78 
ppm for PyBOP (shown in red in Figure 39) and 3.23-3.18 ppm and 1.78-1.76 ppm for 
triethylammonium chloride (shown in green in Figure 39). Purity estimates fi-om the ^H- 
NMR suggests the sample contains approximately 49% PyBOP and 29% TEACl as by­
products and 22% peptide initiator (87a).
Following the unsuccessful purification of (87a), fi-om the PyBOP conjugation in which 
PyBOP and its by-products became a main contaminant, it was decided to synthesise (87b) 
using A)#-dicyclohexylcarbodiimide (DCC) and hydroxybenzotriazole (HOBt) instead. 
The advantage of DCC is that it forms an insoluble urea (DCU) following the reaction which 
can be filtered off prior to chromatographic purification.
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The ^H-NMR resonance at 3.45 ppm (H-d+e) showed the successfiil coupling of peptide 
intermediates (84) and (8 6 ) due to the ethylenediamine CH2 signals overlapping as they 
exhibited in similar environments after coupling. This was confirmed by the integration of the 
methyl singlets at 1.89 (H-a) and 1.41 ppm (H-f) which correspond to the methyl group in the 
bromo-isobutyryl group and Boc group respectively.
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Figure 40. H NMR spectrum of peptide initiator (87b) crude product
The amide bond formation was successful and the product was synthesised as a purer product 
than that through PyBOP coupling with lower amounts of the by-products (approximately 
20%) present as DCU (shown in red in Figure 40) and HOBt (shown in green in Figure 40) in 
the final product. The yield was, however, low (1.4 %) and it was not viable for further 
analysis or for use as an initiator. To increase the yield it was decided to use a water soluble 
coupling agent as this could be easily removed using extraction due to the poor solubility of  
the di-glycine initiator in water.
Following the unsuccessful purification of peptide initiator (87a) produced by PyBOP 
mediated coupling and the poor yield obtained using DCC and HOBt coupling (87b). It was 
decided to synthesise (87c) using water soluble l-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and HOBt.*^  ^ The advantage of EDC is that it can be removed by 
extraction with water.
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In this case ^H-NMR showed that the amide bond formation by the EDC/HOBt coupling was 
successful, the resonance at 3.43 ppm (H-d+e) is due to the CH2 o f the ethylenediamine 
group now occurring in a similar environment. This was confirmed by the correct integral 
values for methyl singlets at 1.90 (H-a) and 1.39 ppm (H-f) which correspond to the methyl 
groups in the bromo-isobutyryl group and Boc group respectively.
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Figure 41. H NMR spectrum of peptide initiator (87c) crude product
The purity of the product was higher than the PyBOP and DCC/HOBt couplings with only 
traces of cyclohexane (shown in green in Figure 41) and HOBt (red in Figure 41) present in 
the final product (87c).
Yields were low and there was not sufficient yield and purity for fiirther analysis or for use in 
initiating controlled polymerisation. To increase the yield and purity it was decided to use 
solid phase peptide synthesis as the product could be synthesised whilst attached to the resin 
and the by-product removed by simple washing steps before the product is cleaved from the 
resin.
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2.1.2 Solid phase peptide synthesis of diglycine peptide initiator
Since SPPS using conventional Fmoc-chemistry proceeds from C-terminus to 7V-terminus, 
where the resin acts as a C-terminus protecting group, in our case, the synthesis o f a di-Gly- 
initiator on the solid phase required a branching point connecting an available W-terminus di- 
Gly unit. This would have been ready for conjugation using Sortase A, to an ATRP or SET- 
LRP initiator (Figure 42). The most widely available amino acid to achieve this would be 
lysine (Figure 42).
Functionalised to 
introduce initiator
Di-glycine
reactive
\
R-i
R
(88)
Figure 42. Resin functionalised with suitable groups to react di-glycine (8 8 ) and introduce 
initiator on solid phase and lysine-functionalised Wang resin (89).
For the incorporation of di-Gly and initiating moiety from Lys, an orthogonal protection of  
the a  and a NH2 groups was required, therefore, A-a-Fmoc-iV-E-4-methoxytrityl-L-lysine was 
chosen as the corresponding building block. The di-glycine could then be attached using 
following removal of the Fmoc group with base and the initiating moiety could be attached 
following removal of the Mmt group with acid.
The synthetic route for the peptide is shown in Figure 43.
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Figure 43. Synthetic route of the peptide initiators (95) and (97) on Wang Resin,
Reaction Conditions: (i) DIC, DMAP, DIPEA, (ii) a) 20% piperidine b) Fmoc-gly-OH, TBTU, 
DIPEA (iii) a) 20% piperidine b) Fmoc-gly-OH, TBTU, DIPEA (iv) a) 3% TFA in DCM b) 2- 
bromoisobutyric acid, TBTU, DIPEA, (v) 95% TEA, 2.5% TIS, 2.5% H2O, (vi) 20% piperidine, 
(vii) 95% TFA, 2,5% TIS, 2.5% H^O.
A tripeptide backbone (glycine-glycine-lysine) was assembled on Wang resin using 
conventional Fmoc-chemistry. The side chain of the lysine was then modified whilst the 
peptide was still attached to the solid phase using 3% TFA to remove the Mmt group 
followed by a coupling with bromo-isobutyric acid. Following modification of the s amino 
group of the lysine, the route diverged to synthesise both the protected derivative peptide 
initiator (95) and the deprotected peptide initiator (97) (Figure 43). The modification of the 
lysine side chain used bromo-isobutyric acid, ’^  ^ rather than the more reactive acid bromide 
derivative as previous studies had shown that the bromide eliminated following either 
deprotection or cleavage to yield the corresponding di-gly-peptide monomer (98) (Figure 44).
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Figure 44. Corresponding di-gly-peptide monomer (98)
After the deprotection step, vivid purple solutions were observed for the Kaiser test on a 
sample o f the resin and red/orange beads were observed for the TNBS test. Following 
coupling o f the Fmoc-lysine(Mmt)-OH an unexpected dilute purple colour was observed for 
Kaiser test, this has been noted before in the literature. The false positive is caused by the 
removal of the Mmt protecting group on the side o f the lysine by ninhydrin to yield a primary 
amine that then subsequently reacted with ninhydrin to give the purple colouration. 
Following omission of phenol from the test this was no longer the case and the expected 
orange/brown colour resulted. The success o f each subsequent coupling o f amino acid and 
removal o f protecting group was then confirmed using the modified Kaiser (Section 4.3.2.11) 
and TNBS (Section 4.3.2.12) tests.
Removal of the Mmt protecting group from the resin (93) was required to attach bromo- 
isobutyric acid. The removal o f the protecting group was initially accomplished using 1% 
trifiuoroacetic acid to cleave the bond between the Mmt group and the amine of lysine and 
5% triisopropylsilane as a scavenger to remove the resulting Mmt cations. However, it was 
found that during the treatment of a sample o f resin (93) with concentrated TFA (Section 
4.3.2.13) a yellow colouration (470 nm) still evolved indicating that the Mmt group was still 
attached to the resin (due to incomplete deprotection of (93))^ ^^  even after the addition o f 1 0 0  
ml of 1 % TFA solution. Therefore, a 3% solution of TFA (DCM) was used instead. 
Following only three treatments with the more concentrated solution, total removal o f the 
Mmt group was confirmed.
The deprotection of lysine was confirmed using the Kaiser and TNBS tests, which yielded a 
vivid purple colour and orange beads respectively. The addition of the initiator was then 
accomplished using 2-bromoisobutyric acid mediated by TBTU and DIPEA. This proved 
successful following 3 couplings as confirmed by the Kaiser and TNBS tests. The resin was 
separated into two portions, one half was used to synthesise (97), the other half was cleaved
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using 95% TFA, 2.5% triisopropylsilane and 2.5% water to yield peptide initiator (95) 
following precipitation in diethyl ether and lyophilisation from water as a white powder 
peptide in 59% yield.
The product identity was confirmed through characterisation by MS and FTIR. The ESI-MS 
gave the expected molecular ions with equal intensity at 631 and 633 m/z indicative of the 
presence of bromine. The presence of the product was further confirmed through the broad 
C=0 band 1644 cm'^  in the FTIR due to the presence of a number of amide bonds.
Unlike bromo-isobutyryl bromide, the use of bromo-isobutyric acid did not lead to the 
elimination of the bromide observed for the former. Since both the deprotection step and the 
cleavage from the resin were performed in the same way in each case, it was concluded that 
the elimination of bromine must therefore proceed during the amide-coupling from the s- 
amino group which involves coupling with 2-bromoisobutyryl bromide using TEA as a base.
Unfortunately, following solubility testing in a number of solvents for NMR, no appropriate 
solvent was found to dissolve the peptide. The peptide was sparingly soluble in DMSO, even 
under heating to 80 °C and sonication, resulting in the ^H-NMR spectrum being too poorly 
resolved. Online simulation of the peptide properties using a peptide property calculator 
(Innovagen),^^  ^ showed that the peptide would have a -1 charge and an iso-electric point o f 
pH 0. This would result in poor peptide solubility in water^ ®^ as was observed experimentally. 
In addition, given the high Gly content of the overall molecule, leading to an analogous 
behaviour to nylons, extensive intermolecular hydrogen bonding can explain the lack of 
solubility in organic solvents too. This poor solubility would also be a major hindrance for its 
use as a di-gly initiator.
The synthesis of peptide initiator (97) followed the same route as peptide initiator (95) but 
diverged prior to the cleavage step. In this case, the peptide initiator (97), an Fmoc-protected 
peptide was cleaved from the resin whereas for the peptide initiator (95) the Fmoc-protecting 
group was removed prior to cleavage. The successfiil removal of the Fmoc-group was 
confirmed by a purple colouration from the Kaiser test and orange beads from the TNBS test.
Cleavage of the peptide followed the same method used for the cleavage o f (95) and 
following precipitation in diethyl ether and lyophilisation from water, an off white solid was 
produced in 39% yield based on theoretical loading of Fmoc-lysine on the resin (90).
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The product identity was confirmed through characterisation by MS. The ESI-MS gave the 
expected molecular ions with equal intensity at 409 and 411 m/z indicative of the presence of 
bromine. As with peptide initiator (95), the peptide was sparingly soluble in DMSO, even 
under heating to 80 °C and sonication, which again prevented analysis by NMR. Online 
simulation of the peptide properties using peptide property calculator (Innovagen),^^  ^showed 
that the peptide would be neutral and have an iso-electric point of pH 4.85. This would result 
in poor peptide solubility in water^ ®^ as was observed experimentally. In addition, the high 
Gly content would again lead to extensive intermolecular hydrogen bonding explaining the 
lack of solubility in organic solvents too. This would again be a major hindrance for its use 
as a di-gly initiator.
Owing to the poor solubility o f our target di-gly-initiator it was decided to add additional 
amino acid residues to increase their solubility. There are 9 natural amino acids that are 
hydrophilic, the simplest are Ser, (99) Lys (100) and Glu (101) (Figure 45).
O
OH
O" OH
OH
(99)
Figure 45. Commonly available hydrophilic amino acid residues of serine (99), lysine (100) and 
glutamic acid (1 0 1 )
In the first instance, Ser was chosen being the cheapest alternative. To further increase 
solubility two residues were introduced as solubility of peptide is significantly increased if 
the peptide is made up of greater than 25% of hydrophilic res id u es.T h e  synthesis o f the 
Ser-containing di-gly-initiator can be seen in Figure 46.
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Figure 46. Synthetic route of peptide initiators (109) and (111) on Wang Resin,
Reaction Conditions: (i) DIC, DMAP, DIPEA, (ii) a) 20% piperidine b) Fmoc-Ser(OtBu)-OH, 
TBTU, DIPEA (iii) a) 20% piperidine, b) Fmoc-Lys(Mmt)-OH, TBTU, DIPEA, (iv) a) 20% 
piperidine b) Fmoc-gly-OH, TBTU, DIPEA, (v) a) 20% piperidine b) Fmoc-gly-OH, TBTU, 
DIPEA (vi) a) 3% TFA in DCM b) 2-bromoisobutyric acid, TBTU, DIPEA, (vii) 95% TFA, 
2.5% TIS, 2.5% H2O, (viii) 20% piperidine, (ix) 95% TFA, 2.5% TIS, 2.5% H2O.
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The synthetic route followed the same method as used for peptide initiator (95) and (97) and 
the success of each cycle was determined by the Kaiser and the TNBS tests as before. The 
route utilised the same successful method that had been used previously for modification of  
the lysine in peptide initiator (93). Following isolation in diethyl ether and lyophilisation 
from water a white solid was isolated with a yield of 9% calculated based on the theoretical 
resin loading. The yield was low compared to peptide initiator (95) and (97) and this, coupled 
with poor solubility, meant that NMR analysis could not be performed.
The product identity of peptide initiator (109) was partially confirmed through 
characterisation by MS and FTIR. The ESI-MS gave the expected molecular ions with equal 
intensity at 805 and 807 m/z indicative o f the presence of bromine. This was further 
confirmed through the broad C=0 band 1633 cm'^  in the FTIR due to the presence of a 
number of amide bonds and the incorporation o f a bromide group can be confirmed by the C- 
Br stretch at 623 cm'\
Peptide initiator (111) was synthesised from the same batch as peptide initiator (109) but 
prior to the final step the Fmoc group was removed from the peptide prior to cleavage. The 
successfiil removal of the Fmoc group was confirmed by a purple colouration from the Kaiser 
test and orange beads from the TNBS test.
Following cleavage of peptide initiator (111) and following precipitation in diethyl ether and 
lyophilisation from water, an off white solid was produced in 29.5% yield calculated based 
on theoretical loading of the resin. In addition, compared to Fmoc-protected peptide initiator 
(109), the solubility of peptide initiator (111) was also higher in methanol, acetonitrile and 
DMSO and would dissolve in water following heating under sonication.
The product identity was confirmed through characterisation by NMR, MS and FTIR. The 
ESI-MS gave the expected molecular ions with equal intensity at 583 and 585 m/z indicative 
of the presence of bromine. The *H-NMR showed a resonance at 1.85 ppm (H-1) due to the 
successful incorporation of the bromo-isobutyryl group and a downfield triplet at 3.17 ppm 
(H-i) that corresponds to the CH2 next to the E-amide bond present in lysine. This was further 
confirmed through carbonyl signals in the ^^C-NMR at 174.5 (C-s), 174.2 (C-m), 173.1 (C-p), 
171.4 (C-b), 171.1 (C-d) and 167.7 ppm (C-j) with the most upfield at 167.7 ppm (C-j) being 
a result o f the carbonyl o f the bromo-isobutyryl group and in the FTIR through a broad C=0 
amide band at 1633 cm'^  and a C-Br stretch at 623 cm'\
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The low solubility of the peptide in water was still a limiting factor at least for use in 
conjugation to eGFP protein. It was therefore decided to make the peptide more soluble 
through the use of glutamic acid residues in the peptide. It was also decided at this stage that, 
due to poor solubility o f the peptides containing the 7V-terminus Fmoc group, peptides would 
subsequently be deprotected on the resin prior to cleavage.
Solubility calculations of amino acid sequences (Innovagen) showed that introducing a single 
glutamic acid residue would result in good solubility in water. The glutamic acid would 
result in the peptide having a -1 charge and an isoelectric point of pH 3.3. The -I charged 
state at pH 7.5 also allow for good solubility in Sortase A buffer (pH = 7.5). The chosen 
synthetic route followed the same method as used for peptide initiator (1 1 1 ) except for the 
final step where the Mmt group was removed and the synthesis route would diverge to 
synthesise a suitable peptide initiator (112) for ATRP and a peptide monomer (113) for 
polymerisation and conjugation (Figure 47 and Figure 48).
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Figure 47. Peptide initiator (112) and peptide monomer (113)
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Figure 48. Synthetic route of peptide initiator (112) and peptide monomer (113) on Wang resin
Reaction Conditions: (i) DIC, DMAP, DIPEA, (ii) a) 20% piperidine b) Fmoc-Lys(Mmt)-OH, 
TBTU, DIPEA (iii) a) 20% piperidine b) Fmoc-GIy-OH, TBTU, DIPEA (iv) a) 20% piperidine, 
b) Fmoc-GIy-OH, TBTU, DIPEA, (v) a) 3% TFA in DCM b) 2-bromoisobntyric acid, TBTU, 
DIPEA, (vi) a) 3% TFA in DCM b) methacryloyl chloride, DIPEA, (viii) 95% TFA, 2.5% TIS, 
2.5% H2O.
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As before, the bromo-isobutyryl amide group was successfully introduced using a TBTU 
mediated coupling with bromo-isobutyric acid. The success of the coupling was monitored 
with the Kaiser and TNBS test. Following cleavage, precipitation into diethyl ether and 
lyophilisation from water of peptide initiator (112), an off white solid was produced in 73% 
yield based on theoretical loading of the resin.
The product identity of peptide initiator (112) was confirmed through characterisation by 
NMR, MS and FTIR. The ESI-MS gave the expected molecular ions with equal intensity at 
538 and 540 m/z indicative o f the presence of bromine. The ^H-NMR showed a resonance at 
1.85 ppm (H-p) due to the successful incorporation of the bromo-isobutyryl group and a 
downfield triplet at 3.06 ppm (H-1) that corresponds to the CH2 next to the E-amide bond 
present in lysine. This was further confirmed through carbonyl signals in the ^^C-NMR at 
174.3 (C-w), 173.1 (C-v), 170.9 (C-f), 170.4 (C-q), 168.2 (C-c), 167.3 ppm (C-n) with the 
most upfield at 167.3 ppm (C-n) being a result of the carbonyl of the bromo-isobutyryl group 
and in the FTIR through a broad C=0 amide band at 1649 cm"^  and a C-Br stretch at 636 cm" 
L The peptide was highly soluble in water at room temperature.
Peptide monomer (113) was synthesised from the same batch used in the synthesis of peptide 
initiator (112), but following removal of the Mmt group from the E-amino group a 
methacrylamide group was introduced using methacryloyl chloride. The success o f the 
coupling was monitored with the Kaiser and TNBS tests. Following cleavage, precipitation 
into diethyl ether and lyophilisation from water o f peptide monomer (113), an off white solid 
was produced in 31.0% yield.
The product identity o f peptide monomer (113) was confirmed through characterisation by 
NMR, MS and FTIR. The ESI-MS gave the expected molecular ions at 526 m/z. The FTIR 
shows that the structure has many amide bonds due to the broadness of the peak at 1650 cm"' 
and incorporation of an alkene group appears to be evident but due to a number of peaks that 
overlap with the carbonyl stretch at 1650 cm'^  this appears to be inconclusive. ’H-NMR 
confirmed that the structure was the expected, showing two doublets at 5.60 (H-mi) and 5.28 
ppm (H-mi) caused by a double bond adjacent to an amide bond. This was further confirmed 
by the NMR where there are six carbonyl groups are present, four present in amide bonds 
at 172.7 (C-d), 170.1 (C-n), 169.6 (C-b) and 166.4 ppm (C-j) and two present at 174.9 (C-s),
173.2 (C-r) as a carboxylic acid group.
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2.1.3 Solid phase peptide synthesis of self-assembling peptides
Self-assembling peptide (131) was synthesised on Wang resin using conventional Fmoc 
chemistry (Figure 49). Following the removal of the Fmoc group from the final phenylalanyl 
residue to leave a free 7V-terminus the resin was divided into portions for fiirther modification. 
The largest portion was deprotected and cleaved from the resin using a combination of 95% 
TFA, 2.5% TIS and 2.5% water.
Following cleavage, precipitation into diethyl ether and lyophilisation from water of self­
assembling peptide (131), an off white solid was produced in a yield of 63.5%. The product’s 
identity was confirmed through characterisation by NMR, MS and FTIR. The ESI-MS gave 
the expected molecular ion at 1249 m/z. The FTIR showed that the structure had a number of 
amide groups due to the broadness of the C=0 band at 1628 cm'L The side chains o f the 
peptide was also confirmed by the presence o f a broad band at 2934 cm"^  due to an OH 
stretch in a carboxylic acid group. There also appeared to be presence of a band at 1660 cm‘  ^
that could also be attributed to this. The presence of aromatic rings is evident due to the 
medium band at 1525 cm'^  caused by ring C=C stretch. This was further confirmed by H^ 
NMR which showed a strong multiplet at 7.21 ppm (H-e+f+g) due to phenyl rings o f the 
peptide. Amide bonds were signified by a number of multiplets from 7.7 to 8.5 ppm (H-i). 
The chemical shifts were consistent with a previous experiment by the Miller group that 
involved the synthesis of a FEFEFKFK peptide derivative."^
To facilitate the synthesis of a polymer from the self-assembling peptide (131) an initiating 
moiety was introduced. This was achieved using a slightly modified method used in section
2.1.2 to incorporate a bromo-isobutyryl group. The methodology involved the incorporation 
of the bromo-isobutyryl group at the A-terminus of the peptide instead of the s-amino group 
of the lysine. (Figure 50)
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Figure 49. Synthesis route of self-assembling peptide (131)
Reaction Conditions: (i) DIC, DMAP, DIPEA, (ii) a) 20% piperidine b) Fmoc-AAn-OH, TBTU, 
DIPEA
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Figure 50. Synthesis scheme of self-assembling peptide initiator (133)
Reaction Conditions: (i)) 2-bromoisobutyric acid, TBTU, DIPEA, (ii) 95% TFA, 2.5% TIS, 2.5% 
H2O
Self-assembling peptide initiator (133) was synthesised from the same batch of resin (130) as 
self-assembling peptide (131), however in this case, prior to cleavage from the resin, the N- 
terminus of the peptide was modified with bromo-isobutyric acid using TBTU/DIPEA.
Following cleavage from the resin, precipitation into diethyl ether and lyophilisation from 
water of self-assembling peptide initiator (133), produced an off white solid in 98% yield 
based on the theoretical loading of the resin.
The product identity was confirmed through characterisation by NMR, MS and FTIR. The 
ESI-MS gave the expected molecular ions with equal intensity at 1397 and 1399 m/z 
indicative of the presence of bromine. The FTIR showed that the structure had a number of
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amide groups due to the broadness of the C=0 band at 1626 cm'l The side chains o f the 
peptide were also confirmed by the presence o f a broad band at 2935 cm'^  due to an OH 
stretch within a carboxylic acid group, the presence of a band at 1660 cm'^  that was also be 
attributed to this. The presence of the bromo-isobutyryl group was confirmed by the C-Br 
stretching band at 697 cm"\ This was further confirmed by NMR which showed the 
disappearance of the multiplet 2H at 8.57 ppm (H-a in A41) due to modification o f the free 
amino group, an increase in the integration of a single proton in the amide bond region of 
multiplets from 7.7 to 8.2 ppm (H-d+1) and an overlapping singlet at 1.75 ppm (H-a) due to 
the incorporation of a bromo-isobutyryl group.
Following the successfiil synthesis for the self-assembling peptide initiator (133) it was 
decided to synthesise a self-assembling peptide monomer (135) that could be used to 
crosslink and graft-through the peptide protein polymer network. This was achieved using a 
slightly modified method to the one used in section 2 .1 .2  to incorporate a methacrylamide 
group. The methodology involved the incorporation of the methacrylamide group at the N- 
terminus of the peptide instead of the s-amino group of the lysine (Figure 51).
Self-assembling peptide monomer (135) was synthesised from the same batch of resin (130) 
as self-assembling peptide (131), however in this case, prior to cleavage from the resin, the 
A-terminus of the peptide was modified with methacryloyl chloride.
Following cleavage from the resin, precipitation into diethyl ether and lyophilisation from 
water. Self-assembling peptide monomer (135) was produced as an off white solid in 79.2% 
yield based on the theoretical loading of the resin.
The product identity was confirmed through characterisation by NMR, MS and FTIR. The 
ESI-MS gave the expected molecular ion at 1317 m/z. The FTIR showed that the structure 
had a number of amide groups due to the broadness of the C=0 band at 1626 cm *. The side 
chains of the peptide were also confirmed by the presence of a broad band at 2935 cm'^  due 
to an OH stretch in a carboxylic acid group, there also appeared to be the presence o f a band 
at 1660 cm'^  that could also be attributed to this. The presence of aromatic rings is also 
evident due to the medium band at 1523 cm'^  caused by C=C stretch.
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Figure 51. Synthesis scheme of self-assembling peptide monomer (135)
Reaction Conditions: (i) methacryloyl chloride, TEA, (ii) 95% TFA, 2.5% TIS, 2.5% H2O
The presence of the alkene group is harder to determine due to nearly all o f the characteristic 
peaks overlapping with the signals of the carbonyl, aromatic and amide groups present in the 
structure. This can, however, be confirmed by NMR which showed the disappearance of  
the multiplet for 2H at 8.57 ppm (H-a in A41) due to modification of the free amino group 
and the introduction of the methacrylamide group present as two IH singlets due to the 
geminal alkene resonances at 5.32 (H-di) and 5.57 ppm (H-di).
To facilitate the coupling to eGFP, an iV-terminus di-gly self-assembling peptide (137) was 
synthesised (Figure 52).
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Figure 52. Synthesis scheme of di-gly self-assembling peptide (137)
Reaction Conditions: (i) a) Fmoc-GlyGly-OH, TBTU, DIPEA, b) 20% piperidine, (ii) 95% TFA, 
2.5% TIS, 2.5% H2O
Di-gly self-assembling peptide (137) was synthesised from the same batch of resin (130) as 
self-assembling peptide (131), however in this case, prior to cleavage from the resin, the N- 
terminus of the peptide was modified with Fmoc-GlyGly-OH using TBTU/DIPEA before the 
Fmoc protecting group was removed with 20% piperidine. Half of the resin was dried for 
cleavage and the other half was used in the synthesis of tetra-gly self-assembling peptide.
Following cleavage from the resin, precipitation into diethyl ether and lyophilisation from 
water, di-gly self-assembling peptide (137), was produced as an off white solid in 44.7% 
yield based on the theoretical loading of the resin.
The product identity of di-gly self-assembling peptide (137) was confirmed through 
characterisation by NMR, MS and FTIR. The ESI-MS gave the expected molecular ion at
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1363 m/z. The FTIR showed that the structure had a number of amide groups due to the 
broadness o f the C=0 band at 1626 cm"\ The side chains o f the peptide were also confirmed 
by the presence of a broad band at 2934 cm'^  due to an OH stretch in the carboxylic acid 
group, the presence of a band at 1669 cm'^  is also a result o f the C=0 stretch o f this group. 
Aromatic rings are also evident due to the medium band at 1523 cm"^  caused by C=C 
bending. The NMR spectrum fiirther confirmed the presence of the multiplet (2H) at 8.57 
ppm (H-a) caused by the presence of a free amino group, there was also an increase in the 
integration of the two protons in the amide bond region of the multiplets from 7.7 to 8.2 ppm 
(H-d) demonstrating the incorporation o f two glycine residues. The presence of two extra 
CH2 groups was inferred due to an increase in peak area of the resonance at 3.55 ppm (H-b) 
overlapping with water that is present in the sample.
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Figure 53. Synthesis scheme of tetra-gly self-assembling peptide (139)
Reaction Conditions: (i) a) Fmoc-GlyGly-OH, TBTU, DIPEA, b) 20% piperidine, (ii) 95% TFA, 
2.5% TIS, 2.5% H2O
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Tetra-gly self-assembling peptide (139) was synthesised from the same batch of resin (136) 
as the di-gly self-assembling peptide (137), however, prior to cleavage of the self-assembing 
peptide (137) from the resin, the iV-terminus of the peptide was modified with Fmoc-GlyGly- 
OH using a TBTU/DIPEA coupling before the Fmoc protecting group was removed with 
2 0 % piperidine.
The peptide cleavage from the resin, precipitation into diethyl ether and lyophilisation from 
water, produced the tetra-gly self-assembling peptide (139) as an off white solid in 67.1% 
yield based on the theoretical loading of the resin.
The identity of the tetra-gly self-assembling peptide (139) was confirmed through 
characterisation by NMR, MS and FTIR. The ESI-MS gave the expected molecular ion at 
1477 m/z. The presence of a broad C=0 band at 1626 cm'  ^ in the FTIR spectrum showed that 
a number of amide groups were present in the structure. The presence of glutamic acid 
residues in the peptide were confirmed due to the presence of a broad band at 2935 cm'^  
caused by an OH stretch in a carboxylic acid group, the presence of a 0 = 0  stretch at 1669 
cm'^  due to the same group. Aromatic rings are also evident due to the medium band at 1523 
cm'^  caused by ring C=C stretching. The H^ NMR spectrum further confirmed the presence 
of the multiplet (2H) at 8.60 ppm (H-a) caused by the presence of a free amino group, an 
increase in integration of two protons in the amide bond region of multiplets from 7.7 to 8.2 
ppm (H-d) demonstrated the incorporation of two glycines. The presence of two extra CH2 
groups was inferred from the increase in peak area of the resonance at 3.55 ppm (H-b) but 
was unfortunately overlapping with water that was present in the sample.
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2.2 Synthesis of functional peptide-polymer conjugates_________
Owing to the vast amount of literature devoted to Atom Transfer Radical Polymerisation 
(ATRP) methods, making it arguably the most popular method of controlled radical polymer 
synthesis, ATRP was chosen initially for this In addition, suitable ligands
and initiating species for ATRP are widely commercially available and straight-forward to 
incorporate into the di-gly-initiator (see Section 2.1).
As the protein can be modified in either: graft-to, graft-fi*om and graft-through manner, 
(Figure 18) a methodology needed to be developed that was either universal to or easily 
adaptable for use in all three methods of modification. As the work would also involve the 
use of proteins, the conditions under which the polymerisation took place needed to be 
compatible with protein-tolerant conditions, {i.e. at room temperature and using either: water, 
aqueous buffer or possibly DMSO).
It was decided that the most suitable conditions to work under were aqueous conditions as 
these would be most relevant for the graft-from methodology due to polymerisation taking 
place under conditions that would not cause denaturing of the protein due to the solvent. 
Research of ATRP in protic media in the literature that were analogous to aqueous systems 
required for the graft-from approach, showed that the use o f copper(I)bromide and bipyridine 
would be most suitable for OEGMA (6 6 ) (Figure 54). Polymerisation under these conditions 
has been demonstrated to be efficient at room temperature producing polymers with 
polydispersity indices as low as 1.12 and as high as 1.89, this can be attributed to the slow 
termination of the sterically hindered radicals derived from OEGMA and good control over 
molecular weight*^  ^ for the lower PDI sample synthesised using bipy and PMDETA in 
acetonitrile and propanol. Loss of control for the higher PDI samples was a consequence of 
using water and DMSO as solvents for ATRP as these cause the greatest reduction of the 
alkyl halide to form the active propagating species. It is also possible to use copper(I)chloride 
and other ligands for ATRP of OEGMA in protic media, however the degree of control over 
molecular weight and PDI is marginally lower than with the CuBr/bpy system described 
above.
°  (6 6 )
Figure 54. Oligo(ethylene glycol) methyl ether methacrylate (6 6 ) (OEGMA)
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2.2.1 Atom Transfer Radical Polymerisation
2.2.1.1 ATRP in water using peptide initiator (83)
01igo(ethylene glycol) methyl ether methacrylate (OEGMA475) was polymerised using 
Fmoc-glycylglycine-2-ethylamide-2-bromo-2-methylpropanamide peptide initiator (83) in 
water, with Cu(I)Br/bpy targeting a Mn of 95,000 g/mol as calculated by the ratio o f initiator 
to monomer. The initiator was chosen to test the feasibility of carrying out ATRP under these 
conditions in the presence of a carboxylic acid, as well as determining its effect on PDI as 
ATRP on methacrylic acid had shown previously that the carboxylic acid group can poison 
the catalyst complex and result in a polydisperse p o ly m er .T h is  has meant that polymer 
synthesis is usually attempted using protected derivatives.Follow ing the addition of 
Cu(I)Br and bypyridine to the reaction mixture, the active catalyst complex formed 
successfiilly and brown solution developed. This was persistent throughout the reaction 
and indicated that the polymerisation was proceeding. It was also noted that the peptide was 
poorly soluble, but increased during polymerisation, as expected. After 20 hours the viscosity 
of the solution had increased significantly, indicating polymerisation had occurred. Following 
removal of water from the reaction mixture through lyophilisation and dissolution in 
deuterated methanol, NMR analysis was performed.
The ^H-NMR spectrum of the peptide-polymer (140) can be seen below in Figure 55. The 
presence of polymer is evident from the reduction in the intensity o f the resonances 
corresponding to the two geminal hydrogen atoms at 5.71 and 6.10 ppm present in the 
methacrylate double bond relative to CH2 signals in the oligo(ethylene glycol) side chain.
By comparing the integral of the two monomer peaks in 5.71 (H-a2) and 6.10 ppm (H-aJ and 
the equivalent broad peaks present as a CH3 group in the polymer at 1.11 and 0.97 ppm (H- 
b), the conversion of the monomer was found to be 98.7%. End-group analysis (based on 
aromatic Fmoc resonances at 7.85 ppm) showed Mn = 98,723 g/mol.
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Figure 55. H NMR of peptide-polymer (140) synthesised using peptide initiator (83)
ppm
Table 4. Molecular weight of peptide-polymer (140), a) GPC, b) NMR
M .  ( g / m o l ) ' M „ ( g / m o l ) ‘ M ,y  ( g /m o I ) ' P D F
101,393 98,723 143,014 1.41
The results from gel permeation chromatographic analysis are summarised in
Table 4, the value for M„ calculated using NMR, shows good agreement (< 3 % difference) 
with that calculated through GPC analysis. The molecular weight (MW) of the polymer is 
higher than the expected theoretical molecular weight of 95,000 g/mol although only 
marginally. The PDI is high for polymerisation of OEGMA (1.41), as lower values for 
similar OEGMA polymerisation systems have been reported (PDI<1.12)*^  ^and although the 
PDI is not the highest value reported for a peptide-OEGMA conjugate (PDI = 1.5)^ ^^ , there 
are other conjugates synthesised by ATRP (PDI = 1.40)^ "^^  and RAFT (PDI = 1.28)’^^  with 
lower polydispersity. These higher values for PDI suggest loss of control o f polymerisation 
compared to those non-peptide systems and may be a result of early termination as has been 
reported p rev iou sly .T h is experiment demonstrated that it is possible to use an Fmoc- 
protected peptide with a free COOH group in ATRP albeit with some loss o f control 
(possibly due to the COOH complexing with copper in a similar manner to
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ethylenediaminetetraacetic acid (EDTA)) and to synthesise conjugates that have suitable 
molecular weight for fiirther testing using this method. The method does, however, require 
fiirther optimisation to control the PDI.
2.2.1.2 A TRP in water using peptide initiator (111)
Since Fmoc-protected di-gly peptide initiator (83) suffered from sparing solubility in water it 
was decided to establish whether it would be possible to perform ATRP using the more 
hydrophilic, unprotected, gly-gly-lys-(2 -bromo-isobutyrylamide)-ser-ser peptide initiator
(111). To this author’s best knowledge this has not been attempted before, with previously 
reported peptide-initiators used for ATRP usually being in the protected state.^°’^ °^’^ °° It was 
hypothesised that the Jfree amino-groups may interfere with the formation of the copper 
complex due to the similarity in structure to the multidentate amino fimctionalised ligands. 
To decrease any possibility of interference of the amino-containing initiator on the Cu-bpy 
complexation, thereby reducing MW control, it was decided to pre-form the CuBr/bpy 
complex before adding it to the monomer and initiator solution. The copper complex formed 
successfully and the brown colouration persisted when the solution was added to the 
monomer/initiator solution. Kinetic samples were taken and the conversion was calculated 
using the NMR spectrum fi*om the crude reaction mixture (Figure 51).
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Figure 56. Monomer conversion during ATRP in water of peptide-polymer (141) using peptide 
initiator (1 1 1 )
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Figure 51 shows that the polymerisation was rapid during the first 10 minutes following 
initiation, indicating poor control of the reaction during the onset of polymerisation. In 
addition, the lack of linear correlation between conversion and time indicates poor control 
throughout the reaction as the conversion of the monomer proceeded quickly and then slowed 
down, analogous to conventional fi*ee radical polymerisation where monomer conversion is 
not linear with time. This was similar to a previous pattern reported by Armes and co-workers 
where it was suggested that sterically hindered OEGMA monomer caused termination to be 
anomalously low even at high conversion. Water has been noted as being an accelerator of 
polymerisation previously and this was attributed to the activation of the polymerisation and 
the formation o f the active Cu(l) co m p lex .W ater  has also been shown to increase 
disproportionation of Cu(ll) and Cu(0) species to Cu(l).^ ^^  This can be reduced by adding a 
small quantity o f Cu(ll) to the Cu(l)/bpy complex and reducing the proportion of water in the 
reaction, for which DMSO was suggested as a particularly good solvent.^ *^ Lyophilisation of 
the sample rendered it insoluble, so it was not possible to perform gel-permeation 
chromatography to establish molecular weight and polydispersity.
2.2.1.3 A TRP in DM SO using peptide initiator (111)
To determine whether the poor MW control in this polymerisation was due to the solvent or 
the presence of fi*ee amino groups in the initiator, the experiment was repeated using DMSO 
instead of water. The use of DMSO did, also, represent a compromise as whilst increasing 
peptide solubility, it posed issues later when performing direct comparisons with graft-fi*om 
due to possible compatibility issues of the protein with DMSO, although use of DMSO has 
been demonstrated previously in the graft-from polymerisation using BSA to have no effect 
on structure of the protein.^ ®^  Kinetic samples were taken and the conversion was calculated 
using the NMR spectra (Figure 57).
Figure 57 shows linearity between monomer conversion and reaction time demonstrating a 
controlled radical polymerisation. The linearity continues across the first 90 minutes and 
appears to become non-linear after this point this may be due to premature termination taking 
place possibly due to the ingress of oxygen into the reaction vessel or may be a result o f loss 
of control of the polymerisation due the effects noted in 2 .2 .1 .2 , although this was difficult to 
confirm due to the lack of high monomer conversion data.
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Figure 57. Monomer conversion during ATRP in DMSO of peptide-polymer (142) using peptide 
initiator (1 1 1 )
As stated previously this could be caused by the Cu disproportionation promoted in water 
but there is the possibility that poor solubility of the initiator in the larger scale of the 
polymerisation could be the cause. However, it does suggest that it is possible to perform 
ATRP with exposed amino groups with some degree of control over Mw in spite of previous 
cases where the removal of the protecting group has taken place as a post-polymerisation 
step.^“
Figure 58 shows the variation of M„ and PDI of the peptide-polymer (142) vs. monomer 
conversion. Although the values of PDI are kept low, the overall trend shows deviation from 
linearity, especially at high conversion, typical o f a non-controlled free-radical process. The 
loss of control that is analogous to free-radical polymerisation could possibly be due to 
disproportionation of copper in DMSO as well as water, poor solubility o f the Cu(I)-ligand 
complex in these solvents or as a result of the peptide complexing the copper, all acting to 
increase the PDI with time. These were the best results generated thus far; it was, therefore, 
decided to keep the solvent and conditions the same and test a more soluble initiator as part 
of our optimisation.
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Figure 58. Mn (♦) and PDI (□) vs. monomer conversion during ATRP in DMSO of peptide- 
polymer (143) using peptide-initiator (112), (—) theoretical number average molecular weight
Next, the peptide initiator (112) that contained a glutamic acid residue instead o f the two 
serines used in the previous polymerisation was evaluated in DMSO. Since the previous 
results showed better control in this solvent than in water, the synthesis of a peptide-polymer 
conjugate ready for a graft-to protein conjugation approach was carried out in the solvent 
most suited to the polymerisation in protein-absent conditions. The extent of reaction was 
monitored by taking kinetic samples and calculating conversion using NMR data, this is 
summarised in Figure 59.
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Figure 59. Monomer conversion during ATRP in DMSO of peptide-polymer (143) using 
peptide-initiator (1 1 2 )
The graph shows linear conversion with time which is indicative of controlled 
polymerisation, however the extent of conversion is low compared to the ATRP experiment 
in section 2.2.1.3.
Table 5. Molecular parameters of peptide-polymer (143) taken at 60 minutes, a) GPC, b) NMR
Time (minutes) Mn (g/moI)“ M„ (g/moI)** M„ (g/mol)' PDI'
60 30,066 3724 43709 1.45
Gel Permeation chromatographic analysis of the samples was only possible for one kinetic 
sample due to poor yield in the case o f the other samples. A higher molecular weight than 
expected was reported for the kinetic sample taken at 60 minutes, the experimental Mn of 
30,066 g/mol was an order of magnitude larger than the expected Mn at 3724 g/mol 
calculated from the NMR analysis o f the same conversion. This can only be explained by the 
poor availability of initiator during polymerisation resulting in a fewer number o f chains 
being generated, with a subsequent de facto increase of the effective monomer/initiator ratio. 
The higher PDI than previously reported also suggests loss o f MW control. Both o f these 
results can be explained by the peptide complexing with the copper during the polymerisation 
through the coordinating free COOH or amide/COOH multi-dentate coordination as seen for 
similar structural motifs.^^  ^(Figure 60)
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Figure 60. Copper coordination to Gly-Lys-Gly^®^
The consequence o f the coordination o f the peptide-initiator to the copper catalyst could have 
three possible effects on the polymerisation mechanism and kinetics. The rapid initiation of 
all chains simultaneously is a key feature of a controlled polymerisation, this might be 
difficult in this case if the initiator is tightly complexed with copper (assuming the bound 
initiator cannot initiate as readily). This means that not all o f the chains may be available to 
initiation at early stages with the consequence that some chains will propagate over a larger 
amount o f monomer than those initiated later.
It is also possible that the veiy carefully controlled equilibrium between kdeact and kact, 
necessary for a controlled polymerisation (Figure 61), is not being established rapidly as a 
result o f a competing complex involving the peptide initiator as the ligand (L2). A competing 
peptide-initiator complex, expectedly with different catalytic activities, would result in a loss 
of control of both molecular weight and molecular weight distribution. For such a complex, it 
would also be uknown whether the catalyst complex is more activated (kaca) or deactivated 
(kdeactz) than the originally intended CuLi complexes (Figure 61). If the peptide-initiator 
complex favours the activated state, loss of control due to the increase in propagating radicals 
would explain the high molecular weight and PDI that is analogous to free-radical 
polymerisation.
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Figure 61. Schematic showing competing ATRP copper complex, where Li is bypyridyl and L% 
is peptide initiator (1 1 2 )
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To test whether peptide initiator (112) could be a ligand for the polymerisation complex, 
another polymerisation was carried out using the peptide initiator (1 1 2 ), under the same 
conditions, without bpy. This showed that polymer formation was possible without the 
selected ligand and strongly suggested that peptide initiator (112) was able to coordinate Cu, 
becoming a relatively effective ligand for the activation of the C-Br bond, required for 
initiation. The polymer that formed was present as a brown gel, due to the presence of 
trapped copper complex (Figure 62), which could be extracted upon treatment with EDTA 
during overnight sonication. Unfortunately, the resulting colourless polymer could not be 
dissolved for GPC and NMR analysis.
Figure 62. Reaction vial containing peptide-polymer (143) after 3 hours synthesised minus the 
bypyridyl ligand
This property has been reported previously and results from the polyamide backbone acting 
as a multi-dentate ligand complex. °^" It was also suggested in the same study that PMDETA 
should be used as this has a higher affinity for copper than the peptide backbone.
2.2.2 Single Electron Transfer-Living Radical Polymerisation
The above reported ATRP results were among the best obtained after attempts to optimise 
this polymerisation ahead of protein conjugation using the chosen di-gly containing peptide- 
initiators. A much larger, unsuccessful set of results, exhibiting poor repeatability and 
uncontrolled reactions, including high PDI (>1.9), off-target molecular weight and simply
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unreacted mixtures, was a common motif in the work using ATRP. The seeming unreliability 
of ATRP, for the peptide-initiators required in this project, forced the use o f other methods 
for the controlled polymerisation of OEGMA from di-gly containing initiators. SET-LRP, a 
Cu-mediated polymerisation method that makes use of the same type o f initiating system as 
ATRP (Section 2.2.1), has proven successfiil in the polymerisation of OEGMA from 
modified Salmon calcitonin, a 32-amino acid peptide by Haddleton et al?^  ^Although RAFT, 
was also a plausible alternative,^^ at this stage having successfully optimised the synthesis of 
bromo-containing di-gly ATRP initiators, SET-LRP appeared to be the most straightforward 
option.
Peptide initiator (144) was used as initiator for the SET-LRP of OEGMA in DMSO. As this 
initiator had shown lack of control under ATRP, producing insoluble polymers, it was 
deemed a best test for the limitations of the new polymerisation method. Conditions reported 
by Haddleton for Salmon calcitonin were reproduced for peptide initiator (144),^ ®^  with the 
exception of using Cu(0)powder in place of Cu-wire to increase the rate of polymerisation as 
a result of a higher surface area.^  ^ The SET-LRP involved the pre-formation of the Cu- 
PMDETA complex following deoxygenation of the DMSO solution with evolution o f a pale 
blue colouration due to the bulk of the complex occurring as copper(II).^  ^Following addition 
to the monomer and initiator, there was a noticeable increase in viscosity with time, this 
indicated that polymerisation was taking place. The monomer conversion was measured 
using ^H-NMR analysis (Figure 63), the analysis showed that conversion was not linear with 
time suggesting that SET-LRP is similar to the case of ATRP whereby the polymerisation 
proceeds in an uncontrolled manner.
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Figure 63. Monomer conversion during SET-LRP synthesis of peptide-polymer (144) using 
peptide initiator (1 1 2 )
The GPC of the kinetic polymer samples during the polymerisation, again showed a non­
linear increase in Mn v^ . conversion (Figure 65). This time, however, the Mn was lower than 
for the corresponding ATRP case (Table 5) increasing from approximately 9000 g/mol to
21,000 g/mol between 10% to 60% monomer conversion. The lower values for M„ and PDI 
(<1.3 and final 1.26) indicated marginally better control than for ATRP, this time producing a 
soluble polymer. It does, however, suggest that there may be a competing mechanism where 
the peptide initiator coordinates the Cu system for SET-LRP, similarly to the one as 
suggested for ATRP.
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Figure 64. Single Electron Transfer-Living Radical Polymerisation (SET-LRP) showing 
competing complex, where L% is PMDETA and L2 is initiator (112)
The mechanism of SET-LRP demonstrates that this competing complex is most likely to 
affect copper(II) as loss of control of polymerisation is a result of a reduction in deactivation 
step of the mechanism. As copper(II) is a requirement for deactivation to take place, the 
peptide initiator must complex with copper (II). If the initiator is a better ligand for copper(II) 
than PMDETA, a result of this would not only be a reduction in deactivation but also an 
excess of PMDETA that could further complex with copper(O) and the halido-polymer to 
further activate the polymerisation. This may be a result of octahedral copper(II) undergoing 
Jahn-Teller distortions to a more energetically favourable state (as a result of the d^  
configuration of copper (II) ion giving rise to three electrons in the two degenerate orbitals, 
leading to a doubly degenerate electronic ground state) as has been reported previously with 
peptides involving glycine and glutamic acid.^ ®^ ’^ ^^
Most importantly, while the ATRP system resulted in a less than 50 % success rate from 
experiment-to-experiment in obtaining a polymer that was suitable for use in graft-to 
conjugation, SET-LRP demonstrated a 100% success rate and efficiently delivered a soluble 
peptide-polymer (144) with reasonable PDI values (<L3) using an initiator that had high 
solubility in water (112). This approach did however not present a fully controlled 
polymerisation system for polymer conjugates. These results could be considered inferior 
compared to RAFT^ ’^^  ^ and ATRP^ ^^ ^^  OEGMA conjugates synthesised from simple novel 
initiators that are reported in the literature. However, these previously reported initiators do 
not feature a peptide backbone, which is required for our methodology. In any case, the PDI 
values highlight that further optimisation of the polymerisation was required.
79
Factors that had limited this optimisation included: the expense to produce the initiator (£200 
per 1 0 0  mg) and difficulty in producing repeatable products from synthesis to synthesis using 
ATRP and SET-LRP. It was, however, decided to test polymer-peptide conjugates prepared 
in way as they were suitable to evaluate how well Sortase A could conjugate polymers to 
eGFP. In addition, this would enable the suitable comparison of the graft-to and graft-from 
conjugation approaches (see Section 2.3.5.2) using polymers synthesised from the same 
initiator.
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Figure 65. Molecular weight (♦) and polydispersity index (□) versus conversion during SET- 
LRP synthesis of peptide-polymer (144) using peptide initiator (109), (—) theoretical number 
average molecular weight
A polymer containing di-gly-side chains ready for graft-through protein conjugation (peptide- 
polymer (145)) was also synthesised by SET-LRP under the same conditions used for 
peptide-polymer (144) using peptide initiator (112) and peptide monomer (113) as an initiator 
and monomer respectively (Figure 6 6 ).
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Figure 6 6 . Graft-through polymerisation of peptide-polymer (145)
Reaction Conditions: [Monomer] : [Monomeric diglycine] : [Initiator] : [Copper(0)powder] : 
[Copper(II)bromide] : [PMDETA] 200 : 2 : 2 :1 :  2 : 5
The ratios of monomer to initiator and monomeric diglycine (100 : 1 : 1) would result in a 
polymer chain containing a minimum of two sites for eGFP ligation, it would be possible to 
include more sites but due to a shortage of peptide monomer (113), two sites were used for 
testing purposes. Following addition of the initiating complex to the monomer, monomeric 
diglycine and initiator, there was a noticeable increase in viscosity with time indicating that 
polymerisation was taking place. The monomer conversion was measured using ^H-NMR 
analysis (Figure 67) and showed non-linear correlation with time and it was, however it was 
noted that conversion was much faster than for the formation of peptide-polymer (145). This, 
may be a result of both the initiator (1 1 2 ) and the monomeric diglycine (113) coordinating 
copper(II) . The monomeric diglycine is after all analogous to that of the initiator and would 
represent a two-fold increase of competing ligand. Following the previous discussion, this is 
likely to increase the polymerisation rate resulting in an uncontrolled polymerisation. The 
lower values for Mn, again, suggest that SET-LRP and the PMDETA ligand may be more 
tolerant to COOH and NH groups than ATRP, where the M„ is much higher (30,066 g/mol) 
and bpy is used. The tolerance results in more control over the polymerisation reaction and a 
lower Mn than ATRP, due to a copper(II) having a higher affinity o f PMDETA than the 
initiator and monomer.
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Figure 67. Monomer conversion during SET-LRP synthesis of graft-through peptide-polymer 
(145) using peptide initiator (112) and peptide monomer (113)
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Figure 6 8 . Molecular weight (♦) and polydispersity index (□) versus conversion during SET- 
LRP synthesis of graft-through peptide-polymer (145) using peptide initiator (112) and peptide 
monomer (113), (—) theoretical number average molecular weight.
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Loss of control of the reaction was represented by an increase in PDI with time, this reaction 
can be confirmed to be uncontrolled due to the PDI reaching a level that would be 
comparable to a standard free-radical polymerisation. Interestingly the increase in Mn vs. 
conversion remains linear and agreement with the theoretical Mn is closer than in previous 
polymerisation reactions. This provides further evidence that the loss of control might not be 
a result of an increase of termination processes, which would cause deviations off a linear 
correlation (Mn/conversion). These results, suggest a variety of Cu-complexes with different 
catalytic activities that result in a statistical variation in availability o f active chains for 
propagation leading to an increase in PDI.
OEGMA was also grafred-from the self-assembling peptide initiator (133) using SET-LRP in 
DMSO. The ^H-NMR analysis of kinetic samples taken during this polymerisation (Figure 
64) showed linear conversion over the first 30 minutes of polymerisation with conversion 
reaching 60%. At 60 minutes, the self-assembling polymer (146) was found to be no longer 
soluble and formed an insoluble gel in commonly available NMR and GPC solvents.
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Figure 69. Monomer conversion during SET-LRP synthesis of graft-from self-assembling 
peptide-polymer (146) using self-assembling peptide initiator (133)
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The analysis of PDI and M„ vs. Monomer conversion (Figure 70) suggests poor control 
during the initial stages of polymerisation with subsequent small improvement as the 
polymerisation progresses. The polymer conjugates still have a relatively high PDI in 
comparison to other similar types of conjugate in the literature^  ^and also those synthesised 
from the short peptide initiators. This, could be a result of either the peptide again competing 
with the ligand (a higher density of free COOH and NH2 groups is present in FEFEFKFKK 
peptide initiator (133) than in peptide initiator (111)) to produce alternative copper complexes 
or could be due to the peptide chains aggregating in DMF leading to observed higher MW 
values. Most likely, both effects operated simultaneously, with initiator-complexation 
leading to higher PDI values during polymerisation, but peptide-aggregation, being 
expectedly more pronounced at lower MW due to a higher peptide/polymer ratio, which 
would result in higher observed PDI values at lower conversion.
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Figure 70. Molecular weight (♦) and polydispersity index (□) versus conversion during SET- 
LRP synthesis of graft-from self-assembling peptide-polymer (146) using self-assembling 
peptide initiator (133) (—) theoretical number average molecular weight.
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2.2.3 Reversible Addition Fragmentation Polymerisation
2.2.3.1 RAFT Polymerisation
Owing to the problems arising from possible interference in the active copper catalyst by the 
peptide-initiator and peptide-monomer it was decided to try an approach that would first 
synthesise the polymer and then modify with a di-glycine for conjugation to the protein. This 
approach would allow for greatly optimised polymerisation conditions to be used in which 
the peptide could be used as a handle for further modification. It is rationalised that 
modification of dithioester RAFT-agents leading to thiol end-groups post-polymerisation, 
could be used for the introduction of di-gly peptides for Sortase conjugation.^*®
Polymerisation using oligo(ethylene glycol) methyl ether methacrylate, the RAFT agent, 2- 
phenyl-2 -propyl benzodithioate and the initiator, a,a'-azoisobutyronitrile resulted in a pink 
viscous liquid following polymerisation overnight. The molecular weight of the RAFT- 
polymer at 30,066 g/mol (147) was in specification for the use in conjugation to a protein for 
nano-therapeutics and was comparable to similar materials synthesised in the literature 
(13,500 g/mof** and 43,800 g/mol).^*  ^The polydispersity of the polymer was higher at 1.45 
than reported in the literature (at 1.18^ ** and 1.25^ *^  respectively) and demonstrated that 
further optimisation was required, however the RAFT-polymer (147) was suitable to 
demonstrate that it would be possible to modify the thiol groups of the RAFT-polymer (147) 
with the diglcine monomeric peptide (113) in a thiolene ‘click’ reaction.
Table 6 . Molecular parameters of RAFT-polymer (147) after 16 hours, a) GPC, b) NMR
M„ (g/mol)“ Mn (g/mol)*’ Mw (g/mol)* PD F
30,066 40,675 43,709 1.45
2.2.3.2 Modification o f  tkiol group o f  RAFT agent
2. (113)
1.n-Butylamine _ ^  n
8-9
(148)
Figure 71. Synthesis Scheme showing modification of RAFT-polymer (148) with peptide 
monomer (113)
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The successful modification of OEGMA was achieved through aminolysis with w-butylamine 
and was followed by a thiolene reaction with the methyacrylamide group of the peptide 
monomer (113). After dialysis and lyophilisation, the product was found to have lost its 
distinctive pink colour as a result of the removal of the benzodithioate group. Subsequently, 
^H-NMR analysis of the peptide-polymer (148) was performed. The attachment of the 
peptide monomer (113) was difficult to confirm as a result of the overlapping signals of the 
RAFT-polymer (148) and the peptide monomer (113) making any integration not possible.
RAFT-Peptide Polymer 
RAFT Polymer 
Peptide monomer
Figure 72, H NMR spectra of RAFT-peptide-poIymer (148), RAFT Polymer (147) and peptide 
monomer (113)
Despite inconclusive NMR analysis it was decided to proceed with attachment of the peptide- 
polymer (147) to eGFP as this would establish whether the diglycine group was present.
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2.3 Protein Ligation
2.3.1 eGFP-LPETGG-His6 expression
eGFP was expressed incorporating the LPETGG C-terminus sequence for Sortase A 
recognition using plasmid transformed into Escherichia coli BL21(DE3)pLysS. A Hisô tag 
was also incorporated to facilitate protein purification using affinity chromatography with 
Nickel-nitrilotriacetic acid (Ni-NTA) resin as had been reported previously/^ Following 
expression, the cells were lysed, centrifuged and purified by Ni-NTA resin.
SDS-PAGE analysis of eGFP expression and purification is presented below in Figure 67.
The symbols in Table 7 will be used to describe the components present in the gels.
Table 7. Gel component symbols
Component Symbol Component Symbol
Sortase A C Peptide ♦
eGFP Peptide-polymer ♦ s A .
eOFP-peptide initiator Tus
(a) (b) (c) (d) (f) (g)
116,000
66,000
55.000
45.000
36,000
29.000
20.000
Figure 73. SDS-PAGE image of eGFP expression and purification (a) Sigma Wide Range 
Marker, (b-c) 20 mM ammonium acetate, 20 mM imidazole, pH 7.0 buffer resin wash fractions 
1-2, (d-g) 20 mM ammonium acetate, 400 mM imidazole, pH 7.0 buffer, eGFP elution fractions 
1-4.
The gel staining clearly indicated there were significant concentrations of eGFP-LPETGG- 
His6 in lanes (e, f  and g)
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Owing to the presence of eGFP in the fraction of the 20 mM Ammonium Acetate, 20 mM
imidazole, pH 7.0 resin wash buffer and 20 mM Ammonium Acetate, 400 mM imidazole, pH
7.0 eGFP elution fractions, the eluents were combined and concentrated using ultra-filtration. 
Dialysis and lyophilisation of the fluorescent green solution yielded purified eGFP-LPETGG- 
Hisô (Protein (149)) as a fluorescent green powder (141 mg, 23.5mg/litre o f culture). This 
was considered in good yield based on prior experience in the group.
The successful expression and isolation o f eGFP-LPETGG-Hisg was confirmed using 
MALDI-TOF-MS in addition to the SDS-PAGE analysis (Figure 74). A molecular ion at 
28,703 g/mol was indicative of eGFP and is consistent with data shown in the literature.
ISU n, Baseline subtracted(O .I) ;
< 3  eGFP-LPETGG-Hiss [M]'
<□ eGFP-LPETGG-His6 [M]2+
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t45.5S.4U)I44%510l44Si(.7i9
11558,601 11578 038
11428 948 11.3:6 688
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Figure 74. MALDI-TOF-MS spectrum of eGFP-LPETGG-HiSfi (Protein (149))
2.3.2 Sortase A-Hisg expression
Sortase A was expressed using plasmid transformed into Escherichia coli BL21(DE3)pLysS. 
A Hisô tag was also incorporated to facilitate protein purification using affinity 
chromatography with nickel-nitrilotriacetic acid (Ni-NTA) resin as had been reported 
previously.^  ^Following expression the cells were lysed, centrifuged and purified by Ni-NTA 
resin. SDS-PAGE analysis of Sortase A expression and purification is presented below in 
Figure 75, The gel staining clearly indicates there are significant concentrations of Sortase A- 
His6 .
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(a) (b) (c) (d) (e) (f) (g) (h) (i) (j)
2(N),000
116,000
97.000
66,000
55.000
45.000
36,000
29,000
204)00
Figure 75. SDS-PAGE image of eGFP expression and purification (a) Sigma Wide Range 
Marker, (b) Sortase A elution fraction (c) Tris-HCI, 100 mM KCl, 8  mM imidazole, pH 7.7 
buffer resin wash, (c) 20 mM ammonium acetate, 20 mM imidazole, pH 7.0 buffer resin wash, 
1** Fraction, (d-g) 20 mM ammonium acetate, 400 mM imidazole, pH 7.0 buffer, eGFP elution 
fractions 1-4.
Owing to the presence of Sortase A in the 20 mM Ammonium Acetate, 20 mM imidazole, pH
7.0 resin wash buffer and 20 mM Ammonium Acetate, 400 mM imidazole, pH 7.0 Sortase A 
elution fractions, the eluents were combined and concentrated using ultra-filtration. Dialysis 
and lyophilisation of the brown solution yielded purified Sortase A-His6 as a off-white solid 
(Protein (150)) (141 mg, 23.5 mg/litre of culture)
The molecular weight of Sortase A according to gel electrophoresis was higher than expected 
but this has been noted previously in the literature (Figure 75).^^  MALDI-TOF-MS analysis 
of the protein a molecular weight of 22,820 g/mol in agreement with those described in the
literature for Sortase A.56
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Sortase A-Hisô [M]^
820 3>
Figure 76. MALDI-TOF-MS spectrum of Sortase A-Hisg (150)
2.3.3 Solubility of peptides
The solubility of the peptides-initiators developed earlier presented a major hurdle to 
overcome since the “grow-from” approach requires the conjugation to eGFP using Sortase A 
in aqueous media. Solubility tests of the deprotected peptide initiators with biocompatible 
solvents can be seen below in Table 8 .
Table 8. Solubility of GGK[COCBr(CH3 )2 ]-OH (97), (Figure 43) GGK[COCBr(CH3 )2 ]-SS-OH 
(111), (Figure 46) GGE[COCBr(CH3 )2 ]-E-OH (112) (Figure 48) peptides in solvent
P e p t i d e W a t e r
S o r t a s e  A  
B u f f e r
D i m e t h y l s u l f o x i d e M e t h a n o l A c e t o n i t r i l e
GGK[COCBr(CH3)2l- 
OH (97) Poor Poor Partial on Heating Partial Poor
GGK[COCBr(CH3)2]- 
SS-OH (111) Partial Partial Good Partial Poor
GGK[COCBr(CH3 >2 ]- 
E-OH ( 1 1 2 )
Very
Good Very Good Very Good Very Good Very Good
The ideal peptide would have excellent solubility in Sortase A assay buffer (50 mM Tris, 150 
mM NaCl, 5 mM CaCL, pH 7.5).
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Figure 77. Lysinyl-bromoisobutyryl (151) and Lysinyl-acetyl (152)
Prediction of the isoelectric point, charged state and solubility using a peptide property 
simulator, where the bromo-isobutyryl group was substituted for an acetyl group due to 
the unavailability of the prior for use in the calculation (Figure 77), suggested that the 
GGK[COCBr(CH3)2]-OH peptide initiator (97) would offer poor solubility due to a lack of 
charge at pH 7.0 (Table 9). It was similar for the GGK[COCBr(CH3)2]-SS-OH peptide 
initiator (111), with the prediction suggesting a good solubility in water. This did not match 
experimental evidence and is again probably a result of the lack of charge on the peptide at 
pH 7.0 and the isoelectric point being close to pH 7.0. The GGK[COCBr(CH3)2]-E-OH 
peptide initiator (1 1 2 ) had a high solubility both experimentally and theoretically, this can be 
attributed to both the charge and the low isoelectric point at pH 3.3 meaning that the peptide 
is charged over a wide pH range further improving the usefiilness of the peptide as an 
initiator.
Table 9. Solubility, iso-electric point and charge at pH 7.0 of peptides in water
Peptide W ater Solubility p i Charge at pH 7.0
GGK[COCBr(CH3)2l-
O H (97) Poor pH 4.9 0
GGK[COCBr(CH3)2]-
S S -O H (lll) Good pH 6.0 0
GGK[COCBr(Œ 3 )2 ]E-
0 H (1 1 2 )
Good pH 3.3 -1
Due to the highly soluble nature of GGK[COCBr(CH3)2]E-OH peptide initiator (109) in 
water and Sortase A buffer it was decided to use this initiator for incorporation into eGFP 
using Sortase ligation on a large scale.
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2.3.4 Large scale coupling of peptide initiator (112) and purification of 
modified eGFP protein-peptide conjugate (153)
Large scale incorporation of GGK[COCBr(CH3)2]E-OH peptide initiator (112) into eGFP- 
LPETGG-His6 (Protein (149)) using Sortase A (Protein (150)) was performed according to 
the method described in section 4.5.11 that was modified from Neylon and co-workers 
Since the Hise tag is removed from the eGFP during conjugation, it was possible to purify the 
modified eGFP-LPETGGGK[COCBr(CH3)2]E-OFl (Protein-peptide conjugate (153)) using
Co-NTA resin. Using a method modified from Antos et the Hise-tagged proteomic 
material was successfully separated from the modified protein-peptide conjugate (153) using 
Co-NTA resin. The modified protein-peptide conjugate (153) was then successfully modified 
from the unincorporated peptide and excess salts and was concentrated using an Amicon 
centrifugal filter to yield fluorescent green liquid. SDS-PAGE analysis (Figure 72) showed 
the removal of the His6-Tagged proteins by the Co-NTA resin to yield protein-peptide 
conjugate (153) as a single band in lane (e). The increase in migration of the protein-peptide 
conjugate (153) compared to native protein (149) is due to a reduction in mass o f 357 g/mol 
due to the loss of the G-His6 and the incorporation of GGK[COCBr(CH3)2]E peptide initiator
(112). Following lyophilisation, a green powder was produced in a yield of 1 mg.
(a) (b) (c) (d) (e) (f) (g) (a) (b) (c) (d) (e) (f) (g)
135,000
954M0
724)00
524)00
344)00
26,000
104)00
Daltons
135,000
954X10 )
72,000
524)00
42.000
3*4)00
26,000
Daltons
Figure 78. SDS-PAGE image of the conjugation reaction of peptide initiator (112) and protein
(149) (a) Sigma Wide Range Ladder, (b) GGFIuorophore Control, (c) eGFP and 
GGFluorophore (-Sortase A) control, (d) eGFP and GGFIuorophore (+Sortase) control (e) 
purified eGFP-peptide conjugate (153)), (f) eGFP (149), (g) Sortase A (150)
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The conjugation reaction between GGFIuorophore and eGFP-LPETTGG (protein (149)) 
showed that the Sortase A ligation was working as GGFIuorophore was present at the same 
molecular weight in lanes (b) and (c) for the GGFIuorophore control and the reaction that 
does not contain Sortase A. The lane (d) that contained GGFIuorophore and Sortase A (150) 
for use in ligation to eGFP showed an increase in migration again due to a decrease in 
molecular weight due to the incorporation of oligoglycine materials.
Size-exclusion chromatographic analysis of the protein-peptide initiator confirmed the results 
of the SDS-PAGE and showed the presence of a single peak of ligated eGFP- 
LPETGGGK[COCBr(CH3)2]E-OH protein-peptide conjugate (153), this had a longer 
retention time than the eGFP-LPETGG-Hise due to the lower molecular weight of the 
modified protein, this can be seen in Figure 79.
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Figure 79. Size-exclusion chromatogram of purified eGFP-LFETGGGK[COCBr(CH3 )2 lE-OH 
protein-peptide initiator (153) and eGFP-LPETGG-His6 (149)
The incorporation of the GGK[COCBr(CH3)2]E-OH peptide-initiator (112) on to the C- 
terminus of eGFP presented a suitable initiator for grafting-from protein-polymer conjugate 
synthesis.
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2.3.5 Grafting-from protein-polymer conjugates
2.3.5.1 ATRP synthesis o f  protein-polymer conjugate (154) in water using
protein-peptide initiator (153)
A polymer was grafted-from the eGFP-LPETGGGK[COCBr(CH3)2]E-OH protein-peptide 
conjugate (153) using ATRP. The successful formation of the copper complex at initiation 
was evident due to the formation of a brown solution. SDS-PAGE analysis (Figure 80) of the 
reaction mixture after 16 hours showed an unresolved streak on the polyacrylamide gel (b). 
This is indicative of a high molecular weight polydisperse conjugate (GFP-LPETGGGK 
[COCBr(CH3)2]E-OEGMA) (154). The lack of staining for the protein-peptide conjugate 
(153) and peptide-polymer conjugate control sample (Figure 80, lane (c)) made the results 
slightly ambiguous as there is no way to determine whether the eGFP was simply just binding 
to the polymer or was covalently bonded but it appears by looking at the eGFP control (d) 
and comparing this to the reaction sample (153) that conjugation had reached completion.
(b) (c) (d) (e)
260,000
135,000
(b) (c) (d) (e)
95.000
72.000
52.000
42.000
34.000
260,000
135.000
95.000 
723)00
52.000
42.000 
343)00
►♦A.
103)00
Daltoiis
Figure 80. SDS-PAGE image of graft-from ATRP conjugate synthesis (a) Sigma Wide Range 
Marker, (b) graft-from eGFP-OEGMA conjugate (144) (c) eGFP-peptide conjugate (153) and 
peptide-polymer conjugate (112), (d) eGFP-peptide conjugate (153) control, (e) Sortase A 
control (150)
A Native-PAGE was run as this enabled a more specific monitoring on the presence of GFP, 
since the SDS treatment results in loss of fluorescence (Figure 75).
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(l)(a ) (b)(c) (1) (a) (b) (c)
K C
Figure 81. Native-PAGE image graft-from ATRP conjugate synthesis visualised under UVaoznm 
(I) and stained under visible light (2) (a) eGFP-peptide conjugate (153) control (b) Sortase A
(150) control (c) graft-from GFP-OEGMA conjugate (154)
The native-polyacrylamide gel electrophoresis showed fluorescence in the lanes containing 
the eGFP-LPETGGGK[COCBr (CH3)2]E-OH protein-peptide conjugate (153) control (a) and 
the graft-from ATRP eGFP-LPETGGGKE-OEGMA protein-polymer conjugate (c) (154) 
present as a defined band and streak respectively. This is a clear indication that the eGFP- 
protein-polymer conjugate (154) was running at a higher molecular weight than the un­
modified eGFP (149).
Size-exclusion chromatography of the purified conjugate product showed a shift in the 
retention from 11 minutes to 12 minutes. Although this clearly shows that eGFP has indeed 
been modified, this was unexpected as a reduction in retention time would be expected due to 
the increased molecular weight of the protein-polymer conjugate (154) compared to the 
protein-initiator conjugate (153).
Two scenarios could account for this result. On the one hand, it is known the ability o f eGFP 
to form dimers in the unbound state as has been demonstrated before.^’  ^ in this case, a dimer 
of GFP, with higher molecular weight than conjugate (154) could elute at shorter times, 
assuming the polymer attached in the eGFP-OEGMA conjugate prevented this dimérisation 
from taking place. On the other hand, SEC works on the principle of separation based solely 
on the hydrodynamic volume of the analyte and since the stationary phases are adapted to 
specific analytes, with clear specialisation between protein SEC and polymer-suited GPC 
columns, it is also possible that the cause may be a result of a non-specific interaction of the 
polymer component of the conjugate with the SEC stationary phase in a manner that was not 
a result of hydrodynamic volume.
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To establish which the case was, eGFP-LPETGG-His^ was run against protein standards of 
known molecular weights to determine whether eGFP was present in monomeric or dimeric 
form. The SEC analysis (Figure 82) confirmed that eGFP was present in its monomeric form 
with an approximate molecular weight of 30,000 g/mol, due to the retention time occurring 
nearest to myoglobin (17,000 g/mol ).
- eGFP-peptide initiator
- eGFP-OEGMA conjugate
- eGFP-peptide initiator + pOEGMA
a>
(0co
Q.
s
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Figure 82. Size-exclusion chromatogram of graft-from ATRP eGFP-OEGMA conjugate (144), 
eGFP-peptide initiator (153) and peptide-polymer conjugate (112) and eGFP-peptide initiator 
control (153)
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Figure 83. Size-exclusion chromatogram of eGFP and Protein Standards (a) Bovine 
Thyroglobulin, (b) IgA, (c) IgB, (d) Ovalbumin, (e) Myoglobin and (f) Uridine
As the eGFP was found to be in the monomeric form, the contribution of the polymer on the 
retention time of the protein-polymer conjugate was evaluated. Poly (ethylene oxide) (PEO) 
(155) standards that are analogous to the side chain of OEGMA were used for this purpose.
H
O
OH O'
.o CH.
(155) (66)
Figure 84. Chemical structure of poly(ethylene oxide) (PEO) (155) and OEGMA (6 6 )
SEC analysis of two standards of PEO (25 kDa and 50 kOa) showed exactly the same 
retention time for each standard. This is indicative that the stationary phase is not separating 
the polymer component based on a size exclusion mechanism. The retention time was also 
comparative to the protein- polymer conjugate. This confirms that the conjugation of a 
polymer is having an effect on the retention time of the protein and also that the polymer is 
not interacting with the stationary phase of the SEC column purely through the size of the 
hydrodynamic radius. The composition of the stationary phase being composed of native 
silica with minimal diol crosslinking would suggest that this may be due to hydrogen bonding 
and dipole interactions between the OEGMA polymer chain and the stationary phase
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resulting in a longer retention time as had been noted previously by Daly et al in experments 
with pegylated lysozyme/^"^
25 kDA PEO 
50 kOA PEO
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Figure 85. Size-exclusion chromatogram of 25 kDa and 50 kDa PEO standards
2 3 .5 2  SET-LRP synthesis o f  protein-polymer conjugate (156) in DM SO  
using protein-peptide initiator (153)
A polymer was grafted-from the eGFP-LPETGGGK[COCBr(CH3)2 ]E-OH protein-peptide 
initiator conjugate (153) using SET-LRP in DMSO. DMSO was used as the method of 
synthesis had been used previously^^  ^ and there was not sufficient time to optimise the 
procedure using aqueous media. The successful synthesis of the eGFP- 
LPETGGGK[COCBr(CH3 )2 ]E-OH-OEGMA protein-polymer conjugate (156) can be seen by 
the unresolved band in lane (c) of the SDS-PAGE analysis (Figure 90). There appeared to be 
the presence of minimal un-modified eGFP in comparison to the eGFP band present in the 
eGFP-peptide initiator lane (b), this demonstrated nearly quantitative modification.
98
(a) (b) (c)
127.000
97.000
66,000
55,000
127,000
972MI0
66,000
55,000
(a) (b) (c)
•ISJMH)
362)00
29.000
20.000
14,200
6,500
Daltons
14,200
6,500
Daltons
Figure 8 6 . SDS-PAGE image of graft-from SET-LRP conjugate synthesis of (a) Sigma Wide- 
Range Ladder, (b) eGFP-peptide initiator (153), (c) graft-from SET-LRP eGFP-OEGMA 
conjugate (156)
Size-exclusion chromatography of the graft-from SET-LRP eGFP-OEGMA purified 
conjugate product showed a shift in the retention time from 10.6 minutes to 12.9 minutes, this 
was due to the successful grafting of pOEGMA from the eGFP-peptide initiator (153) 
resulting in more interaction with the stationary phase and a longer retention time than un­
modified eGFP. Both graft-from conjugates were synthesised successfully as mono-disperse 
conjugates with a single site of modification, this is expected as the molecular weight 
difference between the protein-initiator and the monomer is significantly different (> 1 0 )^ and 
the polymer chain grafts away from the protein.
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Figure 87. Size-exclusion chromatogram of graft-from SET-LRP eGFP-OEGMA conjugate 
(146), and eGFP-peptide initiator (153)
2.3.6 Graft-to conjugates
2.3.6.1 Synthesis o f  protein-polymer conjugate (157) using ATRP peptide-
polymer conjugate (143)
GGK[COCBr(CH3 )2 ]E-OEGMA peptide-polymer conjugate (133) was grafted-to the eGFP- 
LPETGG-His6  (149) using Sortase A (150) according to the small scale method in section
4.5.11). The synthesis of the eGFP-LPETGGGK[COCBr(CH3 )2 ]E-OEGMA protein-polymer 
conjugate (157) is shown to have been successful due to the unresolved streak in the native- 
PAGE analysis (Figure 8 8 , lane (a)). The band also demonstrated that grafting OEGMA to 
eGFP did not affect the fluorescence of eGFP. The band spreading is similar to that seen for 
graft-from eGFP-LPETGGGKE-OEGMA conjugate in band (c) (Figure 81) and confirms the 
presence of a protein-polymer conjugate.
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Figure 8 8 . Native-PAGE image graft-to ATRP conjugate synthesis visualised under UVaoznm (1) 
and visible light (2) (a) graft-to eGFP (149) and peptide-polymer conjugate (143) reaction 
mixture) (+ Sortase A) (b) graft-to eGFP (149) and peptide-polymer conjugate (143) reaction 
mixture (- Sortase A), (c) eGFP-peptide initiator (153) control, (d) Sortase A (150) control
eGFP-OEGMA conjugate 
eGFP-LPETGG-His.
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Figure 89. Size-exclusion chromatogram of graft-to eGFP-LPETGGGKE-OEGMA conjugate
Size-Exclusion chromatography of the crude conjugate product shows a shift in the retention 
time from 10.6 minutes to 13.4 minutes, this can be explained by the peptide-polymer (143) 
successfully grafting to the eGFP causing an increase in molecular weight that resulted in the 
conjugate remaining on the stationary phase longer than the un-modified eGFP.
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The additional peak at 11.9 minutes is a result of unconjugated peptide-polymer (133) and 
suggested that complete conjugation did not take place. This is expected due to the steric 
factors caused by the random-coiled brush structure making the access to the conjugation site 
difficult for Sortase A (Figure 30). A yield of approximately 70%, however, can be 
considered a success and suggests this system is highly suitable for graft-to conjugate 
synthesis.
2.3.6.2 Synthesis o f  protein-polymer conjugate (158) using SET-LRPpeptide-
polym er conjugate (144)
The grafting of the peptide-polymer conjugate (144) synthesised using SET-LRP to eGFP- 
LPETGG-His6 (149) using Sortase A ligation proved successful. This is evident from the 
unresolved band in lane (d) as a result of protein-polymer conjugation (158) (Figure 90). The 
incorporation of the protein is not simply due to interactions between the polymer chain and 
the protein, as the reaction controls minus eGFP (e) and Sortase A (^ showed two separate 
bands, a single unresolved band at the top of the lane due to the polymer and a resolved band 
at around 28,000 Da due to the eGFP and Sortase A.
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Figure 90. SDS-PAGE image of graft-to SET-LRP conjugate synthesis of (a) Sigma Wide-Range 
Ladder, (b) GGF conjugate (+ Sortase A), (c) GGF conjugate (- Sortase A), (d) graft-to SET- 
LRP eGFP-OEGMA conjugate (158) (+ Sortase A), (e) graft-to SET-LRP eGFP OEGMA 
conjugate reaction (158) (- eGFP), (f) graft-to SET-LRP eGFP-OEGMA conjugate reaction 
(158) (- Sortase A)
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Size-exclusion chromatography of the graft-to SET-LRP eGFP-OEGMA crude conjugate 
product showed a shift in the retention time from 10.6 minutes to 13.1 minutes, this was due 
to the successful grafting of peptide-OEGMA (144) to the eGFP resulting in greater 
interaction with the stationary phase and a longer retention time than un-modified eGFP. The 
efficiency of conjugate synthesis was not as high as the graft-from method of conjugate 
synthesis (Figure 87), this is expected due to the steric factors caused by the random-coiled 
brush structure making the access to the conjugation site difficult for Sortase A (Figure 35). 
An injection of the crude (158) protein-polymer mixture showed that the conjugation was 
90% efficient, this demonstrates how efficient the system is considering Sortase A 
conjugation is an equilibrium process.
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Figure 91. Size-exclusion chromatogram of graft-to SET-LRP GFP-OEGMA protein-polymer 
conjugate (158)
2.3.6.3 Synthesis o f  protein-polymer conjugate (159) using RAFT peptide-
polym er conjugate (148)
A graft-to conjugate (159) was successfully prepared from peptide-polymer conjugate (148) 
(that had previously been synthesised via RAFT polymerisation using a commercially 
available initiator and modified post-polymerisation for Sortase A conjugation). The 
synthesis of the protein-polymer conjugate was not quantitative as demonstrated by two 
bands present in lane (b), (Figure 92) for the peptide-polymer conjugate and un-modified
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eGFP. There was, however, less un-modified eGFP present than the control reaction (minus 
Sortase A) in lane (c), this suggested that conjugation had taken place. Poor yield could be a 
result of access difficulties of the enzyme to the substrate or may have been a result of 
incomplete characterisation of the end group functionalisation in peptide-polymer conjugate 
(148) having resulted in a low concentration of peptide-polymer conjugate being added to the 
eGFP conjugation reaction.
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Figure 92. SDS-PAGE image of graft-to RAFT conjugate synthesis of (a) Sigma Wide-Range 
Ladder, (b) graft-to RAFT eGFP-OEGMA conjugation reaction (159) (+ Sortase A), (c) graft-to 
RAFT eGFP-OEGMA conjugation reaction (159) (- Sortase A) (d) RAFT GGKE-OEGMA 
conjugate (148) (e) GGF conjugate (+ Sortase A), (f) GGF conjugate (- Sortase A),
Size-exclusion chromatography of graft-to RAFT eGFP-OEGMA crude conjugate product 
showed a shift in the retention time from 10.6 minutes to 13.1 minutes, this was due to the 
successful grafting of RAFT GGKE-OEGMA conjugate (148) to the eGFP resulting in 
greater interaction with the stationary phase and a longer retention time than un-modified 
eGFP.
There were three additional peaks in the chromatogram, the peak at 10.6 minutes was a result 
of un-modified eGFP and integration of peak area showed the conjugation to be 29% efficient 
The two other peaks are probably a result of the presence of di-gly modified and un-modified 
peptide-polymer conjugate, although further analysis would be required to establish this.
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Figure 93. Size-exclusion chromatogram of graft-to RAFT eGFP-OEGMA conjugate (159) and 
eGFP (148)
The results demonstrated that using a RAFT-prepared polymer for the graft-to conjugation 
method requires further optimisation due to the number of products generated from the 
conjugation reaction. The graft-to conjugate synthesised from the SET-LRP peptide 
conjugate (158) was purer than the RAFT conjugate (159), with only the di-gly peptide 
polymer being present following purification of the reaction mixture. Whereas due to a 
subsequent modification of the RAFT-polymer with di-gly, the un-modified and modified 
polymer could be present following conjugation to eGFP and could result in a number of 
products. This demonstrates that the use SET-LRP-peptide (158) gave better results in the 
preparation of protein conjugates that the RAFT-peptide (159). It would be possible, 
however, with slight modifications to the concentration of reagents used in the RAFT-protein 
conjugate synthesis and prior modification to increase the efficiency of the conjugation and 
synthesise the solely ligated protein-polymer conjugate with ease. This is due to the small 
amount of monomeric peptide that is required to generate a reactive peptide polymer 
conjugate for ligation.
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2.3.6.4 Synthesis o f  graft-through protein-polymer conjugate (160) using
SET-LRP peptide-polymer conjugate (145)
Grafting-through was similar to grafting-to, in the manner that the protein is ligated post­
polymerisation. (Figure 18) The polymer was synthesised so that the ratio of functionalised 
di-gly monomer (113) to OEGMA in the polymer backbone was 100 to 1, this would have 
resulted in 2-3 sites of attachment for the eGFP. SDS-PAGE analysis of the graft-through 
protein-polymer conjugate (160) (Lane (f), Figure 94) showed quantitative attachment of 
eGFP to the di-gly functionalised side chains in the polymer. The lack of a band for eGFP 
shows that all of the un-modified eGFP has been successfully incorporated into the polymer. 
The control reactions (minus Sortase A and eGFP) showed clearly resolved bands in lanes (d) 
and (e) due the presence of the respective proteins, this suggested that conjugation had taken 
place. It was however not possible to confirm the loading of eGFP on the polymer using the
gel, so further analysis would be required to confirm the exact extent.
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Figure 94. SDS-PAGE image of graft-through SET-LRP conjugate synthesis of (a) Sigma Wide- 
Range Ladder, (b) GGF conjugate (+ Sortase A), (c) GGF conjugate (- Sortase A), (d) graft- 
through SET-LRP GFP-OEGMA conjugation reaction (- Sortase A), (e) graft-through SET- 
LRP GFP-OEGMA conjugation reaction (- eGFP), (f) graft-through SET-LRP GFP-OEGMA 
conjugate (160)
Size-exclusion chromatography of graft-through SET-LRP eGFP-OEGMA conjugate showed 
a shift in the retention time from 10.6 minutes (un-modified eGFP) to three time points 12.3 
minutes, 12.6 minutes and 13.1 minutes. The presence o f three peaks suggested that three
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possible conjugates (160) were successfully synthesised, although defining the number of 
eGFP proteins attached to each polymer chain was be difficult to ascertain without further 
analysis. However, it was possible to identify the peak at 13.1 minutes to most likely contain 
the attachment of the greatest number of eGFP proteins due to the broad nature of the peak.
The size-exclusion chromatographic analysis also confirmed that the conjugation reaction 
was 100% efficient due to the lack of un-modified eGFP in the chromatogram. This was 
surprising as it was expected that the graft-through method of conjugate synthesis offered the 
greatest steric hindrance to ligation due to the large tangled network of the peptide-polymer 
chain. The large number of peaks could either be due to incomplete ligation of the eGFP to 
the polymer chain or as a result of a statistical distribution of polymers that contain different 
numbers of di-gly units within the polymer chain. In any case, it indicates the presence of 
conjugates differing in the number of protein attached to a single chain. Since the number of 
available repeating units containing a diglycine is a statistical event, this is to be expected.
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Figure 95. Size-exclusion chromatogram of graft-through SET-LRP GFP-OEGMA conjugate 
(160) and eGFP (149)
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2.3.7 Protein-self assembling peptide conjugate
2.3.7.1 Synthesis Tus-LPETGGGFEFEFKKK protein-peptide conjugate
Tus is a sequence specific DNA binding protein that recognises 21 base-pair termination 
{Ter) sites.^’^  The use of a functional protein such as Tus was due to two factors, one to 
establish that the protein was accessible once the hydrogel network had formed around it and 
two to determine whether this attachment had any effect on protein function. This is simple 
with Tus because the monitoring requires an easy separation of free-labelled DNA from Tus- 
bound labelled DNA which is easily attained by filtration and washing of the gel-bound Tus 
with buffer. Tus-LPETGG-His6 protein(161) was conjugated to self-assembling di-gly 
peptide (133) using Sortase A using the method described in section 4.5.12 that was modified 
from Neylon and co-workers.^  ^ SDS-PAGE analysis of the crude reaction mixture and the 
Co-NTA purified protein-self-assembling peptide conjugate (163) showed that the attachment 
of Tus (161) was successful due the presence of a single band in lanes (d, f, h and j) and that 
protein-self-assembling peptide conjugate (163) was isolated as a single product.
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Figure 96. SDS-PAGE image of (a) Sigma Wide-Range Ladder, (b) Conjugation Tus reaction (- 
Sortase A) (c) Crude Tus conjugation reaction (163) (d+f) Unbound fraction of protein-self 
assembling peptide conjugate (163) (e+g) Elution fraction of bound protein 1-2 ( (h+g) Purified 
and concentrated protein-self assembling peptide conjugate fractions 1-2 (163)
It was also shown that the unconjugated Hise proteomic material (lanes e and g) is removed 
from the crude mixture by binding to the resin before being subsequently washed off.
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2.3.7.2 Hydrogel preparation using self-assembling peptide (131) and protein-
self-assembling peptide conjugate (163)
Two hydrogels were prepared using self-assembling peptides (131) and (163), The first (163) 
was prepared using solely self-assembling peptide (131) and the second (164) was prepared 
incorporating 5% of the protein-self-assembling peptide conjugate (163) with the remainder 
being (131). The self-assembling peptides were mixed at 40 °C for 30 minutes and incubated 
overnight at room temperature to prevent protein denaturing at the typical self-assembling 
conditions at T > 60 The formation of the gel was observed by inversion using the
tilted test tube test with no flow being observed. As a control an attempt was made to 
assemble peptide (131) in the presence of unconjugated Tus protein, this resulted in no 
gelation being observed and suggested that covalent bonding of the Tus-protein to the self­
assembling peptide was essential for the formation of a hydrogel.
Transmission Electron Microscopy (TEM) (Figure 91) of the fibre formation of each gel 
system showed that there was no significant difference in the fibre morphology observed for 
the self-assembling peptide only gel (163) and the gel containing Tus (164).
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Figure 97. TEM image of self-assembling peptide only gel (163) and the gel containing Tus 
(164).
2.3.7.3 Binding o f  FAM-ter-DNA to Tus-self-assembling hydrogel (164)
To establish whether Tus was still accessible in the hydrogel network, the gel was treated 
with a 21 base specific DNA sequence called rer that is recognised by the Tus DNA-binding 
protein. The Tus-protein self-assembling peptide gel (164) was treated with mixtures of ter 
DNA labelled with fluorescein (FAM-rer-DNA) and a non-/er-related 21 base pair DNA 
sequence labelled with Cy5 (Cy5-DNA) at a total concentration of 10 pM.
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Figure 98. Fluorescence data for Tus-protein self-assembling peptide gel (164) (A) 25 % FAM- 
/er-DNA + 75 % Cy5-DNA (B) 50 % FAM-Zer-DNA + 50 % Cy5-DNA (C) 75 % FAM-ter-DNA 
+ 25 % Cy5-DNA (D) 100 % FAM-ter-DNA (E) Tus-protein self-assembling peptide gel (164) 
in incubation buffer without DNA (F) self-assembling peptide gel (163) incubated with 100 % 
FAM-ter-DNA
Following washings, the fluorescence of the gel was measured under the green and red 
channels using a plate reader, the data (Figure 98) suggested a concentration dependent 
behaviour, although it is evident that under these conditions the hydrogel Tus-functionality 
was at near saturation even at a 2.5 pM concentration of FAM-ter-DNA. Non-specific 
binding of the Tus-protein self-assembling peptide gel with Cy5-DNA was negligible as 
expected. These observations were confirmed by confocal fluorescence microscopy (Figure 
99)
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Figure 99. Confocal fluorescence microscopy image for Tus-protein self-assembling peptide gel 
(164) using FITC green fluorescence filter (top row and (f)) and G-2A red fluorescence filter 
(bottom row) (a) 25 % FAM-ter-DNA + 75 % Cy5-DNA (b) 50 % FAM-ter-DNA + 50 % Cy5- 
DNA (c) 75 % FAM-ter-DNA + 25 % Cy5-DNA (d) 100 % FAM-ter-DNA (e) Tus-protein self­
assembling peptide gel (164) in incubation buffer without DNA (f) self-assembling peptide gel 
(163) incubated with 100 % FAM-ter-DNA
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This demonstrated that the proteins are accessible following the formation of a gel and the 
enzyme activity is not affected during this process, although fiirther work is required to 
quantify the extent of the retention of fiinctionality with regards to overall amount of 
conjugated protein.
These results open up the possibility of using the temperature response of the hydrogel for 
controlled activation/deactivation of a protein that is chemically bonded to the peptide due to 
exposure of the protein below the LCST temperature and exclusion within the gel network 
above the LCST as demonstrated by Thompson et The advantage of this synthetic route 
is not only due to the functional protein being accessible and retaining activity following 
hydrogel formation, but the hydrogel also prevents degradation of protein due to the mesh 
size of the gel preventing or slowing the diffusion of degradating enzymes and antibodies. 
The advantage of using Sortase A for this chemical bonding is that it is possible to attach any 
protein or enzyme that contains the LPETG tag to the iV-terminus diglycine of the peptide 
despite the peptide containing three free amino and carboxyl groups in the peptide backbone, 
this would not be possible using chemical modification and shows that Sortase A is site- 
specific for di-glycine. This means that optimising therapeutics fi-om a matrix o f materials is 
both simple and efficient using Sortase A as a conjugation tool.
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3 Conclusions and suggested future work
Using solid-phase peptide synthesis, ATRP, SET-LRP, RAFT and Sortase A mediated 
ligation, a near monodisperse protein-polymer conjugate of eGFP was synthesised. This 
opens up the possibility to use this methodology to synthesise conjugates with other 
ftinctional proteins, already demonstrated in the case o f the Tus-self-assembling peptide. This 
method of synthesis also represented a platform that can be used universally with other 
proteins and polymers.
The synthesis of the peptide initiator was more difficult than previously anticipated due to the 
inherent nature of the insolubility of diglycine. Solution phase synthesis proved unsuccessful 
as a result o f this and the Fmoc and Boc peptide initiators (84) and (87) were synthesised in 
poor yield (24 mg and 7.3 mg respectively). Solid phase peptide synthesis proved more 
rewarding with a number of peptide initiators (namely (1 1 1 ) and (1 1 2 )) synthesised in good 
yield (43 mg and 198 mg respectively). Solubility o f the initiator again proved an issue and 
the peptide initiators (97) and (111) were found to be poorly soluble in water. The peptide 
initiator (1 1 2 ) was found to be highly soluble in water and a good initiator for polymerisation, 
although there were issues with the peptide interfering with the copper complex used to 
control the ATRP and SET-LRP polymerisations.
It may therefore be necessary to go full circle and synthesise polymers using polymer- 
analogous reactions whereby the polymer is synthesised fi*om a simple dithioester initiator 
and modified post polymerisation using a large excess of methacryl containing di-gly short 
peptide prior to conjugation using Sortase A. Peptide initiator (85) would be suitable for this 
and a proposed scheme is presented below in Figure 100, although a diol derivative would be 
equally as suitable.^*  ^Unfortunately, this methodology is only suitable for a graft-to or post­
polymerisation graft-through approach. For the graft-from approaches, Glu-containing 
peptides, which exhibited the best solubility, are required.
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Figure 100. Proposed synthesis scheme for post-polymerisation modification a peptide initiator 
(85) for use in Sortase A ligation
The use of ATRP for both graft-to and graft-from polymerisation generated three low- 
polydisperse peptide-polymer conjugates (140) (98,723 g/mol, PDI 1.41), (142) (20,387 
g/mol, PDI 1.19) and (143) (30,066 g/mol, PDI 1.45). These could all be utilised for 
conjugation although greater optimisation of the process would be required to establish the 
exact factors that are affecting the mechanism before the conjugates were comparable to 
those in the literature. The methodology exhibited poor repeatability and uncontrolled 
reactions that included: high PDI (>1.9), off-target molecular weights and unreacted 
mixtures.
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Figure 101. Peptide-polymer conjugates (140), (142) and (143)
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SET-LRP was a much more robust methodology and a number of near monodisperse, 
targeted molecular weight polymers were generated including a peptide-polymer conjugate 
(144) (20,066 g/mol, PDI 1.26) for graft-to conjugation and peptide-polymer conjugate (145) 
(26,861 g/mol, PDI 1.19) for graft-through conjugation, and a less polydisperse self- 
assembling peptide-polymer conjugate (146) (34,465 g/mol, PDI 1.52) synthesised fi*om the 
self-assembling peptide initiator (131). It is evident that both ATRP and SET-LRP suffered 
from interference by the Glu-containing peptide initiator in the catalytic mechanism, so the 
use of unprotected peptides would require extensive fiirther optimisation to result in 
monodisperse polymers suitable for the protein conjugation in the future.
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Figure 102. Peptide-polymer conjugates (144), (145) and (146)
RAFT presented an alternative pathway. This shared similarities with the synthesis scheme 
shown in Figure 100, where the polymer was synthesised first and then modified for 
conjugation. This generated peptide-polymer (148) (30,066 g/mol, PDI 1.45), but problems 
arose due to difficulties in determining the degree in which the polymer had been modified as
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a result of the overlapping peaks in NMR analysis of the product and the intermediate (Figure 
72).
Sortase A and enhanced green fluorescent protein were expressed and purified successfully 
from Escherichia coli in modorate yields of 141 mg (23.5 mg per litre of culture) in each 
case, there are no comparative yields given in the literature, although prior experiences in 
other studies indicated a value of 40 mg per litre of culture would be expected.^ Graft-to, 
graft-through and graft-from synthesis of eGFP-OEGMA conjugates using ATRP and SET- 
LRP all successfully generated protein polymer conjugates, with the most efficient being the 
graft-from conjugates. This demonstrates that the use o f Sortase A and the peptide initiator 
presents a universal method for graft-to, graft-from and graft-through conjugation.
It was successfully demonstrated that the site-specific attachment of the ftinctional protein 
Tus onto a self-assembling peptide using Sortase A could be used in the formation of a 
hydrogel (164) with little effect on the gel-morphology. The protein functionality was 
retained in the final hydrogel and these sites were accessible to complementary DNA 
sequences.
Further work would include studies into the effect of the copper(II)peptide initiator/monomer 
complex on the overall control of the polymerisation mechanism in both ATRP and SET- 
LRP. Possible experiments to be carried out would first require that the complex is isolated 
and characterised before measuring the bond lengths of the peptide copper complex to see, if  
the complex is undergoing Jahn-Teller distortion and testing the binding efficiency and 
strength of the peptide initiator/monomer compared to PMDETA or bpy to establish if 
controlled polymerisation is possible.
It would also be pertinent to synthesis polymers using a polymer analogous group as has been 
done previouslyT his would allow the polymer to be synthesised under inexpensive, highly 
optimised conditions prior to the attachment of the conjugate. The thioester group o f RAFT 
and the bromine of ATRP/SET-LRP would be suitable for modification (Figure 103).
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Figure 103. Post-polymerisation modifications for Sortase A attachment
The success o f the graft-through methodology using Sortase A presents an interesting 
opportunity to develop a variety of materials fi*om a large matrix of proteins and polymers for 
use in widely ranging therapies. The benefit of using Sortase A is that triple targeted therapy 
formulations could be made by simply mixing three LPETGG tagged therapeutic proteins or 
peptides and using Sortase A to attach them to the polymer (Figure 104). These kinds of 
therapeutics have been shown to be more effective in treating non-Hodgkin's lymphoma, 
cancer^ ^^  and anal incontinence^^® than single therapies to name a few.
SortaseA
LPETGG tagged proteins
Di-gly polymer
Triple targeted conjugate
Figure 104. Proposed graft-through synthesis of a tripled targeted conjugates
In summary this work demonstrated the successful synthesis of eGFP-OEGMA conjugates 
using graft-to, graft-from and graft-through methods of synthesis. Graft-from proved the best 
method of synthesis for the protein-polymer conjugate due to the highest efficiency of 
conjugate synthesis. This technology presents the site-specific universal route to generate 
protein polymer conjugates and could easily be transferred to a number o f fields of science 
including: nanomedicines, biosensors, fuel cells and other areas of biotechnology.
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4 Experimental
4.1 Instrumental Analysis
4.1.1 Nuclear Magnetic Resonance spectroscopy (NMR)
NMR spectroscopy experiments were performed on a 500 MHz Bruker AVANCE NMR and 
300 MHz Bruker AV-300 NMR spectrometer at the University o f Surrey. The spectra were 
recorded at 298 K in deuterium oxide (D2O), deuterated chloroform (CDCI3), deuterated 
methanol (MeOD) or deuterated dimethyl sulphoxide (DMS0-d6) obtained from Cambridge 
Isotope Laboratories. The deuterium oxide was referenced according to the solvent peak in 
the *H NMR spectrum at 4.80 ppm. The deuterated chloroform was referenced according to 
the solvent peak in the H^ NMR spectrum at 7.27 ppm and in the ^^ C NMR spectrum at 77.23 
ppm. The deuterated methanol was referenced according to the solvent peak in the H^ NMR 
spectrum at 4.87 ppm and in the ^^ C NMR spectrum at 49.15 ppm. The DMSO-d6  was 
referenced according to the solvent peak in the H^ NMR spectrum at 2.50 ppm and in the ^^ C 
NMR spectrum at 39.51 ppm.
4.1.2 Fourier Transform Infrared spectroscopy (FTIR)
The infrared spectra were recorded using an Agilent Technologies Cary 640 FTIR 
spectrometer. The samples were analysed using a Specac Golden Gate Single Reflection 
Diamond ATR at 2 cm'^  using 256 scans at the University o f Surrey.
4.1.3 Electrospray Ionisation-Mass Spectrometry (ESI-MS)
Samples were dissolved in LC-MS grade acetonitrile, methanol or water, depending on 
solubility, to give a 100 ng/ml concentration. A 100 pL sample was introduced into a 
Micromass Q-TOF mass spectrometer in ESI+ mode at a flow rate of 100 pL/min, by direct 
infusion.
4.1.4 Liquid Chromatography-Mass Spectrometry (LC-MS)
LC-MS was performed at the University o f Surrey on a Thermo Scientific LCQ DECA XP 
Plus Ion Trap Mass spectrophotometer. Samples were dissolved in LC-MS grade acetonitrile, 
methanol or water depending on solubility to give a 1 mg/ml concentration. Samples were 
introduced via a Thermo Scientific Liquid Chromatography instrument. The system was 
equipped with a C-14 Jupiter 4 pm 150 x 2.0 mm Proteo 90 Â column and was run in ESI+ 
mode.
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Samples were eluted at a flow rate of 150 pL/min with a mobile phase composition of (A) 
0.1% trifluoroacetic acid in LC-MS grade water, (B) 0.1% trifluoroacetic acid in 80% LC-MS 
grade acetonitrile.
4.1.5 Matrix Assisted Laser Desorption Ionisation-Mass Spectrometry 
(MALDI-MS)
The MALDI-MS experiments were performed using a Bruker Daltronics Reflex IV reflectron 
Matrix Assisted Laser Desorption Ionisation-Time of Flight Mass Spectrometer, equipped 
with a 337 nm nitrogen laser. The instrument was calibrated with Bruker Daltronics Protein 
Standard II. Lyophilised samples were resuspended in water: acetonitrile (90:10) with 0.1% 
trifluoroacetic acid (TFA). 0.4 pL of sample was spotted on to the target plate and was co­
crystallized using a sinapinic acid matrix (10 mg/ml in acetonitrile). The samples were 
analysed in positive, linear mode using 350 accumulated laser shots at a laser power of 38%.
4.1.6 Organic Gel Permeation Chromatography
Gel permeation chromatographic analysis (except for (140)) was performed on a Polymer 
Laboratories PL-GPC-50 Plus integrated system instrument equipped with two PLgel 5 pm 
MDŒD-D 300 x 7 . 5  mm columns and a PLgel 5 pm 50 x 7 , 5  mm guard column. Samples 
were eluted with DMF with 0.1% lithium bromide as an additive at 50 °C at 1 ml/min. Data 
were recorded using triple detection and analysed using Cirrus 2.0 software. Molecular 
weights were determined using triple detection relative to narrow poly(methyl methacrylate) 
standards.
(140) was analysed using the same system eluting with dimethylacetamide and data being 
recorded and analysed using a linear calibration using polystyrene standards.
4.1.7 Aqueous Size Exclusion Chromatography
Size exclusion chromatographic analysis was performed on a Varian Prostar instrument 
equipped with a BioSep SEC s3000 300 x 7.5 mm column and a Security Guard GFC 3000 4 
X 3.0 mm guard column. Samples were eluted with 20 mM TrisBase, 150 mM NaCl, and 1 
mM EDTA buffer at room temperature at 1 ml/min. Data were recorded using 2 channels 
monitoring 395 nm and 280 nm and analysed using Galaxie Chromatography Data System
1.9 software.
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4.1.8 Transmission Electron Microscopy
Samples were analysed at the University of Manchester by Dr Susanna Piluso and Jonathon 
Gibbons using carbon-coated copper grids (400 mesh, Agar Scientific, UK) that were glow 
discharged for 5 seconds and placed shiny side down on the surface of a 10 p-1 droplet of 
sample solution, blotted after 1 0  seconds, washed with 1 0  p.1 of double deionised water and 
subsequently blotted for a fiirther 10 seconds. Washed grids were then placed on a 10 |il 
droplet of uranyl acetate solution (4% w/v) for 60 seconds for negative staining and then 
blotted against double folded Whatman 50 filter paper. The air-dried samples were then 
examined by a FBI Tecnail2 BioTwin transmission electron microscope. Images were taken 
using an inbuilt Orius CCD SC1000 camera and Gatan Digital Micrograph software, and 
analysed using Fiji image processing software.
4.2 Chemicals_____________________________________________
All amino acids for peptide synthesis were obtained from Novabiochem, AGTC Bioproducts 
Alfa Aeser or Apollo chemical and were used as received. 01igo(ethylene glycol) methyl 
ether methacrylate (OEGMA4 7 5 ) was obtained from Sigma Aldrich and was passed through a 
column of silica ( 1  g per 1 ml of monomer) to remove the butylated hydroxytoluene and the 
monomethyl ether hydroquinone inhibitors. The purified monomers were then stored under 
nitrogen at -20 °C for use in polymerisation. Copper(I)bromide was obtained from Sigma and 
was purified by stirring with glacial acetic acid overnight. After filtration, it was washed with 
ethanol and diethyl ether and then dried in vacuo and stored under nitrogen ready for use. 
Bipyridyl was obtained from Aldrich and was recrystallized from methanol prior to use. All 
other reagents and solvents were obtained from Sigma Aldrich, Apollo Chemical and Fisher 
Scientific and were used as received.
119
4.3 Peptide Synthesis
4.3.1 Solution Phase Synthesis of Peptide Initiators
4.3.1.1 Peptide intermediate (80)
IUPAC:iV-a-(9“Fluoren-2-ylmethyloxycarbonyl)-glycylglycine^^®
iV-(9-Fluoren-2-ylmethoxycarbonyloxy)succinimide (Fmoc-OSu) (920 mg, 2.75 mmol) was 
dissolved in 1,4-dioxane (25 ml) at 0 °C and stirred for 15 minutes, Glycylglycine (327 mg,
2.5 mmol) and sodium bicarbonate (520 mg, 4.95 mmol) were dissolved in distilled water (25 
ml) at 0 °C and stirred for 15 minutes, (524 mg). The Fmoc-OSu solution was added 
dropwise to the aqueous mixture at 0 °C over 2 hours. The vessel was left to warm to room 
temperature and was left to stir for 2 1  hours.
The dioxane was removed under vacuo and the aqueous solution was acidified to pH 4 using 
20% acetic acid. Following precipitation the product was filtered and washed with IM 
hydrochloric acid. The product was dried overnight to yield a white solid (624 mg, 70%).
‘H NMR (DMSO, 300 MHz): 5 8.14 (t, J=5.7 Hz, IH), 7.88 (d, Hz, 2H), 7.72 (d, J=73  
Hz, 2H), 7.60 (t, J=6.\ Hz, IH), 7.41 (t, .7=7.0 Hz, 2H), 7.33 (d, J=6.9Hz, 2H), 4.30 (d,.7=6.4 
Hz, 2H ), 4.23 (t, .7=6.4 Hz, IH), 3.77 (d, .7=5.8 Hz, 2H), 3.68 (d, J=6.1 Hz, 2H).
” C NMR (DMSO, 75 MHz): 8  171.1, 169.4, 156.4, 143.8, 140.6, 127.6, 127.0, 125.2, 120.0, 
65.7,46.76,43.2.
IR (ATR): Vmax 3350, 1729, 1655, 1545, 1425,1282, 1212,1164, 993, 817, 786, 739 cm '. 
Electrospray-ionization mass spectrometry (ESl-MS) nvi (%); 377 (100, [M+Na]'*),
1 2 0
4.3.1.2 Peptide intermediate (81)
lUPAC: JV-a-(9-Fluoren-2-ylmethyloxycarbonyl)-glycyIglycyl-2-(tert-butyIoxycarbonylamin 
o)ethylamide
°  B I
A-a-(9-Fluoreii-2-ylmethyloxycarbonyl)-glycylglycine (340 mg, 1.0 mmol) was dissolved in 
dimethylformamide (1 ml) and the solution cooled to 0 °C. 1-Hydroxybenzotriazole (150 mg, 
1.1 mmol) was added, followed by -diisopropylcarbodiimide (176 pL, 1.1 mmol). The 
reaction was stirred for 1 2  hours at room temperature and the solvent was removed under 
reduced pressure. The residue was redissolved in dichloromethane (5 ml) and was washed 
with brine (5 ml). The organic layer was then dried over sodium sulphate and concentrated 
under vacuo. The concentrated sample was then loaded on to a silica gel column. The product 
was isolated by elution with dichloromethaneiethyl acetatermethanol (15:4:1) followed by 
dichloromethane:methanol (96:4), it was isolated as a brown solid (167 mg) in yields o f 33%.
NMR (CDCI3 , 300 MHz): 6  7.77 (d, J=4.5 Hz, 2H), 7.60 (d, J=4.5 Hz, 2H), 7.41 (t, J=A.5 
Hz, 2H), 7.30 (t, J=-4.5 Hz, 2H), 6.90 (s, IH), 6.50 (s, IH), 5.55 (s, IH), 5.05 (s, IH), 4.50 (s 
J=4.5Hz), 4.22 (t, J=3.6 Hz, IH), 3.96 (d, .7=3.3 Hz, 2H), 3.90 (m, 2H), 3.36 (m, 2H), 3.27 
(m, 2H), 1.41 (s, 9H).
Electrospray-ionization mass spectrometry (ESI-MS) nv  ^(%): 519 (100, [M+Na]^.
A3 .1 3  Peptide intermediate (82)
IUPAC:N-a-(9-Fluoren-2-ylmethyloxycarbonyl)-glycylglycine-2-aminoethylamide
4M hydrochloric acid in dioxane (6 . 6  ml) was added to V-a-(9-fluoren-2- 
ylmethyloxycarbonyl)-glycylglycyl-2-(tert-butyloxycarbonylamino)ethyl amide (167 mg.
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0.33 mmol) at 0 °C. The reaction was allowed to warm to room temperature and was stirred 
for 40 minutes. The solvent was removed under reduced pressure and the product loaded onto 
a silica gel column. The product was isolated by elution with dichloromethanezmethanol 
(90:10) and was isolated as a brown solid (30.1 mg) in a yield of 79%.
*H NMR (MeOD, 300 MHz): Ô 7.79 (d, .7=5.8 Hz, 2H), 7.66 (d, .7=6.1 Hz, 2H), 7.39 (t, 7=4.5 
Hz, 2H), 7.31 (t, 7=4.5 Hz, 2H), 4.39 (d, 7=4.5Hz, 2H), 4.24 (t, 7=3.6 Hz, IH), 3.84 (d, 7=3.3 
Hz, 2H), 3.82 (d, 7=4.5 Hz, 2H), 3.46 (m, 2H), 3.03 (m, 2H).
Electrospray-ionization mass spectrometry (ESI-MS) nvè (%): 397 (100, [M+H]^.
4.3.1.4 Peptide initiator (83)
lUPAC: iV-a-(9-Fluoren-2-ylmethyloxycarbonyl)-glycylglycine-2-ethylamide-2-bromo-2-
methylpropanamide
A-a-(9-Fluoren-2-ylmethyloxycarbonyl)-glycylglycine-2-aminoethylamide (117 mg, 0.29 
mmol) was dissolved in dimethylformamide (2 ml) and triethylamine was added (80 pi, 0.58 
mmol). The solution was cooled to 0 °C and 2-bromoisobutyryl bromide (55 pL, 0.44 mmol) 
was added dropwise. The reaction was then allowed to warm to room temperature overnight 
whilst stirring. The solvent was removed under reduced pressure to yield a yellow solid. This 
was redissolved in dichloromethane (5 ml) and was extracted twice with saturated sodium 
carbonate solution (5 ml). The organic layer was then washed with 0.5 M hydrochloric acid 
and water, and dried over magnesium sulphate. The solvent was then remove under reduced 
pressure to yield a tan coloured solid (24 mg, 59% crude yield).
‘H NMR (300 MHz, CDC13) 8  7.76 (d, 7=7.76, 2H), 7.58 (d, 7=7.84, 2H), 7.40 (t, 7=6.89, 
2H), 7.32, (t, 7=7.3 Hz, 2H), 7.08, (br s, IH), 6.84 (br s,), 5.87 (t, 7 =  5.5 Hz, IH), 4.47 (d, 
> 6 .3  Hz, 2H), 4.21 (t, 7=6.7 Hz, 2H), 3.91 (t, 7 =  6.1 Hz, 4H), 3.64 (s, 2H), 3.39 (s, 2H), 
1.92 (m, 6 H).
Electrospray-ionization mass spectrometry (ESI-MS) nv2 (%): 567 (100,[M+Na]^, 569 (95, 
[M+Na]'').
122
4.3.1.5 Peptide intermediate (84)
IUPAC:7V-a-[(/er/-butoxy)carbonyl]-glycylglycine^^^
1,4-Dioxane (17.5 ml) and triethylamine (5.5 ml) were added to a solution of glycylglycine 
(3.3 g, 25 mmol) in water (ultrapure ELGA grade) (12 ml). To this di-/er/-butyl dicarbonate 
( B 0 C 2 O )  (6.0 g, 27.5 mmol) was added. The solution was allowed to stir for 16 h at room 
temperature, after which it was diluted with water (37.5 ml). The aqueous phase was washed 
twice with ethyl acetate (60 ml) prior to being acidified with 10 % citric acid (250 ml) to a 
pH of 2.0. The aqueous layer was extracted 3 times with EtOAc (100 ml). The organic layer 
was dried over sodium sulphate, filtered and dried under vacuo to yield a white solid (2.65 g, 
yield 45.6%).
'H NMR (CDCI3, 300 MHz): 5 12.49 (br s, IH), 8.06 (t, > 5 .7 6  Hz, IH), 7.00 (t, > 6 .0 6  Hz, 
IH), 3.75 (d, > 5 .3 4  Hz, 2H,), 3.55 (d, > 5 .8  Hz, 2H), 1.38 (s, 9H).
'^CNMR(CDCl3,75M H z):8 171.1,169.7,155.7,78.0,42.9,42.6,28.1,
IR (ATR): Vmax 3358, 3048 2977, 2936, 1735, 1685, 1645, 1620, 1524, 1426, 1366, 1195, 
1166,1115,1055,1033,991,886,848,780,659,633 cm ’.
Electrospray-ionization mass spectrometry (ESI-MS) nv2 (%): 232 (100, [M+H]^.
4.3.1.6 Peptide intermediate (85)
lUPAC: JV-rert-Butoxycarbonyl-2-aminoethyl-2-bromo-2-methylpropanamide.’*’
A solution of A-Boc-ethylenediamine (2.5 ml, 16 mmol), and diisopropylethylamine (2.9 ml,
16.5 mmol) in anhydrous dichloromethane (17.5 ml) was cooled in an NaCl/ice bath (-10 °C, 
bath temperature). Over a period of 15 min, 2-bromoisobutyryl bromide (2.1 ml, 16.5 mmol) 
was added to this solution.
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After 1 h, the ice hath was removed and the reaction was allowed to warm to room 
temperature and stirred for 18 h. The reaction mixture dried was under reduced pressure to 
yield a tan coloured solid which was dry-loaded on to a silica gel column. The product was 
isolated by elution with ethyl acetate:dichloromethane (3:2) as an off white solid (4.26 g, 
87%).
'H NMR (CDCb, 300 MHz): 8  7.28 (broad singlet (bs), IH), 4.99 (bs, IH), 3.38 (m, 4H), 
1.95 (singlet (s), 6 H), 1.45 (s, 9H).
"CNMR(CDCl3, 75 MHz): 8  172.7, 156.8, 79.8, 61.7,41.8,39.8,32.3,28.4.
IR (ATR): Vmax 3356, 3332, 2980, 2945, 1691, 1643, 1520, 1472, 1445, 1387, 1365, 1319, 
1275,1236, 1171,1105,1037,972,931,879,856,777,631 cm ’,
Electrospray-ionization mass spectrometry (ESI-MS) m/z (%): 331 (10, [M+Na]^, 333 (8 , 
[M+Na]"), 347 (52, [M+K]'’), 349 (53, [M+K]"), 370 (37, [M+K+Na]^, 372 (35, 
[M+K+Na]'’).
4.3.1.7 Peptide intermediate (86)
IUPAC:iV-(2-aminoethyl)-2-bromo-2-methylpropanamidemonohydrochloride’*’
NH 3  Cl
A-Boc-(2-aminoethyl)-2-bromo-2-methylpropanamide (1.00 g, 3.2 mmol) was dissolved in 4 
M HCI in 1,4-dioxane (8.16 ml, 32.6 mmol) and stirred at room temperature for 1 h. The 
reaction mixture was dried under reduced pressure to yield an off-white solid (0.78 g, 99%).
’HNMR (CD3OD, 300 MHz): 8  3.51 (t, 7=6.2 Hz, 2 H), 3.09 (t, 7=6.2 Hz, 2H), 1.95 (s, 6 H).
’ C^ NMR (CD3OD, 75 MHz): 8  175.6,60.1,40.6,39.1,32.0.
IR (ATR): Vmax 3387, 3326, 3047, 2974, 2930, 1645, 1580, 1527, 1457, 1425, 1366, 1302, 
1194,1166,1114, 1070,1033,930,887,847,815,666,632 cm ’.
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4.3.1.8 Peptide initiator (87a)
lUPAC: A-a-[(/er/-butoxy)carbonyl]-glycylglycine-(2-ammoethyl)-2-bromo-2-methylpropan 
amide
H II H
N-a-[(tert-butoxy)carbonyi]-glycylglycine (169 mg, 0.73 mmol) and #-(2-aminoethyl)-2- 
bromo-2-methylpropanamide-HCl (251 mg, 1.02 mmol) were dissolved in anhydrous 
V,V-dimethylformamide (7.5 ml). The reaction was cooled to 0 °C and PyBOP (484 mg, 
0.93 mmol) was added, followed dropwise by anhydrous triethylamine (206 pL, 1.48 
mmol). The reaction was allowed to warm to room temperature and stirred for 22 hours. 
The reaction mixture was concentrated under reduced pressure to yield a brown oil. Isolation 
of the product was attempted by silica gel column chromatography eluting with 
methanol lethyl acetate (2:98), however this was unsuccessfiil and a crude brown mixture 
resulted.
NMR (CDCI3, 300 MHz): Ô 8.69 (bs, 2H), 5.29 (bs, IH), 3.93 (d, J  =  6.0 Hz, 2H), 3.84 (d, 
J  = 6.0 Hz, 2H), 3.45 (t, J =  5.9 Hz, 4H), 1.89 (s, 6 H), 1.42 (s, 9H).
4.3.1.9 Peptide initiator (87b)
lUPAC: iV-a-[(tert-butoxy)carbonyl]-glycylglycine-(2-aminoethyl)-2-bromo-2-methylpropan 
amide
A-a-[(/er/-butoxy)carbonyl]-glycylglycine (281 mg, 1.21 mmol), 1-Hydroxybenzotriazole 
(174 mg, 1.29 mmol) and triethylamine (119 pL, 0.86 mmol) were dissolved in 
dichloromethane (5 ml). To the solution A-(2-aminoethyl)-2-bromo-2- 
methylpropanamide-HCl. (250 mg, 0.86 mmol) was added and the mixture was cooled to 0 
°C in an ice bath after which V,V-dicyclohexylcarbodiimide (177 mg, 0.86 mmol) was 
added. After 24 h the solution was added to water and extracted with DCM. The combined 
organic layers were washed twice with an aqueous citric acid solution ( 1 0  %) and twice with
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brine. The organic layer was dried over MgS04 and concentrated under reduced pressure. 
Isolation of the product was attempted by silica gel column chromatography eluting with 
ethyl actetateiethanol (80:20), however this was unsuccessfiil and resulted in a brown oil (7.3 
mg, 1.5% yield).
NMR (CDCls, 300 MHz): Ô 3.95 (d, J  = 6.0 Hz, 2H), 3.85 (d, J  = 3.0 Hz, 2H), 3.45 (t,
5.9 Hz, 4H), 1.89 (s, 6 H), 1.41 (s, 9H).
A 3.\.\0P ep tide  initiator (87c)
lUPAC: V-a-[(/er/-butoxy)carbonyl]-glycylglycine-(2-aminoethyl)-2-bromo-2-methylpropan 
amide
H TT H
>r°T
7V-a-[(fer/-butoxy)carbonyl]-glycylglycine (0.6 g, 2.6 mmol), 1-hydroxybenzotriazole (0.45 g, 
3.4 mmol) and diisopropylethylamine (2.34 ml, 13 mmol) were dissolved in dichloromethane 
(7.5 ml). To the solution A-(2-aminoethyl)-2-bromo-2-methylpropanamide- HCI (0.96 g, 3.9 
mmol) was added and the mixture was cooled to 0 °C in an ice bath after which l-ethyl-3-(3- 
dimethylaminopropyl)carbodiimide HCl (744 mg, 3.4 mmol) was added. After 24 h the 
solution was added to water (25 ml) and extracted with DCM (25 ml x 3 ). The combined 
organic layers were washed twice with an aqueous citric acid solution (10 %) (50 ml), twice 
with brine (50 ml). The organic layer was dried over MgS04 and concentrated under reduced 
pressure. Isolation of the product was attempted by silica gel column chromatography eluting 
with ethyl actetate:ethanol (80:20), However this was unsuccessful and a crude brown 
mixture resulted.
H^ NMR (CDCI3, 300 MHz): 5 3.97 (d, J  = 6.0 Hz, 2H), 3.86 (d, J  = 3.0 Hz, 2H), 3.43 (t, J =
5.9 Hz, 4H), 1.90 (s, 6 H), 1.39 (s, 9H).
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4.3.2 Solid Phase Peptide Synthesis of Peptide Initiators
4.3.2.1 Solid Phase Peptide Synthesis using Wang Resin
Solid phase peptide synthesis was performed according to the protocols by Chan and 
White. Wang resin (1.1 mmol g"^  loading) was placed in a dry PD-10 column and covered 
with three bed volumes of dichloromethane (DCM). The PD-10 column was then sealed and 
placed on a rotary mixer for 30 minutes to swell the resin. A vacuum was applied to remove 
the DCM and three bed volumes of dimethylformamide (DMF) were then added. The resin 
was then agitated for 1 minute by hand before a vacuum was applied to drain the resin. Three 
bed volumes of DMF were then added and the cycle repeated four times.
Fmoc-amino acid (10 equivalents to resin loading) was added to an oven dried vial equipped 
with a magnetic stirrer. DMF (approximately 1 ml per mmol o f Fmoc-amino acid) was then 
added and the solution stirred until dissolution had taken place. -diisopropylcarbodiimide 
(5 eq.) was added and the solution stirred for 10 minutes to form the symmetrical anhydride. 
The symmetrical anhydride solution was added to the resin followed by a solution of 4- 
(dimethyl)aminopyridine (0.1 eq.) in DMF. The PD-10 column was then sealed and placed on 
a rotary mixer for 2 hours. After 2 hours the residual reactants and solvent were removed 
from the resin and the process was repeated with new reagents. Once complete the unreacted 
reagents were removed by application of a vacuum. The resin was washed 5 times with DMF 
as described above.
The Fmoc group was subsequently removed from the amino acid by adding 20% (v/v) 
piperidine in DMF (10 ml per g of resin) firstly for 5 minutes and then for an additional 20 
minutes. After removal of the piperidine solution, the resin was washed 5 times with DMF. 
The extent of Fmoc removal from the amino acid was determined using the Kaiser test and 
the TNBS test (Section 4.3.2.11). Blue and yellow/red beads were considered a positive result 
for presence of resin-bound free amine.
Fmoc-amino acid (5 eq.) and o-(benzotriazol-1 -yl)-jV^  -tetramethyluronium
tetrafluoroborate (4.9 eq.) were added to a dry glass vial and dissolved in DMF 
(approximately 1 ml per mmol of Fmoc-amino acid). A,A^-diisopropylethylamine (DIPEA) 
(10 eq.) was added to the coupling agent and amino acid solution and mixed thoroughly. The 
solution was then added to the resin and mixed for 1 hour. After 1 hour, 10 mg of resin was 
transferred with a wide-mouthed Pasteur pipette to a small glass fritted funnel. The resin was
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washed and dried by washing successively 5 times with DMF, DCM, methanol and hexane. 
The extent of acylation was then determined using the Kaiser test and the TNBS test (Section
4.3.2.11). colourless beads were considered a negative result for the presence of resin-bound 
free amine. If a positive result is present the resin was allowed to mix for an additional hour. 
After 2 hours if a positive result still remained, the unreacted solution was removed under 
vacuo and the process was repeated with new reagents. The resin was then washed 5 times 
with DMF. The cycle of deprotection and coupling described above was repeated to add the 
additional amino acids. An exception was made for the coupling of Fmoc-Lysine(Mmt)-OH 
where half the equivalence of each reagent was used.
4.3.2.2 Removal o f  the 4-monomethoxytrityl protecting group from  Wang 
resin bound peptide
The 4-monomethoxytrityl (Mmt) protecting group was removed from the lysine side chain 
whilst the peptide was still attached to the Wang resin. The Mmt protecting group was 
removed by treating the resin with 3% trifluoroacetic acid (TFA), 5% triisopropylsilane (TIS) 
in dichloromethane (DCM, 5 ml) solution every 5 minutes. The removal o f the Mmt group 
was monitored by observing the orange colour produced by Mmt cations as they were 
removed from the peptide. Deprotection was repeated until the supernatant was colourless. 
The extent of deprotection was then confirmed using the concentrated TFA, Kaiser and 
TNBS tests with a colourless solution, blue and yellow/red beads confirming the presence of 
resin-bound free amine respectively.
4.3.2.3 Modification o f  the lysine side chain on Wang resin bound peptide
Modification with a functional carboxylic acid was accomplished in a similar manner to the 
Fmoc-amino acid coupling, where the fiinctional carboxylic acid (5 eq.) and o-(benzotriazol-
l-yl)-AT,W,A^ ’,W-tetramethyluronium tetrafluoroborate (4.9 eq.) were added to a dry glass vial 
and dissolved in DMF (approximately 1 ml per mmol of functional carboxylic acid). N,N- 
diisopropylethylamine (DIPEA) (10 eq.) was added to the coupling agent and amino acid 
solution and mixed thoroughly. The solution was then added to the resin and mixed for 1 
hour. After 1 hour, 10 mg of resin was transferred with a wide-mouthed Pasteur pipette to a 
small glass fritted funnel. The resin was washed and dried by washing successively 5 times 
with DMF, DCM, methanol and hexane. The extent of acylation was then determined using 
the Kaiser test and the TNBS test (Section 4.3.2.11). Colourless beads were considered a 
negative result for presence of resin-bound free amine. If a positive result was present the
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resin was allowed to mix for an additional hour. After 2 hours if a positive result still 
remained, the unreacted solution was removed under vacuo and the process was repeated 
with new reagents. The resin was then washed and dried by washing successively 5 times 
with DMF, DCM, methanol and hexane.
Modification with functional acid chloride was achieved by mixing the functional acid 
chloride (2.49 eq.) and triethylamine (2.5 eq) with DMF (approximately 1 ml per mmol of 
functional acid chloride). This solution was added to the resin and mixed for 10 minutes. The 
excess reagents were then removed and the resin was washed 5 times with DMF. The extent 
of acylation was then determined using the Kaiser test and the TNBS test (Section 4.3.2.11). 
Colourless beads were considered a negative result for presence of resin-bound fi'ee amine. 
The resin was then washed and dried by washing successively 5 times with DMF, DCM, 
methanol and hexane.
4.3.2.4 Cleavage and isolation o f  the Wang resin bound peptide
A cleavage mixture of 95% TFA, 2.5% TIS and 2.5% H2O by volume (1 ml per 100 mg of 
resin) was prepared and added to the resin in the PD-10 column. The column was then placed 
on a rotary mixer for 3 hours. The column was then placed over an Eppendorff containing a 
10 fold excess of cold ether. The column cap was then removed and the cleavage solution 
eluted into the ether. The resin was washed 3 times with concentrated TFA (1 ml per 500 mg 
of resin). The precipitated peptide was centrifuged at 4000 rpm for 5 minutes to isolate the 
peptide. The ether was carefully decanted off before fi-esh ether was added, and the 
Eppendorff was sealed and shaken to re-suspend the peptide. The cycle of centrifugation and 
suspension was repeated four times before the pellet o f peptide was dissolved in water, frozen 
at -20 °C and lyophilised (-55°C >0.5 mPa) overnight to obtain a dry, off-white solid.
4.3.2.5 Peptide initiator (95)
lUPAC: Fmoc-Glycylglycyl-A^-(2-bromoisobutyryl)-lysine
Fmoc-Glycylglycyl-A^-(2-bromoisobutyryl)-lysine was synthesised according to the 
procedure in 4.3.2.1 with the exception of the estérification of Fmoc-lysine(Mmt) to the 
Wang Resin where half the number of equivalences of each reagent was used. The mass of 
each reagent used is shown in Table 10. Half of the resin by dry-weight was removed prior to 
cleavage for use in 4.3.2.6 and the rest was cleaved to yield an off-white solid (30 mg, 62%).
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Table 10. Masses of reagents used for the synthesis of Fmoc-glycylgIycyl-N^-(2- 
bromoisobutyry!)-Iysine
Mass o f Resin
300 mg
Estérification Amino Acid DIG DMAP
Fmoc-lysine(Mmt) 1057.3 mg 127.7 pL 4.0 mg
Coupling Amino Acid TBTU DIPEA
Fmoc-glycine 490.5 mg 519.2 mg 574.8 pL
Fmoc-glycine 490.5 mg 519.2 mg 574.8 pL
a»Bromoisobutyric acid 275,6 mg 519.2 mg 574.8 pL
IR (ATR): Vmax 3285, 3073, 2936, 2755, 1644, 1530, 1437, 1186, 1140, 960, 905, 841, 798, 
721, 629 cm \
Electrospray-ionization mass spectrometry (ESl-MS) nv2 (%): 631 (98, [M+H]^, 633 (100, 
[M+H]"), 653 (60, [M+Na]^, 655 (57, [M+Na]").
4.3.2.6 Peptide initiator (97)
lUPAC: Glycylglycyl-A^-(2-bromoisobutyryl)-lysine
Glycylglycyl-7V^-(2-bromoisobutyryl)-lysme was synthesised from the same batch as used in 
4.3.2.5, the Fmoc group was removed prior to cleavage using 20% piperidine in 
dimethylformamide. The product was cleaved from the resin to yield an off-white solid (24 
mg, 39%).
Electrospray-ionization mass spectrometry (ESl-MS) nv2 (%): 409 (100, [M+H]^, 411 (98, 
[M+H]").
4.3.2.7 Peptide initiator (109)
lUPAC: Fmoc-glycylglycyl-A^-(2-bromoisobutyryl)-lysinoserinyl serine
Fmoc-glycylglycyl-A^-(2-bromoisobutyryl)-lysinoserinylserine was synthesised according to 
the procedure in 4.3.2.1 with the exception of the estérification of Fmoc-lysine(Mmt) to the 
Wang Resin where half the number of equivalences of each reagent was used. The mass of 
each reagent used is shown in Table 11. Half of the resin by dry-weight was removed prior to
130
cleavage for use in 4.3.2.S and the rest was cleaved to yield a cream coloured solid (18.0 mg,
OK
Table 11. Masses of reagents used for the synthesis of Fmoe-glycylglycyl-N^-(2- 
bromoisobutyryI)-serinylserine
Mass o f  Resin
500.0 mg
Estérification Amino Acid D ie DM AP
Fmoc-s€rine(tBu)-OH 2108.7 mg 425.8 mg 6.7 mg
Coupling Amino Acid TBTU DIPEA
Fmoc-serine(tBu)-OH 1635.2 mg 432.7 mg 479.0 pL
Fmoc-lysine(Mmt)-OH 1762.2 mg 865.3 mg 958.0 pL
Fmoc-glycine-OH 1635.2 mg 865.3 mg 958.0 pL
Fmoc-glycine-OH 1635.2 mg 865.3 mg 958.0 pL
a-Bromoisobutyric acid 918.5 mg 865.3 mg 479.0 pL
IR (ATR): Vmax 3281, 3083, 2937, 1633, 1531, 1371, 1266, 1184, 1139, 960, 905, 841, 798, 
623 cm'\
Electrospray-ionization mass spectrometry (ESl-MS) nv2 (%): 805 (100, [M+H]^, 807 (98, 
[M+H]^.
4.3.2.8 Peptide initiator (111)
lUPAC: Glycylglycyl-iV^-(2-bromoisobutyryl)-lysinoserinylserine
Glycylglycyl-A^-(2-bromoisobutyryl)-serinylserine was synthesised from the same batch as 
used in 4.3.2.7, the Fmoc group was removed prior to cleavage using 20% piperidine in 
dimethylformamide. The product was cleaved from the resin to yield an off-white solid (43.0 
mg, 29.5%).
NMR (D2O, 300 MHz): 5 4.49 (t, J=3.0 Hz, IH), 4.46 (t, J=3.0 Hz, IH), 4.31 (t, J=3.0 Hz, 
IH), 3.97 (d, J=3.0 Hz, 2H), 3.93 (dd, J=3.0 Hz, 2H), 3.82 (m, 4H), 3.17 (t, J=6.0 Hz, 2H ),
1.85 (s, 6 H), 1.81-1.65 (m, 2H), 1.51 (quin, .7=4.5 Hz, 2H), 1.34 (m, 2H).
NMR (D2O, 75 MHz): Ô 174.5, 174.2, 173.1, 171.4, 171.1, 167.7, 61.1, 59.8, 55.4, 54.9, 
53.8,42.1,40.3, 39.6, 30.7,30.6,27.1,22.2.
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IR (ATR): Vmax 3281, 3083, 2937, 1633, 1531, 1371, 1266, 1184, 1139, 960, 905, 841, 798, 
623 c m \
Electrospray-ionization mass spectrometry (ESI-MS) nÿz (%): 583 (100, [M+H]^, 585 (96, 
[ M + H f ) .
4.3.2.9 Peptide initiator (112)
lUPAC: Glycylglycyl-A^-(2-bromoisobutyryl)-lysinoglutamic acid
GlycyIglycyl-A^-(2-bromoisobutyryl)-lysinoglutamic acid was synthesised according to the 
procedure in 4.3.2.1 with the exception of the estérification o f Fmoc-lysine(Mmt) to the 
Wang Resin where half the number of equivalences of each reagent was used. The mass of 
each reagent used is shown in Table 12.40% of the resin by dry-weight was removed prior to 
coupling of the final amino acid for use in 4.3.2.10 and the rest was modified with a- 
bromoisobutyric acid. The Fmoc group was then removed using 20% piperidine in 
dimethylformamide and the peptide cleaved to yield a cream coloured solid (198 mg, 73%).
Table 12. Masses of reagents used for the synthesis of glycylglycyl-N^-(2-bromoisobutyryI)- 
glutamic acid
Mass o f  Resin
500.0
Estérification Amino Acid D ie DM AP
Fmoc-glutamic acid(OtBu)-OH 2340.1 mg 425.8 pL 6.7 mg
Coupling Amino Acid TBTU DIPEA
Fmoc-lysine(Mmt)-OH 1762.2 mg 432.7 pL 479.0 pL
Fmoc-glycine-OH 1635.2 mg 865.3 pL 958.0 pL
Fmoc-glycine-OH 1635.2 mg 865.3 pL 958.0 pL
a-Bromoisobutyric acid 918.5 mg 865.3 pL 479.0 pL
'H NMR (DMSO, 300 MHz): 8  8.43 (m, IH), 8.15 (d .V = 8.1 , IH), 8.03 (t, J=5.7 Hz, IH),
7.95 (d, y=6 . 6  Hz, 2H), 4.22 (m, 2H ), 4.03 (q, J=6.9 Hz, 2H), 3.82 (m. 2H), 3.52 (s, 2H),
3.06 (m, 2H), 2.23 (t, J=1.5 Hz, 2H), 1.85 (s, 6 H), 1.80-1.52 (m, 2H), 1.40 (m, 2H), 1.27 (m.
2H).
'^ C NMR (DMSO, 75 MHz): 5 174.3, 173.1, 170.9, 170.4, 168.2, 167.3, 60.8, 52.6, 52.1,
44.4, 40.3,31.1,28.7,27.1,22.5.
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IR (ATR): V m a x  3284, 3072, 2934, 2362, 1649, 1533, 1440, 1408, 1305, 1197, 1137, 1047, 
958.915, 798,636 cm'\
Electrospray-ionization mass spectrometry (ESI-MS) nv2 (%): 538 (98, [M+H]^, 540 (100, 
[ M + B f ) .
4 3 2A 0Peptide monomer (113)
lUPAC: Glycylglycyl-iV^-(methyacrylamidyl)-lysinoglutamic acid
Glycylglycyl-iV^-(methylacrylamidyl)-lysinoglutamic acid was synthesised from the same 
batch as used in 4.3.2.9, by resuspending the resin in dimethylformamide (3 ml) and adding 
methacryloyl chloride (114 mg, 107 pL, 1.1 mmol) and triethylamine (121 mg, 167 pL, 1.2 
mmol) The reaction was mixed for 20 minutes, washed with DMF (3 ml) and the cycle 
repeated another 2 times. The Fmoc group was then removed prior to cleavage using 20% 
piperidine in dimethylformamide. The product was cleaved from the resin to yield an off- 
white solid (80.0 mg, 31.0%).
NMR (MeOD, 300 MHz): 5 5.60 (d, 7=3.0 Hz, IH), 5.28 (d, 7=3.0 Hz, 2H), 4.32 (m, 2H), 
3.91 (m, 2H), 3.84 (m, 2H), 3.68 (m, 2H) 3.17 (m, 2H), 2.34 (t, 7=9.0 Hz, 2H), 2.11 (m, 2H),
1.86 (m, 3H), 1.49 (m, 2H), 1.34 (m, 2H).
NMR (DMSO, 75 MHz): 5 174.9, 173.2, 172.7, 170.1, 169.6, 166.4, 139.7, 118.8, 53.0, 
51.5,41.7, 39.9,38.7, 30.8,29.6,28.4,26.2,22.5,17.2.
IR (ATR): Vmax 3286,3074,2934, 1650,1538, 1447, 1411,1308, 1197, 1138,1020, 958, 921, 
847, 841,798, 721,648 cm \
Electrospray-ionization mass spectrometry (ESI-MS) nv2 (%): 526 (100, [M+3Na]^. 
4 3 .2 .l\K a ise r  Test
The standard procedure^ ^  ^ used for performing a Kaiser test was to add two drops of Kaiser 
test solutions A, B and C to a small sample (approximately 10 beads) of the solid phase resin 
in a small test tube. This was then placed in a heating block set to 100 °C for 5 minutes.
The procedure was modified for testing during the presence of 4-methyltrityl on the lysine 
side chain by the omission of Kaiser test solution B due to a false positive result that had been 
previously.
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The presence of an exposed amine (positive result) was indicated by a purple colour, a 
negative test was indicated by an orange colour.
The Kaiser test solutions were prepared as follows: Kaiser test A: ninhydrin dissolved (5 g, 2 
mmol) in methanol (100 ml), Kaiser test B: phenol (80 g, 0.425 mol) was dissolved in 
methanol (20 ml), Kaiser test C: 0.00 IM aqueous potassium cyanide (2 ml, 2 pmol) was 
added to pyridine (98 ml, 96.2 g, 1.21 mol).
4 3 2 A 2 T N B S  Test
The standard procedure^ ^  ^ used for performing a TNBS test was to wash a small sample 
(approximately 10 beads) o f the solid phase resin several times with DMF. The beads were 
then suspended in DMF and one drop o f TNBS test solutions A and B were added and the 
solution left for 1 0  minutes.
The beads were washed with DMF and examined. The presence of an exposed amine 
(positive result) was indicated by intense orange/red beads, a negative test was indicated by 
colourless beads.
A32A 2C oncentrated TFA Test
A small sample (approximately 10 beads) of the solid phase resin in a small test tube and two 
drops of concentrated TFA were added. The presence of complete removal of the Mmt group 
was indicated by colourless beads. Incomplete removal was indicated by orange beads and 
solution.
4.3.3 Solid Phase Peptide Synthesis o f Self-Assembling Peptides
4.3.3.1 Self-assembling peptide (131)
lUPAC: Phenylalaninylglutamylphenylalaninylglutamylphenylalaninyllysinylphenylalaninyl 
Lysinyllysine - Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys-Lys
Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys-Lys was synthesised according to procedure 4.3.2.1. The 
mass of each reagent used is shown in Table 13. 60% of the resin by dry-weight was 
removed prior to cleavage for use in 4.3.3.2-4.3.3.5. The product was cleaved from the resin 
to yield an off-white solid (349.3 mg, 63.5%).
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Table 13. Masses of reagents used for the synthesis of phenylalaninylglutamylphenylalaninyl 
glutamylphenylalanlnyllysinylphenylalaninyllysinyllysine
Mass o f Resin
1000 mg
Estérification Amino Acid D ie DMAP
Fmoc-lysine(Boc)-OH 2574.0 mg 428.0 pL 13.4 mg
Coupling Amino Acid TBTU DIPEA
Fmoc-Iysine(Boc)-OH 2574.0 mg 1730.6 mg 1916 pL
Fmoc-phenylalanine-OH 2128.5 mg 1730.6 mg 1916 pL
Fmoc-lysine(Boc)-OH 2574.0 mg 1730.6 mg 1916 pL
Fmoc-phenylalanine-OH 2128.5 mg 1730.6 mg 1916 pL
Fmoc-glutamic acid(OtBu)-OH 2237.5 mg 1730.6 mg 1916 pL
Fmoc-phenylalanine-OH 2128.5 mg 1730.6 mg 1916 pL
Fmoc-glutamic acid(OtBu)-OH 2237.5 mg 1730.6 mg 1916 pL
Fmoc-phenylalanine-OH 2128.5 mg 1730.6 mg 1916 pL
'H NMR (DMSO, 300 MHz): 8  8.57 (s, 2H), 8.00 (m, lOH), 7.21 (m, 12H), 4.54 (m, 2H), 
4.04 (m, 2H), 3.00 (m, 4H) 2.85 (m, 8 H), 2.22 (m, 2H), 1.84 (m, 2H), 1.76 (m, 2H), 1.55 (m, 
8 H), 1.26 (m, 6 H).
IR (ATR): Vmax 3277,3073,2934,1628,1525, 1440,1417, 1307,1197,1135,1049, 959, 913, 
838,798,721 cm '.
Electrospray-ionization mass spectrometry (ESI-MS) nv2 (%): 625 (100, [M+2H])^* 1249 
(36, [M+H]").
4.3.3.2 Self-assembling peptide initiator (133)
lUPAC: 2-Bromoisobutyrylphenylalaninylglutamylphenyl alaninylglutamylphenylalaninyl 
lysinylphenylalaninyllysinyllysine - 2-Bromoisobutyryl-Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys- 
Lys
2-Bromoisobutyryl-Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys-Lys was synthesised from the same 
batch of resin as used in 4.3.3.1. 20% of the resin by dried weight was modified using 2- 
bromoisobutryric acid (275 mg, 1.6 mmol), o-(benzotriazol-l-yl)-A,A^,A',A- 
tetramethyluronium tetrafluoroborate (519 mg, 1.6 mmol) and diisopropylethylamine (425
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mg, 574 pL, 4.4 mmol) in dimethylformamide (3 ml) according to procedure 4.3.2.1. The 
product was cleaved from the resin to yield a white solid (301.5 mg, 98.0%).
'H NMR (DMSO, 300 MHz): 5 7.99 (m, 8 H), 7.20 (m, 12H), 4.51 (m, 2H), 4.29 (m, 3H), 
3.02 (m, 4H), 2.76 (m, 8 H), 2.18 (m, 2H ), 1.84 (m, 2H), 1.72 (m, 6 H), 1.53 (m, 12H), 1.35 
(m, 6 H).
IR (ATR): Vmax 3734, 3406, 3276, 3062, 2935, 1626, 1523, 1454, 1302, 1198, 1134, 1048, 
960, 881,838,798,697 cm '.
Electrospray-ionization mass spectrometry (ESl-MS) nVz (%): 699 (92, [M+2H]^^, 700 (100, 
[M+2H]"'), 1397 (15, [M+H]^, 1399 (12, [M+H]").
4.3.3.3 Self-assembling monomer (135)
lUPAC: Methacrylamidylphenylalaninylglutamylphenylalaninylglutamylphenylalaninyl 
Lysinylphenylalaninyllysinyllysine -  Methacrylamidyl-Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys- 
Lys
Methacrylamidyl-Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys-Lys was synthesised from the same 
batch of resin as used in 4.3.3.1. 20% of the resin by dried weight was modified using 
methacryloyl chloride (114 mg, 107 pL, 1.1 mmol) and triethylamine (121 mg, 167 pL, 1.2 
mmol) in 3 ml of dimethylformamide The reaction was mixed for 20 minutes, washed with 
DMF (3 ml) and the cycle repeated another 2 times. The product was cleaved from the resin 
to yield a white solid (229.4 mg, 79.2%).
'H NMR (DMSO, 300 MHz): 8  7.99 (m, 9H), 7.20 (m, 12H), 5.57 (s, IH), 5.32 (s, IH), 4.53 
(m, 2H), 4.28 (m, 3H), 2.99 (m, 4H), 2.75 (m, 8 H), 2.15 (m, 2H ), 1.81 (m, 2H), 1.66 (m, 
4H), 1.66 (m, 3H), 1.51 (m, 6 H), 1.26 (m, 6 H).
IR (ATR): Vmax 3276, 3063,2935, 1627, 1523, 1454,1302,1198, 1134, 1057, 960, 837, 799, 
697 cm'.
Electrospray-ionization mass spectrometry (ESl-MS) nvi (%): 659 (100, [M+2H]^^, 660 (26, 
[M+2H]^^, 1317 (22, [M+H]"), 1319 (7, [M+H]").
4.3.3.4 Self-assembiing di-glypeptide (137)
lUPAC: glycylglycylphenylalaninylglutamylphenylalaninylglutamylphenylalaninyllysinyl
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Phenylalaninyllysinyllysine-Gly-Gly-Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys-Lys
Gly-Gly-Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys-Lys was synthesised from the same batch of 
resin as used in 4.3.3.1. 20% of the resin by dried weight was modified using Fmoc- 
glycylglycine (584 mg, 1.6 mmol), o-(benzotriazol-1 -yl)-jV)7yj#',7V -^tetramethyluronium 
tetrafluoroborate (519 mg, 1.6 mmol) and diisopropylethylamine (425 mg, 574 pL, 4.4 
mmol) in dimethylformamide (3 ml) according to procedure 4.3.2.1. The Fmoc group was 
removed prior to cleavage using 2 0 % piperidine in dimethylformamide, the resin dried and 
10% of the dried weight was used for cleavage. The product was cleaved from the resin to 
yield a white solid (134 mg, 44.7%).
‘H NMR (DMSO, 300 MHz): 8  8.60 (m, 2H), 8.00 (m, 12H), 7.21 (m, 12H), 4.30 (m, 2H),
4.18 (m, 3H), 3.55 (m, 4H)*, 3.00 (m, 4H), 2.80 (m, 8 H), 2.22 (m, 2H), 1.84 (m, 2H), 1.75 
(m, 4H), 1.61 (m, 8 H), 1.34 (m, 6 H).
* overlapping with water.
IR (ATR): Vmax 3412, 3277, 3062, 2934, 1669, 1626, 1523, 1439, 1301, 1198, 1134, 1048, 
960, 882, 837, 798, 721,697 cm \
Electrospray-ionization mass spectrometry (ESI-MS) m4 (%): 455 (100, [M+3H]^^, 682 (81, 
[M +2Bf%  683 (33, [M+2H]^") 1363 (19, [M+H]"), 1364 (14, [M+Uf).
4.3.3.5 Self-assembling tetra-gfypeptide (139)
lUPAC: glycylglycylglycylglycylphenylalaninylglutamylphenylalaninylglutamylphenyl
Alaninyllysinylphenylalaninyllysinyllysine - Gly-Gly-Gly-Gly-Phe-Glu-Phe-Glu-Phe-Lys- 
Phe-Lys-Lys
Gly-Gly-Gly-Gly-Phe-Glu-Phe-Glu-Phe-Lys-Phe-Lys-Lys was synthesised from the same 
batch of resin as used in 4.3.3.4. The resin was modified using Fmoc-glycylglycine (584 mg,
1.6 mmol), o-(benzotriazol-l-yl)-A^Aj#',A^-tetramethyluronium tetrafluoroborate (519 mg,
1.6 mmol) and diisopropylethylamine (425 mg, 574 pL, 4.4 mmol) in dimethylformamide (3 
ml) according to procedure 4.3.2.1. The Fmoc group was removed prior to cleavage using 
20% piperidine in dimethylformamide and the resin dried. The product was then cleaved 
from the resin to yield a white solid (218 mg, 67.1%).
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'h  NMR (DMSO, 300 MHz): 6  8.60 (m, 2H), 8.00 (m, 16H), 7.25 (m, 12H), 4.30 (m, 2H),
4.18 (m, 3H), 3.60 (s, 4H), 3.00 (m, 4H), 2.80 (m, 8 H), 2.15 (m, 2H), 1.84 (m, 2H), 1.75 (m, 
2H) 1.61 (m, 8 H), 1.34 (m, 6 H).
IR (ATR): 3424, 3275, 3067, 2935, 1669, 1626, 1523, 1439, 1302, 1198, 1135, 1049,
960, 880, 838, 798, 721, 697 cm '.
Electrospray-ionization mass spectrometry (ESI-MS) m^ (%): 493 (100, [M+3H]^^, 739 (94 
[M+2H]^"), 1477 (8 , [M+H]"), 1478 (6 , [M+H]").
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4.4 Controlled Radical Polymerisation
4.4.1 Graft-to/through polymer synthesis
4.4.1.1 A TR P synthesis o f  peptide-polymer conjugate (140) in water using 
peptide initiator (83)
01igo(ethylene glycol) methyl ether methacrylate (250 mg, 475 g/mol, 0.59 mmol), deionised 
water (500 pi) and a magnetic stirrer bar were added to a 5 ml Schlenk flask. A rubber 
septum was fitted to the open neck. A small needle was placed into the septum to act as a 
vent and a large needle placed to act as a bubbler. The flask was bubbled with nitrogen for 2 
hours.
To a nitrogen filled sample vial, copper(I)bromide (4.3 mg, 0.03 mmol) and 2,2-bipyridine 
(9.3 g, 0.06 mmol) were added and the vial sealed with a cap. The copper(I)bromide and 2,2- 
bipyridine were added to the Schlenk flask under a positive pressure on nitrogen and the flask 
was sealed with a rubber septum. The flask was bubbled for an additional 30 minutes to 
deoxygenate the solution and peptide-initiator (83) (17 mg, 0.03 mmol) was then added under 
a positive pressure of nitrogen. The flask was then immersed in a water bath maintained at 25 
°C, under constant stirring.
After 20 hours the polymerisation reaction was terminated by exposing the reaction vessel to 
air and diluting the reaction mixture in deionised water. The resulting mixture was passed 
through a silica column to remove the catalyst complex then analysed by GPC and NMR 
spectroscopy (Yield: 4 mg).
'H NMR (MeOD, 300 MHz): 8  7.85 (d, J=7.76, O.OIH), 7.71 (d, ,^7.84, O.OIH), 7.38 (t, 
y=6.89, O.OIH), 7.32, (d, J=6 Hz, O.OIH), 4.28 (br s, 2H), 3.72 (br s, 2H), 3.64 (m, 40H), 3.55 
(br s, 2H), 3.29 (t, J=7.5 Hz, 2H), 1.94 (br s, 2H), 1.08-0.94 (br s, 3H).
GPC (DMF + 0.0IM LiBr, 1 ml/min, 50 °C): 12.54 minutes, Mn: 101,393 g/mol, Mw:
143,014 g/mol, PDI: 1.41.
AAA.2 A TRP synthesis o f  peptide-polymer conjugate (141) in water using 
peptide initiator (111)
In a typical polymerisation within this study, an initiator stock solution was prepared by 
dissolving bipyridyl (6.5 mg, 0.04 mmol) was dissolved in de-ionised water (1000 pi) in a
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dry vial. The solution was deoxygenated by purging with nitrogen for 1 hour before 
copper(I)bromide (3.0 mg, 0.02 mmol) was added and solution deoxygenated for an 
additional 30 minutes.
01igo(ethylene glycol) methyl ether methacrylate (100 mg, 475 g/mol, 0.21 mmol) and 
peptide initiator (1 1 1 ) (1 . 2  mg, 0 . 0 0 2  mmol) were dissolved in deionised water ( 1 0 0  pi) in a 
dry vial. The solution was deoxygenated by purging with nitrogen for 1 hour. To start the 
polymerisation the initiator stock solution (100 pL) was transferred via a deoxygenated 
syringe.
Aliquots of solution were removed via a deoxygenated syringe for kinetic analysis, these 
were quenched by dilution in deuterated water and analysed for monomer conversion using 
proton NMR. (Yield: 5 mg)
'H NMR (D2O, 300 MHz): 8  6.17* (br s, 2H), 5.75* (br s, 2H), 4.35 (q, J=3 Hz, 2H), 3.84 
(m, 2H), 3.70 (m, 40H), 3.63 (br s, 2H), 3.40 (m, 2H), 1.94** (m, 2H), 1.01-0.99 (br s, 3H)
*monomer, ** monomer overlap
4.4.1.3 ATRP synthesis o f  peptide-polymer conjugate (142) in DM SO using
peptide initiator (111)
In a typical polymerisation, an initiator stock solution was prepared by dissolving bipyridyl 
(6.5 mg, 0.04 mmol) in DMSO (1000 pi) in a dry vial. The solution was deoxygenated by 
purging with nitrogen for 1 hour before copper(I)bromide (3.0 mg, 0.02 mmol) was added 
and the solution was deoxygenated for an additional 30 minutes.
01igo(ethylene glycol) methyl ether methacrylate (100 mg, 475 g/mol, 0.21 mmol) and 
peptide initiator (111) (1.2 mg, 0.002 mmol) were dissolved in DMSO (100 pi) in a diy vial. 
The solution was deoxygenated by purging with nitrogen for 1 hour. To start the 
polymerisation the initiator stock solution (100 pL) was transferred via a deoxygenated 
syringe.
Aliquots of solution were removed via a deoxygenated syringe for kinetic analysis, these 
were quenched by dilution in deuterated water and analysed for monomer conversion using 
proton NMR. The kinetic samples were then dialysed against distilled water for 24 hours 
prior to lyophilisation and analysis with gel-permeation chromatography. (Yield: 5 mg)
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‘h  NMR (D2O, 300 MHz): 8  6.17* (br s, 2H), 5.74* (br s, 2H), 4.37 (m, 2H), 3.84 (br s, 2H), 
3.70 (m, 40H), 3.64 (br s, 2H), 3.39 (t, J=1.5 Hz, 2H), 1.95** (m, 2H), 1.07-0.93 (br s, 3H)
*monomer, ** monomer overlap
GPC (DMF + O.OIM LiBr, 1 ml/min, 50 °C): 11.5 minutes, M„: 25,511 g/mol, M :^ 30,613 
g/mol, PDI: 1.2.
4.4.1.4 synthesis o f  peptide-polymer conjugate (143) in DM SO using
peptide initiator (112)
In a typical polymerisation, an initiator stock solution was prepared by dissolving bipyridyl 
(3.9 mg, 0.02 mmol) in DMSO (200 pi) in a dry vial. The solution was deoxygenated by 
purging with nitrogen for 1 hour before copper(I)bromide (1.8 mg, 0.01 mmol) was added 
and the solution deoxygenated for an additional 30 minutes.
01igo(ethylene glycol) methyl ether methacrylate (600 mg, 475 g/mol, 1.2 mmol) and peptide 
initiator (112) (6 . 8  mg, 0.01 mmol) were dissolved in DMSO (200 pi) in a dry vial. The 
solution was deoxygenated by purging with nitrogen for 1 hour. To start the polymerisation 
the initiator stock solution was transferred via a deoxygenated syringe.
Aliquots of solution were removed and prepared for analysis as described in section 4.4.1.3 
(Yield: 4.6 mg).
'H NMR (D2O, 300 MHz): 8  6.21* (br s, 2H), 5.80* (br s, 2H), 4.39 (br s, 2H), 3.84 (m, 2H),
3.73 (m, 40H), 3.67 (br s, 2H), 3.42 (m, 2H), 1.99** (m, 2H), 1.01 (br s, 3H).
^monomer, ** monomer overlap
GPC (DMF + O.OIM LiBr, 1 ml/min, 50 °C): 11.41 minutes, M^ : 30,066 g/mol, M^: 43,709 
g/mol, PDI: 1.45.
4.4.1.5 SET-LRP synthesis o f  graft-to peptide-polymer conjugate (144) in 
DM SO using peptide initiator (112)
In a typical polymerisation, an initiator stock solution was prepared by dissolving 
copper(II)bromide (3.13 mg, 0.01 mmol), copper (0) powder (1.7 mg, 0.02 mmol) and 
PMDETA (8.7 mg, 0.05 mmol) in previously degassed (3 hours nitrogen purging) DMSO (5
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ml) in a dry vial. The solution was then deoxygenated by purging with nitrogen for an 
additional hour.
Oligo (ethylene glycol) methyl ether methacrylate (1000 mg, 475 g/mol, 2.1 mmol) and 
peptide initiator (112) (15.1 mg, 0.02 mmol) were dissolved in DMSO (575 pi) in a dry vial. 
The solution was deoxygenated by purging with nitrogen for 1 hour. To start the 
polymerisation the initiator stock solution (500 pi) was transferred via a deoxygenated 
syringe.
Aliquots of solution were removed and prepared for analysis as described in section 4.4.1.3 
(Yield: 7.5 mg).
'H NMR (D2O, 300 MHz): 8  6.20* (br s, 2H), 5.78* (br s, 2H), 4.37 (q, 7=3 Hz, 2H), 3.86 
(m, 2H), 3.75 (m, 40H), 3.67 (br s, 2H), 3.42 (m, 2H), 1.99** (m, 2H), 1.01-0.99 (br s, 3H).
*monomer, ** monomer overlap
GPC (DMF + O.OIM LiBr, 1 ml/min, 50 °C): 11.73 minutes, Mr,: 20,666 g/mol, M^: 26039 
g/mol, PDI: 1.26.
4.4.1.6 SET-LRP synthesis o f  graft-through peptide-polymer conjugate (145)
in DM SO using peptide initiator (112)
In a typical polymerisation, an initiator stock solution was prepared by dissolving 
copper(II)bromide (3.13 mg, 0.01 mmol), copper(0)powder (1.7 mg, 0.02 mmol), PMDETA 
(8.7 mg, 0.05 mmol) in previously degassed (3 hours nitrogen purging) DMSO (5 ml) in a 
dry vial. The solution was then deoxygenated by purging with nitrogen for an additional hour.
01igo(ethylene glycol) methyl ether methacrylate (1000 mg, 475 g/mol, 2.1 mmol), peptide 
initiator (112) (15.1 mg, 0.02 mmol) and peptide monomer (113) (12.7 mg, 0.02 mmol) were 
dissolved in DMSO (575 pi) in a dry vial. The solution was deoxygenated by purging with 
nitrogen for 1 hour. To start the polymerisation the initiator stock solution (500 pi) was 
transferred via a deoxygenated syringe.
Aliquots of solution were removed and prepared for analysis as described in section 4.4.1.3 
(Yield: 5.7 mg).
'H NMR (D2O, 300 MHz): 8  6.23* (br s, 2H), 5.81* (br s, 2H), 4.39 (m, 2H), 3.87 (m, 2H), 
3.74 (m, 40H), 3.67 (br s, 2H), 3.42 (m, 2H), 2.00** (m, 2H), 0.99 (br s, 3H).
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*monomer, ** monomer overlap
GPC (DMF + O.OIM LiBr, 1 ml/min, 50 °C): 10.96 minutes, Mn: 31,773 g/mol, M :^ 47,977 
g/mol, PDI: 1.51.
4.4.1.7 SET-LRP synthesis o f  self-assembling peptide-polymer conjugate 
(146) in DM SO using self-assembling peptide initiator (133)
In a typical polymerisation, an initiator stock solution was prepared by dissolving 
copper(II)bromide (3.13 mg, 0.01 mmol), copper(0)powder (1.7 mg, 0.02 mmol) and 
PMDETA (8.7 mg, 0.05 mmol) in previously degassed (3 hours nitrogen purging) DMSO (5 
ml) in a dry vial. The solution was then deoxygenated by purging with nitrogen for an 
additional hour.
01igo(ethylene glycol) methyl ether methacrylate (1000 mg, 475 g/mol, 2.1 mmol) and self­
assembling peptide initiator (133) (27.9 mg, 0.02 mmol) were dissolved in DMSO (575 pi) in 
a dry vial. The solution was deoxygenated by purging with nitrogen for 1 hour. To start the 
polymerisation the initiator stock solution (500 pi) was transferred via a deoxygenated 
syringe.
Aliquots of solution were removed and prepared for analysis as described in section 4.4.1.3. 
(Yield: 21.9 mg).
'H NMR (D2O, 300 MHz): 5 6.21* (br s, 2H), 5.79* (br s, 2H), 4.37 (m, 2H), 3.86 (m, 2H),
3.73 (m, 40H), 3.66 (br s, 2H), 3.41 (m, 2H), 1.98** (m, 2H), 0.97 (br s, 3H).
*monomer, ** monomer overlap
GPC (DMF + O.OIM LiBr, 1 ml/min, 50 °C): 11.28 minutes, M„: 34,465 g/mol, M^: 52,386 
g/mol, PDI: 1.52.
4.4.1.8 RAFT Polymerisation synthesis o f  RAFT-polymer (147)
Ethanol (10 ml) was deoxygenated for 1 hour by purging with nitrogen. 01igo(ethylene 
glycol) methyl ether methacrylate (1500 mg, 3.1 mmol), 2-phenyl-2-propyl benzodithioate 
(8 . 8  mg, 0.03 mmol) and a,a'-azoisobutyronitrile (1.3 mg, 0.008 mmol) were added to a 
three-necked round bottomed flask. The flask was deoxygenated by briefly purging with 
nitrogen and cooled to 0 °C. Deoxygenated ethanol (3 ml) was then added through a 
deoxygenated syringe and the flask was purged with nitrogen for an additional twenty
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minutes. An initial sample was taken before the reaction vessel was then heated to 70 °C and 
stirred for 16 hours.
After 24 hours the solution was quenched by dilution in deuterated water and analysed for 
monomer conversion using proton NMR. The sample was then dialysed against distilled 
water for 24 hours prior to lyophilisation and analysis with gel-permeation chromatography 
(Yield: 548 mg).
'HNMR (D2 0 , 300 MHz): 8  4.20 (m, 2H), 3.72 (m, 42H), 3.65 (br s, 2H), 3.40 (m, 2H), 1.92 
(m, 2H), 1.08-0.93 (br s, 3H).
GPC (DMF + O.OIM LiBr, 1 ml/min, 50 °C): 12.08 minutes, M„: 30,666 g/mol, Mw: 40,675 
g/mol, PDI: 1,45.
4.4.1.9 Modification o f  thiol group o f  RAFT-polymer (147) to fo rm  peptide- 
polym er (148)
RAFT-Polymer (147) (5 mg, 4680 g/mol determined by GPC, 1.06 xlO'  ^ mmol) was 
dissolved in methanol (100 pL) and deoxygenated by purging with nitrogen for 30 minutes. 
Butylamine (20 pL in 500 pL of methanol) was deoxygenated separately by purging with 
nitrogen. Peptide-monomer (113) (4.5 mg, 0.01 mmol) was dissolved in PBS buffer (100 pL) 
and deoxygenated by purging with nitrogen for 1 hour.
The dexoxgenated butylamine solution (17 pL) was added to the RAFT-Polymer (147) 
solution via a deoxygenated syringe and the resulting solution was stirred for 10 minutes. The 
peptide solution was then added via deoxygenated syringe and the solution stirred overnight. 
The solution was then dialysed against distilled water for 24 hours prior to lyophilisation and 
analysis by NMR.
4.4.2 Graft-from Protein-polymer synthesis
4.4.2.1 A TRP synthesis o f  protein-polymer conjugate (154) in water using
protein initiator (153)
The graft-from polymerisation was performed using a method modified from Matyjazewski 
and co-workers.^® In a typical polymerisation, an initiator stock solution was prepared by 
dissolving bipyridyl (16.7 mg, 0 .1  mmol) and Cu(II)Br2 ( 6  mg, 0.026 mmol) in deionised 
water (10 ml) in a Schlenk tube. The solution was deoxygenated by purging with nitrogen for
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1 hour before copper(I)bromide (3.8 mg, 0.026 mmol) was added and the solution 
deoxygenated for an additional 30 minutes.
01igo(ethylene glycol) methyl ether methacrylate (21 mg, 475 g/mol, 0.04 mmol) and 
protein-peptide initiator (153) (1 mg, 0.01 mmol) were dissolved in water (100 pi) in a dry 
vial. The solution was deoxygenated by purging with nitrogen for 1 hour. To start the 
polymerisation the initiator stock solution (250 pi) was transferred via a deoxygenated 
syringe.
After 16 hours the sample was diluted with deionised water (500 pi) to quench 
polymerisation and was dialysed against distilled water for 24 hours. The sample was then 
concentrated using a centrifugal filter (Section 4.5.14) prior to analysis with size-exclusion 
chromatography.
4.4.2.2 SET-LRP synthesis o f  protein-polymer conjugate (156) in DM SO
using peptide initiator (153)
In a typical polymerisation, an initiator stock solution was prepared by dissolving 
copper(II)bromide (3.13 mg, 0.01 mmol), copper(0)powder (1.7 mg, 0.02 mmol) and 
PMDETA (8.7 mg, 0.05 mmol) in previously degassed (3 hours nitrogen purging) DMSO (5 
ml) in a dry vial. The solution was then deoxygenated by purging with nitrogen for an 
additional hour.
01igo(ethylene glycol) methyl ether methacrylate (100 mg, 475 g/mol, 0.21 mmol) and 
protein-peptide initiator (153) (3 mg, 0.0008 mmol) were dissolved in DMSO (575 pi) in a 
dry vial. The solution was deoxygenated by purging with nitrogen for 1 hour. To start the 
polymerisation the initiator stock solution (50 pi) was transferred via a deoxygenated syringe.
After 3 hours the polymerisation was terminated by dilution with water, the sample was then 
dialysed against distilled water for 24 hours prior to lyophilisation and analysis with SDS- 
PAGE and size-exclusion chromatography.
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4.5 Protein Ligation
4.5.1 eGFP-LPETGG-HiSô Expression
The plasmid containing the eEGFP-LPETGG-Hise sequence (pLLC146, 1 pi) was 
transformed into E. coli strain BL21(DE3) competent cells (Novagen) and incubated for 30 
minutes on ice. The cells were then heat shocked at 42 °C for 30 seconds and placed back on 
ice before adding warm super Optimal broth with Catabolite repression medium and 
incubating at 37 °C for one hour. The culture (50 pi) was then plated on to lysogeny broth 
plates with 100 ug/ml ampicillin. Six antibiotic-resistant colonies were selected to inoculate 
lysogeny broth medium (10 ml) overnight under shaking. After overnight incubation, the 
culture ( 1 0  ml) was transferred to six 1 litre stocks of sterile lysogeny broth medium and 
incubated at 37 °C until the OD600 reach -0.6. The culture was then induced with 0.1% w/v 
of isopropyl-p-D-1 -thiogalactopyranoside and the cells were grown overnight at 37 °C under 
shaking. The culture was then centrifuged (SS-34, 18,000 rpm, 20 minutes, 4 °C). The 
supernatant was discarded and the pellets were collected as a bright green solid in a yield of 
10.5g.
4.5.2 eGFP-LPETGG-His6 Lysis
Pellets of GFP expressing cells were resuspended in 20 mM Tris-HCl pH 7.7, 100 mM KCl, 
8  mM imidazole buffer (50 ml). The suspended cells were then lysed by sonication (3 x 10 
minutes, 30 seconds on/off, on ice) and the lysate was then centriftiged (SS-34, 18,000 rpm, 
20 minutes, 4 °C), the supernatant was collect for further purification
4.5.3 eGFP-LPETGG-His6 Purification
The supernatant was applied to a pre-equilibrated 10 ml column of Ni-NTA sepharose resin. 
The resin was washed with Tris-HCl, 100 mM KCl, 8  mM imidazole, pH 7.7 buffer (90 ml) 
and then 20 mM ammonium acetate, 20 mM imidazole, pH 7.0 buffer (100 ml) to remove 
any unbound protein. The resin was then washed 5 times with 20 mM ammonium-acetate, 
400 mM imidazole, pH 7.0 buffer (20 ml) and the eluent collected as fi-actions. The purity o f  
the fractions were then determined using SDS-PAGE analysis (4.5.9).
4.5.4 eGFP-LPETGG-Hise Concentration and Lyophilisation
The eGFP fractions were combined and then concentrated using Amicon Ultracel 
ultrafiltration discs (10 kDa cutoff). The resulting concentrated solution (about 30 ml) was
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then dialysed against water (4 L) overnight and then against three further changes of water 
(4L) every 4 hours. The sample was then frozen at -80 °C and lyophilised for 48 hours to 
yield freeze-dried eGFP-LPETGG-HiSô (145) as a green solid in a yield of 141 mg.
4.5.5 Sortase A-Hise Expression
Sortase A-Hisg was expressed according to the procedure used in section 4.5.1 using the 
plasmid containing the Sortase A-Hise sequence (pSOT092, 1 pi) and transforming into E. 
coli strain BL21(DE3) competent cells (Novagen). Six pellets were collected as an off white 
solid in a yield of 2 1 . 1  g
4.5.6 Sortase A-Hisg Lysis
Pellets of Sortase A-Hise expressing cells were resuspended in 20 mM Tris-HCl pH 7.7, 100 
mM KCl, 8  mM imidazole, pH 7.7 buffer (105 ml). The cells were then lysed according to 
the procedure in section 4.5.1
4.5.7 Sortase A-Hisg Purification
The supernatant was purified according to the procedure in section 4.5.3. The resin was then 
washed 10 times with 20 mM ammonium-acetate, 400 mM imidazole, pH 7.0 buffer (15 ml) 
and the eluent collected as fractions. The purity of the fractions was then determined using 
SDS-PAGE analysis (4.5.9).
4.5.8 Sortase A-His^ Concentration and Lyophilisation
The Sortase A was concentrated and lyophilised according to the procedure in section 4.5.4 to 
yield freeze-dried Sortase A-Hisg (146) as a white solid in a yield of 141 mg.
4.5.9 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
The separating gel was prepared using RO water (5 ml), 40% v/v acrylamide solution (6.24 
ml), 2% v/v bisacrylamide solution (3 ml), 1.5 M Tris HCl pH 8 . 8  buffer (2.5 ml), 10% w/v 
SDS solution (0.2 ml), 10% ammonium persulphate solution (320 pi) and TEMED 
(Y,A ,^A '^,A-tetramethylethylenediamine, 32 pi). The stacking gel was prepared using RO 
water (3.14 ml), 40% v/v acrylamide solution (750 pi), 2% v/v bisacrylamide solution (400 
pi), 1.5 M Tris HCl, pH 6 . 8  buffer (620 pi), 10% w/v SDS solution (50 pi), 10% ammonium 
persulphate solution (120 pL) and TEMED (A ,^A/A '^A '^tetramethylethylenediamine, 20 pi).
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Protein samples were diluted 2-fold in Sample Buffer (Sigma Aldrich, catalogue number: 
S3501). Samples were denatured for 5 minutes at 90 °C before loading the sample (10 pi) on 
to gel with multicolour broad range protein marker (5 pi) (Thermo Scientific, catalogue 
number: 26634) run adjacent to the samples to allow molecular weight determination. The 
running buffer was prepared by diluting a lOx stock composed of Tris (75.7 g), glycine (360 
g) and SDS (25 g) in water (2.5 L) to a final Ix concentration.
The proteins were separated according to their size using Bio-Rad Mini-Protean gel 
electrophoresis unit by applying voltage o f 180 V for 50 minutes. Following separation the 
gel was stained with 0.5% Coomassie brilliant blue, 50% methanol, 10% acetic acid stain 
solution for 15 minutes before being destained in 20% methanol, 10% acetic acid destain 
solution for 3 hours. The stained gel was photographed using a Sygene GeneGenius imaging 
system under visible and ultraviolet light.
4.5.10Native-polyacrylamide gel electrophoresis
The separating gel was prepared using RO water (5.33 ml), 30% v/v acrylamide solution (2 
ml), 2% v/v bisacrylamide solution (67 pi), 1.5 M Tris HCl pH 8 . 8  buffer (2.5 ml), 10% 
ammonium persulphate solution (100 pi) and TEMED {N,N,N',N- 
tetramethylethylenediamine, 5 pi). The stacking gel was prepared using RO water (2.75 ml), 
30% v/v acrylamide solution (680 pi), 2% v/v bisacrylamide solution (23 pi), 1 M Tris HCl, 
pH 6 . 8  buffer (500 pi), 10% ammonium persulphate solution (40 pi) and TEMED (N,N,N',N' 
tetramethylethylenediamine, 5 pi).
Protein sample (9 pL) and glycerol (5 pi) were added to loading buffer ( 6  pi) (prepared using 
glycerol (7 ml), IM Tris HCl, pH 6.85 (1.85 ml), bromophenol blue (0.15 ml) and RO 
water(5 ml), the sample (10 pi) was then loaded onto gel. The running buffer was prepared by 
diluting a lOx stock composed of Tris (30.2 g), glycine (144 g), pH 6 . 8  in water (1 L) to a 
final Ix concentration.
The proteins were separated according to their size using a Bio-Rad Mini-Protean gel 
electrophoresis unit by applying a voltage of 70 V for 60 minutes. Following separation the 
gel was stained with 0.5% Coomassie brilliant blue, 50% methanol, 10% acetic acid stain 
solution for 15 minutes before being destained in 20% methanol, 10% acetic acid destain 
solution for 2 hours. The stained gel was photographed using a Sygene GeneGenius imaging 
system under visible and ultraviolet light.
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4.5.1 IProtein-Peptide conjugation o f eGFP-LPETGG-Hise
The small-scale eGFP-LPETGG-Hise ligation reactions with oligoglycine peptides and 
control reactions using were set-up using the volumes and concentration stated in Table 14 
and Table 15 respectively.
Table 14. eGFP-LPETGG-Hise with oligoglycine peptide ligation small-scale reaction mixture
R e a g e n t V o l u m e C o n c e n t r a t i o n
e G F P -L P E T G G -H iS ô 1 0  p L 0 .3 5 8  m M
O l ig o g ly c in e  p e p t id e 1 2 .5  p L 1 .8 5 8  m M
S o r ta s e  A 5 p L 4 .5 1  u M
A s s a y  B u f f e r  ( 5 0  m M  T r is ,  1 5 0  
m M  N a C l ,  5  m M  C a C h ,  p H  7 . 5 )
3 2 .5  p L
Table 15. cGFP-LPETGG-Hisg with oligoglycine peptide ligation control mixture.
R e a g e n t V o l u m e C o n c e n t r a t i o n
e G F P -L P E T G G -H iS ô 1 0  p L 0 .3 5 8  m M
O l ig o g ly c in e  p e p t id e 1 2 .5  p L 1 .8 5 8  m M
A s s a y  B u f f e r  ( 5 0  m M  T r is ,  1 5 0  
m M  N a C I ,  5  m M  C a C h ,  p H  7 .5 )
3 7 .5  p L
A large scale eGFP-LPETGG-Hisg ligation reaction with oligoglycine peptides using Sortase
A-His6 were set up and a control reaction were set up as follows:
Table 16. eGFP-LPETGG-Hise with oligoglycine peptide ligation large scale reaction mixture
R e a g e n t V o l u m e C o n c e n t r a t i o n
e G F P -L P E T G G -H is g 5 0 0  p L 0 . 3 5 8  m M
O l ig o g ly c in e  p e p t id e 6 2 5  p L 1 .8 5 8  m M
S o r ta s e  A 2 5 0  p L 4 .5 1  u M
A s s a y  B u f f e r  ( 5 0  m M  T r is ,  1 5 0  
m M  N a C l ,  5  m M  C a C b ,  p H  7 .5 )
1 6 2 5  p L
10 pL aliquot was taken for SDS-PAGE analysis (4.5.9) and the bulk solution was frozen at - 
80 °C for subsequent purification (4.5.13)
4.5.12Protein-Peptide conjugation of Tus-LPETGG-Hisg
A large-scale Tus-LPETGG-Hise ligation reaction with self-assembling di-gly peptide and 
control reaction were set-up using the volumes and concentrations stated in Table 17.
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Table 17. Tus-LPETGG-Hise with self-assembling di-gly peptide (137) reaction mixture
R e a g e n t V o l u m e C o n c e n t r a t i o n
T u s -L P E T G G -H is g 5 0 0  p L 0 .3 5 8  m M
S e l f - a s s e m b l in g  d i - g ly  p e p t id e  ( 1 3 7 ) 6 2 5  p L 0 .4  m M
S o r ta s e  A 2 5 0  p L 4 .5 1  p M
A s s a y  B u f f e r  ( 5 0  m M  T r is ,  1 5 0  
m M  N a C l ,  5  m M  C a C h ,  p H  7 .5 )
1 0 2 5  p L
4.5.13 Removal o f His-tagged proteins
His-Select Cobalt Affinity Gel (0.5 ml) was added to a 1.5 ml Eppendorff tube and washed 
with 20 mM ammonium acetate, 8  mM imidazole, pH 7.0. The resin was vortexed to mix and 
the centrifuged at 5000G for 2 minutes. The supernatant was decanted off and the ligation 
reaction mixture (1 ml) was added. The reaction mixture and resin were vortexed for 1 
minute before centrifugation at 5000G for 2 minutes. The supernatant was collected and 
subsequently purified. The resin was then washed with 20 mM ammonium acetate, 400 mM 
imidazole, pH 7.0 and centrifuged at 5000G for 2 minutes to remove any bound proteins.
4.5.14 Conjugate concentration, desalting and peptide removal
Amicon Ultracel -  10 K membrane centrifugal filters were centrifuged at 14000G for 5 
minutes. The previously purified protein solution was then added and the filter centrifuged at 
14000G for 5 minutes, when concentrated to desired volume the filter was inverted and 
centrifuged at lOOOG for 2 minutes to collect the purified protein.
4.5.15 Hydrogel preparation using self-assembling peptide (127) and 
protein-self-assembling peptide conjugate (163)
Peptides solutions were prepared in 1.5 ml microtubes by suspending the peptide at a 
concentration of 20 mg/m I in distilled water. The solutions were vortexed to obtain a 
homogeneous mixture and then heated to 40 °C for 30 min to aid complete dissolution. Gel 
formation occurred after incubation overnight leaving the mixture to cool down to room 
temperature. The amounts of peptide for each gel are described below:
Self-assembling peptide gel (163): 100 % (130).
Tus-protein-self-assembling peptide conjugate (164) : 5 % (163)/ 95 % (130) (w/w).
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4.5.16Binding o f FAM-Z^r-DNA to Tus-protein self-assembling peptide gel 
(164)
The single stranded oligonucleotides to create FAM-^er-DNA and a Cy5-DNA were 
synthesised by ADTBio Ltd (University of Southampton, UK). These strands were diluted in 
binding buffer (50 mM Tris, 0.1 mM EDTA, 250 mM, KCl, 0.1 mM DTT, pH 9), incubated 
at 95 °C for 10 min then left to cool to room temperature to yield 10 pM fluorescein labelled 
double stranded D N A .
Peptide gels were then incubated with DNA mixture or incubation buffer (20 pi) (50 mM 
Tris, 0.1 mM EDTA, 250 mM KCl, 0.1 mM DTT, pH 7.5) at room temperature on an orbital 
shaker set at a low speed overnight. DNA mixtures were prepared as stated in Table 18.
D N A  M i x t u r e F A M - t e r - D N A C y S - D N A
A 2 5 % 7 5 %
B 5 0 % 5 0 %
C 7 5 % 2 5 %
D 1 0 0 % 0 %
E 0 % 0 %
Table 18. DNA mixtures for incubation with Tus-protein-self-assembling peptide (164)
All solutions were made up to a final concentration o f 10 pM in incubation buffer (50 mM 
Tris, 0.1 mM EDTA, 250 mM KCl, 0.1 mM DTT, pH 7.5).
4.5.17Confocal fluorescence microscopy
Each gel sample was washed 3 times with incubation buffer (30 pi) (50 mM Tris, 0.1 mM 
EDTA, 250 mM KCl, 0.1 mM DTT, pH 7.5) before analysis. Each gel (20 pi) was pipetted 
onto a glass slide and the fluorescence was viewed at lOOX magnification with an inverted 
fluorescence microscope (Nikon Eclipse TSIOO) equipped with a filter set (FITC) for green 
fluorescence that produces excitation in the range 465-495 nm and emission in the range 515- 
555 nm and also a filter set (G-2A) for red fluorescence that produces excitation in the range 
510-560 nm and emission above 590 nm. Samples were photographed with digital camera 
(Nikon DSVil) and NIS-Elements imaging software (Nikon).
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4.5.1 SFluorescence measurements o f the washed self-assembling gels using
a fluorescent plate reader
Each sample or control (10 pi) was added to incubation buffer (90 pi) (50 mM Tris, 0.1 mM 
EDTA, 250 mM KCl, 0.1 mM DTT, pH 7.5) in a black 96 well flat bottomed plate. 
Fluorescence (RFU) was measured in a Gemini X5 fluorescence plate reader (SpectraMax) 
with SoftMax Pro software. The samples were excited at 494 nm and the fluorescence 
emission intensity was measured at 521 nm for green fluorescence (FAM) and for red 
fluorescence (Cy5), the samples were excited at 649 nm and the fluorescence emission 
intensity was measured at 660 nm.
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